nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,id,nct_id,mesh_term,downcase_mesh_term,mesh_type
"ClinicalTrials.gov processed this data on October 15, 2021",2021-10-08,NA,NA,2021-10-12,2021-10-12,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,October 2021,Anticipated,2021-10-31,October 2021,2021-10-31,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Convalescent Plasma Therapy for Hospitalized Patients With COVID-19,Validation Protocol for The Clinical Use of Convalescent Plasma for Hospitalized Patients With COVID-19. A Prospective Study at a Hospital in Southern Brazil.,Recruiting,NA,Phase 2,200,Anticipated,Science Valley Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:40:25Z,2021-10-17T06:40:25Z,15554181,NCT05077930,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-10-08,NA,NA,2021-10-08,2021-10-08,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-12,Actual,"December 10, 2020",Actual,2020-12-10,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,IICov19PRS,,Index Individuals in SARS-CoV-2 Prevention Research Studies (an Index Individuals Companion Study),Characterization of the Index Individual for Contact Participants Enrolled in Clinical Trials of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Prevention Interventions; CoVPN 3502-01,Recruiting,NA,NA,2000,Anticipated,University of Washington,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      1) mid-turbinate nasal swab sample and 2) dried blood spot sample (optional)
    ",NA,NA,NA,NA,NA,2021-10-17T06:40:58Z,2021-10-17T06:40:58Z,15554616,NCT05074719,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-04,NA,NA,2021-10-05,2021-09-20,2021-10-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,6 Months,Observational [Patient Registry],NA,,Muscle Evaluation of Patients Infected by the Coronavirus,Muscle Evaluation of Patients Infected by the Coronavirus Requiring Mechanical Ventilation,Recruiting,NA,NA,138,Anticipated,Hospital Israelita Albert Einstein,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Data will be available at the end of the study, as soon as the manuscript became published in a journal (following publication). No end date (data will be available indefinitely).",Researchers who provide a methodologically sound proposal and/or investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.,NA,Yes,"Individual participant data (IPD) collected during the study that underlie results reported will be shared after de-identification (text, tables, figures, and appendices).",2021-10-17T06:42:35Z,2021-10-17T06:42:35Z,15556072,NCT05063214,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-29,NA,NA,2021-09-30,2021-09-29,2021-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"July 9, 2020",Actual,2020-07-09,September 2021,2021-09-30,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Observational,NA,,Lung Ultrasound Changes in Covid 19 Patients Discharged From Hospital,Prospective Observational Study Looking at Lung Ultrasound Changes During Recovery From COVID19 Infection,Completed,NA,NA,23,Actual,Chelsea and Westminster NHS Foundation Trust,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:42:39Z,2021-10-17T06:42:39Z,15556147,NCT05062603,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-26,NA,NA,2021-09-13,2021-09-13,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-16,Actual,"October 3, 2020",Actual,2020-10-03,September 2021,2021-09-30,October 2021,Anticipated,2021-10-31,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,,"This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19","Double-blind, Placebo-controlled, Randomized Study of Tolerability, Safety and Immunogenicity of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers at the Age of 18-60 Years","Active, not recruiting",NA,Phase 1/Phase 2,400,Actual,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:44:49Z,2021-10-17T06:44:49Z,15558204,NCT05046548,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-07,NA,NA,2021-09-07,2021-09-07,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"August 10, 2021",Actual,2021-08-10,September 2021,2021-09-30,December 2022,Anticipated,2022-12-31,August 2022,Anticipated,2022-08-31,NA,Interventional,COVER,,Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19),"A Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless Phase I / II Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5-RBD-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Biocad,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:46:07Z,2021-10-17T06:46:07Z,15559432,NCT05037188,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-30,NA,NA,2021-09-03,2021-09-03,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-08,Actual,"August 30, 2021",Actual,2021-08-30,September 2021,2021-09-30,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,NA,,A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults,"A Phase 1/2 Randomized, Observer-Blind Study of the Safety, Reactogenicity, and Immunogenicity of 3 SARS-CoV-2 RNA Vaccine Candidates in Adults Previously Vaccinated and Not Previously Vaccinated Against SARS-CoV-2",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,"Arcturus Therapeutics, Inc.",,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-10-17T06:46:08Z,2021-10-17T06:46:08Z,15559445,NCT05037097,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-30,NA,NA,2021-10-08,2021-09-01,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-15,Estimate,"September 12, 2021",Actual,2021-09-12,October 2021,2021-10-31,January 2024,Anticipated,2024-01-31,November 2023,Anticipated,2023-11-30,NA,Interventional,NA,,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Recruiting,NA,Phase 3,1800,Anticipated,"National Vaccine and Serum Institute, China",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:46:34Z,2021-10-17T06:46:34Z,15559800,NCT05033847,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-16,NA,NA,2021-08-16,2021-08-16,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"January 4, 2021",Actual,2021-01-04,August 2021,2021-08-31,"January 4, 2022",Anticipated,2022-01-04,"January 4, 2022",Anticipated,2022-01-04,NA,Interventional,COMPOSIT,,COvid iMaging With POSitron Emission Tomography,Evaluation of COVID-19 by Whole-body FDG-PET/CT,Recruiting,NA,N/A,50,Anticipated,Semmelweis University Heart and Vascular Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:49:55Z,2021-10-17T06:49:55Z,15562878,NCT05009563,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-12,NA,NA,2021-08-13,2021-08-13,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-16,Actual,"June 12, 2021",Actual,2021-06-12,August 2021,2021-08-31,"June 12, 2023",Anticipated,2023-06-12,"June 12, 2022",Anticipated,2022-06-12,NA,Interventional,NA,,The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial,The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial,Recruiting,NA,N/A,100,Anticipated,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:50:13Z,2021-10-17T06:50:13Z,15563163,NCT05007457,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-03,NA,NA,2021-08-04,2021-08-04,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-06,Actual,"July 9, 2021",Actual,2021-07-09,August 2021,2021-08-31,September 2023,Anticipated,2023-09-30,April 2023,Anticipated,2023-04-30,NA,Interventional,ADAPTCOV,,"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","Phase I/II Double-blind, Randomized, Stepwise, Adaptive, Controlled Clinical Trial to Assess the Safety and Immunogenicity of the COVID-19 Vaccine (Recombinant, Inactivated) in Adults, in Brazil - ADAPTCOV.",Recruiting,NA,Phase 1/Phase 2,5394,Anticipated,Butantan Institute,,32,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:52:12Z,2021-10-17T06:52:12Z,15565068,NCT04993209,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-22,NA,NA,2021-09-21,2021-08-01,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"September 15, 2021",Actual,2021-09-15,August 2021,2021-08-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,IN2COVID,,Inhaled Interferon Î±2b for the Treatment of Coronavirus Disease 19 (COVID-19),"A Phase I/II Randomized, Double-blind, Placebo-controlled Study of Inhaled Interferon Î±2b for the Treatment of Coronavirus Disease 19 (COVID-19)",Recruiting,NA,Phase 1/Phase 2,168,Anticipated,Pontificia Universidad Catolica de Chile,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will become available 1 year after study completion during 5 years upon reasonable request.,Available upon reasonable request.,NA,Yes,Available upon reasonable request.,2021-10-17T06:52:55Z,2021-10-17T06:52:55Z,15565672,NCT04988217,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-23,NA,NA,2021-07-23,2021-07-23,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-08-03,Actual,"June 1, 2021",Actual,2021-06-01,July 2021,2021-07-31,"June 1, 2023",Anticipated,2023-06-01,"December 1, 2022",Anticipated,2022-12-01,NA,Observational,NA,,"Clinical, Functional, Immunological and Genetic Factors on the Severity of the Course of Coronavirus Infection","Assessment of the Influence of Clinical, Functional, Immunological, and Genetic Factors on the Severity of the Course of Coronavirus Infection With SARS-CoV-2 and Post Covid Syndrome",Recruiting,NA,NA,300,Anticipated,"National Research Center for Cardiac Surgery, Kazakhstan",,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      1. blood

        2. deoxyribonucleic acid (DNA) samples
    ",starting 6 months after publication,all types of supporting information will be shared with the interested party within the framework of the legislation of the Republic of Kazakhstan,http://heartcenter.kz,Yes,all IPD that underlie results in a publication,2021-10-17T06:52:58Z,2021-10-17T06:52:58Z,15565713,NCT04987853,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-22,NA,NA,2021-08-03,2021-07-22,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-11,Actual,"July 15, 2020",Actual,2020-07-15,August 2021,2021-08-31,"July 9, 2021",Actual,2021-07-09,"July 9, 2021",Actual,2021-07-09,NA,Observational,AVICOVID,,Impact of Changes in the Use of Care and Reorganization of the Healthcare System Linked to the Covid-19 Outbreak on the Quality of Care Pathways of Patients Suffering From Acute Myocardial Infarction and Stroke in Aquitaine (AVICOVID),Impact of Changes in the Use of Care and Reorganization of the Healthcare System Linked to the Covid-19 Outbreak on the Quality of Care Pathways of Patients Suffering From Acute Myocardial Infarction and Stroke in the Aquitaine Region,Completed,NA,NA,9218,Actual,"University Hospital, Bordeaux",,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:54:12Z,2021-10-17T06:54:12Z,15566813,NCT04979208,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-08,NA,NA,2021-08-20,2021-07-19,2021-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"June 30, 2021",Actual,2021-06-30,August 2021,2021-08-31,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,STAIRS,,Study of Varespladib in Patients Hospitalized With Severe COVID-19,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2",Recruiting,NA,Phase 2,90,Anticipated,"Ophirex, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:55:31Z,2021-10-17T06:55:31Z,15568008,NCT04969991,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-13,NA,NA,2021-07-18,2021-07-18,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-18,2021-07-20,Actual,"June 1, 2021",Actual,2021-06-01,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,,Jing-Si-Herbal-Tea Accelerates SARS-Cov-2 Load Reduction Among COVID-19 Patients,"Taipei Tzu Chi Hospital,The Buddhist Medical Fundation",Recruiting,NA,N/A,200,Anticipated,"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:55:51Z,2021-10-17T06:55:51Z,15568291,NCT04967755,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-04,NA,NA,2021-07-12,2021-07-12,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"March 11, 2021",Actual,2021-03-11,June 2021,2021-06-30,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,COGEVAX-BIO,,Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions,Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions,Recruiting,NA,N/A,80,Anticipated,GÃ©rond'if,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:56:41Z,2021-10-17T06:56:41Z,15569007,NCT04961502,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-08,NA,NA,2021-07-19,2021-07-08,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-23,Actual,"July 3, 2021",Actual,2021-07-03,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2ï¼ˆCOVID-19ï¼‰ Phase I Clinical Trial (3~17 Years Old),"A Randomized, Blinded, Placebo-controlled Phase â…  Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age",Recruiting,NA,Phase 1,75,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:56:42Z,2021-10-17T06:56:42Z,15569031,NCT04961359,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-02,NA,NA,2021-10-12,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Actual,"March 22, 2021",Actual,2021-03-22,October 2021,2021-10-31,"January 1, 2023",Anticipated,2023-01-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,,Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Impact of the Immune System on Response to COVID-19 Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Recruiting,NA,Phase 3,50,Anticipated,University of Liege,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:58:06Z,2021-10-17T06:58:06Z,15570258,NCT04951323,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-18,NA,NA,2021-06-28,2021-06-28,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"April 9, 2021",Actual,2021-04-09,June 2021,2021-06-30,"July 9, 2022",Anticipated,2022-07-09,"June 9, 2022",Anticipated,2022-06-09,NA,Observational,NA,,Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients,Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients,"Active, not recruiting",NA,NA,950,Anticipated,Hospital Italiano de Buenos Aires,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:59:04Z,2021-10-17T06:59:04Z,15571182,NCT04944433,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-20,NA,NA,2021-06-20,2021-06-20,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-20,2021-06-28,Actual,"June 11, 2021",Actual,2021-06-11,June 2021,2021-06-30,"February 28, 2022",Anticipated,2022-02-28,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,,imPulseâ„¢ Una Infrasound-to-ultrasound E-stethoscope,imPulseâ„¢ Una Infrasound-to-ultrasound E-stethoscope 2-minute to Result COVID-19 Self-directed & Point-of-care Screening Test,Recruiting,NA,NA,1000,Anticipated,"Level 42 AI, Inc.",,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:59:29Z,2021-10-17T06:59:29Z,15571610,NCT04941209,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-24,NA,NA,2021-06-21,2021-06-21,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"March 5, 2021",Actual,2021-03-05,May 2021,2021-05-31,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COVINUT,,Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (COVID-19) Status (Positive or Negative) During Hospitalization,Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (Covid-19) Status (Positive or Negative) During Hospitalization,Recruiting,NA,N/A,135,Anticipated,GÃ©rond'if,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:00:34Z,2021-10-17T07:00:34Z,15572587,NCT04933929,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-11,NA,NA,2021-06-14,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-15,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,,Dexamethasone and COVID-19 Inpatient Mortality,Effect of Dexamethasone on Inpatient Mortality Among Hospitalized COVID-19 Patients,"Active, not recruiting",NA,NA,20000,Anticipated,"Aetion, Inc.",,NA,3,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Study results will report aggregated findings,2021-10-17T07:01:37Z,2021-10-17T07:01:37Z,15573504,NCT04926571,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-03,NA,NA,2021-09-10,2021-06-03,2021-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"April 30, 2020",Actual,2020-04-30,September 2021,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,COPE,,"Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada","Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada",Recruiting,NA,NA,100,Anticipated,Ottawa Hospital Research Institute,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Should residual samples (i.e. maternal serum, umbilical cord serum, amniotic fluid, breast
      milk, placental tissue [frozen and fixed]) remain after the purposes of the primary outcomes,
      samples will be retained for 10 years for future, related REB approved studies.
    ",NA,NA,NA,No,"IPD that underlie the results reported in this article, after deidentification, will be made available to other researchers upon request.",2021-10-17T07:03:30Z,2021-10-17T07:03:30Z,15575177,NCT04913948,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-09,NA,NA,2021-08-20,2021-06-10,2021-06-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"July 15, 2021",Actual,2021-07-15,August 2021,2021-08-31,"December 30, 2022",Anticipated,2022-12-30,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NECTAR,,Novel Experimental COVID-19 Therapies Affecting Host Response,"CONNECTS Master Protocol for Clinical Trials Targeting Macro-, Micro-immuno-thrombosis, Vascular Hyperinflammation, and Hypercoagulability and Renin-angiotensin-aldosterone System (RAAS) in Hospitalized Patients With COVID-19 (ACTIV-4 Host Tissue)",Recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Vanderbilt University Medical Center,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:01:55Z,2021-10-17T07:01:55Z,15573763,NCT04924660,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-01,NA,NA,2021-06-01,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"January 31, 2021",Actual,2021-01-31,June 2021,2021-06-30,"July 28, 2022",Anticipated,2022-07-28,"May 28, 2022",Anticipated,2022-05-28,NA,Observational,NA,,Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year,Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year,Recruiting,NA,NA,60,Anticipated,LifeBridge Health,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,Samples Without DNA,"
      Urine for urinary 11-dehdro thromboxane Blood for platelet fibrin-clot strength as measured
      by Thrombelastography, IgG and IgM antibodies to SARS-CoV-2
    ",NA,NA,NA,No,NA,2021-10-17T07:03:57Z,2021-10-17T07:03:57Z,15575575,NCT04910971,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-17,NA,NA,2021-05-21,2021-05-21,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"July 22, 2020",Actual,2020-07-22,May 2021,2021-05-31,"June 30, 2021",Anticipated,2021-06-30,"March 12, 2021",Actual,2021-03-12,NA,Interventional,NA,,Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction,Olfactory and Neurosensory Rehabilitation in Coronavirus 2019 (COVID-19)-Related Olfactory Dysfunction (OD),Recruiting,NA,Phase 2,25,Anticipated,The University of Hong Kong,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:05:28Z,2021-10-17T07:05:28Z,15576952,NCT04900415,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-03,NA,NA,2021-05-03,2021-05-03,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-07,Actual,"April 29, 2021",Actual,2021-04-29,May 2021,2021-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Performance Study of SONA Saliva C-19 Rapid Test,Novel Salivary Rapid Testing of SARS_CoV_2,Recruiting,NA,N/A,500,Anticipated,Sona Nanotech Inc,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:08:53Z,2021-10-17T07:08:53Z,15579900,NCT04877002,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-09,NA,NA,2021-05-23,2021-05-23,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-23,2021-05-25,Actual,"November 20, 2020",Actual,2020-11-20,May 2021,2021-05-31,May 2022,Anticipated,2022-05-31,January 2022,Anticipated,2022-01-31,NA,Interventional,CONTRAST-3,,Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19,"Evaluation of Long-term Lipid-lowering Therapy on Myocardial Electrical Heterogeneity, Myocardial Deformation, Arterial Stiffness and Quality of Life in Patients With Primary STEMI/NSTEMI With Coronavirus Infection COVID-19",Recruiting,NA,N/A,200,Anticipated,Penza State University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:05:30Z,2021-10-17T07:05:30Z,15576986,NCT04900155,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-11,NA,NA,2021-09-28,2021-05-11,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"February 8, 2021",Actual,2021-02-08,September 2021,2021-09-30,"July 15, 2026",Anticipated,2026-07-15,"December 31, 2025",Anticipated,2025-12-31,12 Months,Observational [Patient Registry],NA,,Post COVID-19 Biorepository,Post COVID-19 Biorepository,Recruiting,NA,NA,100,Anticipated,University of Kansas Medical Center,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Future projects might include genetic testing. Your sample may be sent to a lab for genetic
      testing.
    ",NA,NA,NA,Yes,The plan will be discussed between the Principal Investigator and the PI requesting access to Biospecimens.,2021-10-17T07:07:38Z,2021-10-17T07:07:38Z,15578877,NCT04885504,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-25,NA,NA,2021-06-10,2021-05-09,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-14,Actual,"May 20, 2021",Actual,2021-05-20,June 2021,2021-06-30,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019ï¼ˆCOVID-19ï¼‰Pneumonia,"A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019ï¼ˆCOVID-19ï¼‰Pneumonia",Recruiting,NA,Phase 2,25,Anticipated,Grand Medical Pty Ltd.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:08:20Z,2021-10-17T07:08:20Z,15579440,NCT04880694,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-21,NA,NA,2021-05-01,2021-05-01,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"January 20, 2021",Actual,2021-01-20,March 2021,2021-03-31,"June 15, 2021",Anticipated,2021-06-15,"May 15, 2021",Anticipated,2021-05-15,NA,Observational,OPTIMIST,,Optimization of Patients Long-term Management After the Coronavirus Infection COVID-19,Optimization of Patients Long-term Management After the Coronavirus Infection COVID-19,Recruiting,NA,NA,200,Anticipated,Pirogov Russian National Research Medical University,,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:09:39Z,2021-10-17T07:09:39Z,15580639,NCT04871789,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-01,NA,NA,2021-05-01,2021-05-01,2021-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-05,Actual,"March 15, 2020",Actual,2020-03-15,May 2021,2021-05-31,"May 30, 2020",Actual,2020-05-30,"May 15, 2020",Actual,2020-05-15,NA,Observational,NA,,The Effects of Smoking on Mortality in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection,The Effects of Smoking on Mortality in Intensive Care Unit in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection,Completed,NA,NA,150,Actual,Sisli Hamidiye Etfal Training and Research Hospital,,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:09:16Z,2021-10-17T07:09:16Z,15580307,NCT04874363,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-25,NA,NA,2021-06-19,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-22,Actual,"May 8, 2021",Actual,2021-05-08,June 2021,2021-06-30,"June 18, 2021",Actual,2021-06-18,"June 18, 2021",Actual,2021-06-18,NA,Interventional,NA,,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Completed,NA,Phase 2,100,Actual,Hawler Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:10:20Z,2021-10-17T07:10:20Z,15581161,NCT04867226,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-25,NA,NA,2021-04-28,2021-04-28,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-05-03,Actual,"January 26, 2021",Actual,2021-01-26,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,NA,,When Distance is an Act of Love: Exploring the Use of Video Diaries for Family Members of Intensive Care Patients,When Distance is an Act of Love: Exploring the Use of Video Diaries for Family Members of Intensive Care Patients,Recruiting,NA,NA,28,Anticipated,University of Edinburgh,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:09:51Z,2021-10-17T07:09:51Z,15580811,NCT04870450,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-20,NA,NA,2021-09-06,2021-04-24,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"May 27, 2021",Actual,2021-05-27,September 2021,2021-09-30,"November 15, 2021",Anticipated,2021-11-15,"October 30, 2021",Anticipated,2021-10-30,1 Year,Observational [Patient Registry],NA,,The Investigation Of Exercise Capacity And Exercise-Induced Fatigue in Young Adults Who Survived From Coronavirus,The Investigation Of Exercise Capacity And Exercise-Induced Fatigue in Young Adults Who Survived From Coronavirus,Recruiting,NA,NA,150,Anticipated,Biruni University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:10:47Z,2021-10-17T07:10:47Z,15581531,NCT04864132,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-01,NA,NA,2021-09-07,2021-04-26,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"March 6, 2021",Actual,2021-03-06,September 2021,2021-09-30,"June 3, 2022",Anticipated,2022-06-03,"June 3, 2022",Anticipated,2022-06-03,NA,Interventional,NA,,SARS-CoV-2 Human Challenge Characterisation Study,A Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain,"Active, not recruiting",NA,N/A,36,Actual,Imperial College London,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:10:36Z,2021-10-17T07:10:36Z,15581399,NCT04865237,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-07,NA,NA,2021-04-21,2021-04-21,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"December 10, 2020",Actual,2020-12-10,April 2021,2021-04-30,"April 10, 2021",Actual,2021-04-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,NA,,Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection,"Efficacy of Probiotics (Lactobacillus Rhamnosus, Bifidobacterium Bifidum, Bifidobacterium Longum Subsp. Infantis and Bifidobacterium Longum) in the Treatment of Hospitalised Patients With Novel Coronavirus Infection",Completed,NA,N/A,200,Actual,I.M. Sechenov First Moscow State Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The provision of data is prohibited by Local Ethical Committee and is possible upon receipt of an official request addressed to the principal investigator,2021-10-17T07:12:07Z,2021-10-17T07:12:07Z,15582660,NCT04854941,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-19,NA,NA,2021-04-26,2021-04-19,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-28,Actual,"March 17, 2021",Actual,2021-03-17,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PINCER,,Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia,A Study of the Efficacy and Safety of Pirfenidone vs. Nintedanib in the Treatment of Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia,Recruiting,NA,Phase 4,48,Anticipated,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:11:57Z,2021-10-17T07:11:57Z,15582515,NCT04856111,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-17,NA,NA,2021-05-09,2021-04-17,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"March 18, 2021",Actual,2021-03-18,April 2021,2021-04-30,"May 9, 2021",Actual,2021-05-09,"May 7, 2021",Actual,2021-05-07,NA,Observational,NA,,Evaluation of the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns,the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns,Completed,NA,NA,300,Actual,Kanuni Sultan Suleyman Training and Research Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:12:11Z,2021-10-17T07:12:11Z,15582712,NCT04854408,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-13,NA,NA,2021-04-22,2021-04-18,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-26,Actual,"April 14, 2021",Actual,2021-04-14,April 2021,2021-04-30,"November 30, 2023",Anticipated,2023-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,TICCKD,,Tailored Information About the Coronavirus in Chronic Kidney Disease Patients,Tailored Information About the Coronavirus and the Coronavirus Pandemic for Patients With Chronic Kidney Disease,Recruiting,NA,N/A,192,Anticipated,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:12:11Z,2021-10-17T07:12:11Z,15582716,NCT04854382,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-16,NA,NA,2021-04-13,2021-04-13,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-19,Actual,"August 1, 2020",Actual,2020-08-01,April 2021,2021-04-30,"March 1, 2022",Anticipated,2022-03-01,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,AIDCO,,Important Data on COVID-19 Profile in Africa,Important Data on COVID-19 Profile in Africa,Recruiting,NA,NA,270,Anticipated,Centre de Recherche MÃ©dicale de LambarÃ©nÃ©,,NA,2,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Samples With DNA,"
      Nasopharyngeal mucosal Blood Urine Stool
    ",2 years,NA,NA,Yes,"Results from our COVID-19 AFRICA, AIDCO, project will be published in peer reviewed journals, seeking rapid and open access publication. This will be done as fast and widely as possible. Results will also be submitted and presented in any national, regional and international scientific meetings and congresses dedicated to COVID-19 online or face to face if, permitted. Before submission for publication or presentation, the review process outlined in the Consortium Agreement and agreed upon by all partners will be followed and care will be taken with respect to intellectual property protection.",2021-10-17T07:13:09Z,2021-10-17T07:13:09Z,15583543,NCT04847817,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-12,NA,NA,2021-10-06,2021-04-12,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"February 17, 2021",Actual,2021-02-17,October 2021,2021-10-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,,"Covid-19, Hospitalized, PatIents, Nasafytol",A Comparative Randomized Clinical Trial on Covid-19 Positive Hospitalized Patients Treated With NASAFYTOL,Recruiting,NA,N/A,50,Anticipated,Tilman S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:13:37Z,2021-10-17T07:13:37Z,15583961,NCT04844658,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-14,NA,NA,2021-07-27,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-28,Actual,"April 28, 2021",Actual,2021-04-28,July 2021,2021-07-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,COVID-19,,A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients,"A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) Versus Placebo in Asymptomatic Ambulatory Outpatients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection",Recruiting,NA,Phase 3,801,Anticipated,Grifols Therapeutics LLC,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:13:16Z,2021-10-17T07:13:16Z,15583639,NCT04847141,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-28,NA,NA,2021-04-04,2021-04-04,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-04-04,2021-04-06,Actual,"November 17, 2020",Actual,2020-11-17,April 2021,2021-04-30,"May 30, 2021",Anticipated,2021-05-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Efficacy of Ivermectin in Outpatients With Non-severe COVID-19,Efficacy of Ivermectin in Outpatients With Non-severe COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 3,400,Anticipated,Universidad Nacional de AsunciÃ³n,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The investigators will publish the results to compare data with other studies with ivermectin and SARS-CoV-2 infection.,2021-10-17T07:15:07Z,2021-10-17T07:15:07Z,15585271,NCT04834115,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-09,NA,NA,2021-04-09,2021-04-09,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-14,Actual,"January 5, 2021",Actual,2021-01-05,April 2021,2021-04-30,"March 12, 2021",Actual,2021-03-12,"March 12, 2021",Actual,2021-03-12,NA,Observational,NA,,COVID-19 Testing Pilot Study,Feasibility Testing of a New COVID-19 Testing Platform,Completed,NA,NA,326,Actual,University of Pennsylvania,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No plans to share IPD.,2021-10-17T07:13:43Z,2021-10-17T07:13:43Z,15584082,NCT04843878,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-07,NA,NA,2021-05-02,2021-04-07,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-06,Actual,"February 16, 2021",Actual,2021-02-16,May 2021,2021-05-31,"February 1, 2022",Anticipated,2022-02-01,"January 1, 2022",Anticipated,2022-01-01,12 Weeks,Observational [Patient Registry],NA,,Evaluation of Physical and Functional Status in Patients With COVID-19 in Long Term,"Evaluation of Exercise Capacity, Peripheral Muscle Strength, Balance, Cognitive Status and Quality of Life in Patients With COVID-19 in Long Term","Active, not recruiting",NA,NA,40,Anticipated,Hacettepe University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:14:44Z,2021-10-17T07:14:44Z,15584967,NCT04836767,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-28,NA,NA,2021-03-31,2021-03-31,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"February 24, 2021",Actual,2021-02-24,March 2021,2021-03-31,"September 2, 2021",Anticipated,2021-09-02,"July 8, 2021",Anticipated,2021-07-08,NA,Interventional,SPIDEX-II,,Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19,Spironolactone and Dexamethasone in Patients Hospitalized With Moderate-to-severe COVID-19 (SPIDEX-II): a Randomized Clinical Trial,Recruiting,NA,Phase 3,440,Anticipated,Chita State Regional Clinical Hospital Number 1,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Sharing IPD would require material transfer agreement according to the local rules and regulations. The study protocol, statistical analysis plan, and the translated version of the informed consent form can be shared upon request.",2021-10-17T07:16:10Z,2021-10-17T07:16:10Z,15586185,NCT04826822,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-27,NA,NA,2021-04-04,2021-03-31,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-04,2021-04-06,Actual,"April 1, 2021",Actual,2021-04-01,April 2021,2021-04-30,July 2021,Anticipated,2021-07-31,June 2021,Anticipated,2021-06-30,NA,Observational,NA,,Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients,"Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients, A Prospective Observational Study",Recruiting,NA,NA,100,Anticipated,Diskapi Yildirim Beyazit Education and Research Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will be available for the 6 months after initial publication.,The information mentioned above will be shared upon contact with the corresponding author. The criteria for data sharing would be that the researchers making the request would preferably seek a similar goal in the study proposal.,NA,Yes,"The study protocol will be shared with other researchers working on a similar process, with proper credentials and acknowledgments given according to ICJME clinical trial registration policy. Signed Informed Consent Forms will only be shared with proper legal bodies and ethical committees in case of an ethical dilemma.",2021-10-17T07:16:11Z,2021-10-17T07:16:11Z,15586197,NCT04826731,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-30,NA,NA,2021-04-01,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-05,Actual,"March 1, 2021",Actual,2021-03-01,April 2021,2021-04-30,"June 1, 2021",Anticipated,2021-06-01,"May 30, 2021",Anticipated,2021-05-30,NA,Observational,NA,,Incidence of Infection and Mortality by COVID-19 in Specialists,Incidence of Infection and Mortality by COVID-19 in Specialists in Mexico: A Cross-sectional Study,Recruiting,NA,NA,400,Anticipated,Instituto Mexicano del Seguro Social,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:15:59Z,2021-10-17T07:15:59Z,15586013,NCT04828148,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-29,NA,NA,2021-06-23,2021-03-29,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-24,Actual,"March 29, 2021",Actual,2021-03-29,June 2021,2021-06-30,"March 29, 2023",Anticipated,2023-03-29,"March 29, 2023",Anticipated,2023-03-29,NA,Interventional,NA,,Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19,Exercise Therapy in Cancer Patients Hospitalized for COVID-19: A Digitized Clinical Trial,Recruiting,NA,Phase 1,20,Anticipated,Memorial Sloan Kettering Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-10-17T07:16:30Z,2021-10-17T07:16:30Z,15586512,NCT04824443,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-24,NA,NA,2021-05-21,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"May 21, 2021",Actual,2021-05-21,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients,Adaptive Photo-Protection Trial: To Demonstrate the Safety and Efficacy of NB-UVB Light Therapy to Improve Outcomes in Hospitalized High-risk Patients With COVID-19,Recruiting,NA,N/A,30,Anticipated,"Cytokind, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:17:20Z,2021-10-17T07:17:20Z,15587237,NCT04818970,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-23,NA,NA,2021-06-28,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-07-01,Actual,"April 1, 2021",Actual,2021-04-01,June 2021,2021-06-30,"August 30, 2021",Anticipated,2021-08-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,NA,,Prospective Electroencephalography Evaluation of Sedation in COVID-19,Prospective Evaluation of Aggravated Sedation in COVID-19 ARDS Patients Using Electroencephalography,Recruiting,NA,NA,50,Anticipated,Goethe University,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"The datasets generated and/or analyzed during the current study are not publicly available due to national data protection laws. Upon justified request, the data will be accessible at the primary investigator.",2021-10-17T07:17:54Z,2021-10-17T07:17:54Z,15587712,NCT04815109,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-10,NA,NA,2021-08-23,2021-03-12,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"March 20, 2021",Actual,2021-03-20,August 2021,2021-08-31,"March 1, 2023",Anticipated,2023-03-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,TXCoronavac,,"Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients","Prospective Study in a Single Center to Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients","Active, not recruiting",NA,Phase 4,3371,Actual,Hospital do Rim e HipertensÃ£o,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:19:46Z,2021-10-17T07:19:46Z,15589399,NCT04801667,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-10,NA,NA,2021-06-28,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"June 11, 2021",Actual,2021-06-11,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,CimetrA,,Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19,"A Phase III, Double-blind , Controlled Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19",Recruiting,NA,Phase 3,252,Anticipated,MGC Pharmaceuticals d.o.o,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:19:39Z,2021-10-17T07:19:39Z,15589317,NCT04802382,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-15,NA,NA,2021-10-04,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Actual,"April 1, 2021",Actual,2021-04-01,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,A Study of Intranasal ChAdOx1 nCOV-19,"A Phase I Study to Determine Safety, Tolerability and Immunogenicity of Intranasal Administration of the COVID Vaccine ChAdOx1 nCOV-19 in Healthy UK Adults",Recruiting,NA,Phase 1,54,Anticipated,University of Oxford,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:17:46Z,2021-10-17T07:17:46Z,15587590,NCT04816019,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-12,NA,NA,2021-03-12,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"January 15, 2021",Actual,2021-01-15,March 2021,2021-03-31,"February 15, 2021",Actual,2021-02-15,"February 15, 2021",Actual,2021-02-15,NA,Observational,NA,,Does Coronavirus Disease 2019 (COVID-19) Pandemic Cause a Delay in the Diagnosis of Gastric Cancer Patients?,Does Coronavirus Disease 2019 (COVID-19) Pandemic Cause a Delay in the Diagnosis of Gastric Cancer Patients?,Completed,NA,NA,146,Actual,Adana City Training and Research Hospital,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:20:21Z,2021-10-17T07:20:21Z,15589925,NCT04797624,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2021-03-15,2021-03-11,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-18,Actual,"April 20, 2020",Actual,2020-04-20,March 2021,2021-03-31,"August 31, 2026",Anticipated,2026-08-31,"December 31, 2025",Anticipated,2025-12-31,NA,Observational,KidneyCOVID19,,Kidney in Coronavirus Disease 2019 Registry,Kidney in Coronavirus Disease 2019 Registry,Recruiting,NA,NA,500,Anticipated,University of Cologne,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:20:26Z,2021-10-17T07:20:26Z,15589986,NCT04797091,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-01,NA,NA,2021-09-30,2021-03-10,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"April 5, 2021",Actual,2021-04-05,April 2021,2021-04-30,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patient,Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patients: a Feasibility Study,Recruiting,NA,N/A,32,Anticipated,Universidad San Jorge,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:20:54Z,2021-10-17T07:20:54Z,15590365,NCT04794036,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-02,NA,NA,2021-07-26,2021-03-02,2021-03-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"January 1, 2021",Actual,2021-01-01,July 2021,2021-07-31,"May 13, 2021",Actual,2021-05-13,"April 13, 2021",Actual,2021-04-13,NA,Observational,NA,,COVID-19 Infections and Mortality in Long-term Care Facilities During the First Wave,COVID-19 Infections and Mortality in Montreal Long-term Care Facilities During the First Wave: a Retrospective Cohort Study,Completed,NA,NA,1197,Actual,Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'ÃŽle-de-MontrÃ©al,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"At the time of publication, for 5 years.",Written request submitted to the principal investigator.,NA,Yes,"All deidentified information will be shared, except if there are patient confidentiality issues.",2021-10-17T07:22:34Z,2021-10-17T07:22:34Z,15591810,NCT04782427,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-07,NA,NA,2021-03-09,2021-03-09,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-10,Actual,"March 9, 2021",Actual,2021-03-09,March 2021,2021-03-31,November 2021,Anticipated,2021-11-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients,Effect of N-acetylcysteine on Oxidative Stress And Occurrence of Complications in Patients With COVID 19 Infections,Recruiting,NA,Phase 3,60,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:21:12Z,2021-10-17T07:21:12Z,15590627,NCT04792021,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-07,NA,NA,2021-03-07,2021-03-07,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-07,2021-03-09,Actual,"March 4, 2021",Actual,2021-03-04,March 2021,2021-03-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,ROCCO,,Registry of Coronavirus Complications - CORRELATION WITH GLYCOMIC PROFILE,ROCCO - Registry of Coronavirus Complications. Prospective Observational Study on Coronavirus Complications and Correlation With Glycomic Profile,Recruiting,NA,NA,615,Anticipated,Papa Giovanni XXIII Hospital,,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      plasma samples
    ",NA,NA,NA,No,NA,2021-10-17T07:21:42Z,2021-10-17T07:21:42Z,15591090,NCT04788433,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-07,NA,NA,2021-03-14,2021-03-07,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-14,2021-03-16,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,RIHCC,,Renal Involvement in Hospitalized Children With COVID-19,Renal Involvement in Hospitalized Children With COVID-19,Recruiting,NA,NA,500,Anticipated,Hamad Medical Corporation,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:21:42Z,2021-10-17T07:21:42Z,15591098,NCT04788394,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-15,NA,NA,2021-07-05,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-07,Actual,"February 1, 2021",Actual,2021-02-01,July 2021,2021-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,,Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients,MP3-pulses-COVID-19. Methylprednisolone Pulses Versus Dexamethasone According RECOVERY Protocol in Patients With Pneumonia Due to SARS-COV-2 Coronavirus Infection,Recruiting,NA,Phase 4,290,Anticipated,FundaciÃ³n Instituto de Estudios de Ciencias de la Salud de Castilla y LeÃ³n,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:22:50Z,2021-10-17T07:22:50Z,15592064,NCT04780581,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-26,NA,NA,2021-08-02,2021-02-26,2021-03-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"July 27, 2021",Actual,2021-07-27,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,,Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19,"Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients With Respiratory Distress Due to COVID-19 Infection",Recruiting,NA,Phase 2,184,Anticipated,"US Biotest, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:23:11Z,2021-10-17T07:23:11Z,15592361,NCT04778059,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-15,NA,NA,2021-02-23,2021-02-23,2021-02-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"November 4, 2020",Actual,2020-11-04,February 2021,2021-02-28,September 2023,Anticipated,2023-09-30,March 2021,Anticipated,2021-03-31,NA,Observational,SUEP-NAPKON,,Intersectoral Platform (SÃœP) of the National Pandemic Cohort Network (NAPKON),Intersectoral Platform (SÃœP) of the National Pandemic Cohort Network (NAPKON),Recruiting,NA,NA,6550,Anticipated,Goethe University,,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood, respiratory samples (nose and throat swab, endotracheal aspirate, nasopharyngeal
      aspirate), urine
    ",NA,NA,NA,No,Please see use and access conditions according to www.napkon.de,2021-10-17T07:24:29Z,2021-10-17T07:24:29Z,15593589,NCT04768998,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-24,NA,NA,2021-07-23,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-27,Actual,"July 14, 2021",Actual,2021-07-14,July 2021,2021-07-31,June 2023,Anticipated,2023-06-30,December 2022,Anticipated,2022-12-31,NA,Interventional,COVFIS-HOME,,COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications,COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients,Enrolling by invitation,NA,Phase 2,150,Anticipated,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:24:07Z,2021-10-17T07:24:07Z,15593219,NCT04771611,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-17,NA,NA,2021-03-01,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"February 1, 2021",Actual,2021-02-01,March 2021,2021-03-31,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,NA,Observational,MS COVID-19,,A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,An Open-label Observation Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,Recruiting,NA,NA,1400,Anticipated,"University Hospital, Basel, Switzerland",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:25:41Z,2021-10-17T07:25:41Z,15594617,NCT04760990,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-18,NA,NA,2021-04-21,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"March 3, 2021",Actual,2021-03-03,February 2021,2021-02-28,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,COPreDex,,"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19","Comparison Between Prednisolone and Dexamethasone on D28 Mortality in Patients on Oxygen Therapy, With CoViD-19: Multicenter, Randomized, Open-label Non-inferiority Study",Recruiting,NA,Phase 3,220,Anticipated,Centre Hospitalier RenÃ© Dubos,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:25:02Z,2021-10-17T07:25:02Z,15594033,NCT04765371,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-19,NA,NA,2021-02-19,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-19,2021-02-21,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"March 31, 2021",Anticipated,2021-03-31,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,COVID-19,,Persistence of Symptoms After Improvement of Acute COVID-19,"Persistence of Symptoms After Improvement of Acute COVID19 Infection in Sohag Governorate, Egypt, A Longitudinal Study",Recruiting,NA,NA,250,Anticipated,Sohag University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:25:07Z,2021-10-17T07:25:07Z,15594104,NCT04764773,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-12,NA,NA,2021-03-14,2021-02-12,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-14,2021-03-16,Actual,"May 1, 2020",Actual,2020-05-01,March 2021,2021-03-31,"April 30, 2021",Anticipated,2021-04-30,"March 30, 2021",Anticipated,2021-03-30,NA,Observational,NA,,Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?,Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019 (COVID-19)?,Recruiting,NA,NA,1150,Anticipated,Zagazig University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After publication,by contacting the principal investigator,NA,Yes,After publication,2021-10-17T07:26:18Z,2021-10-17T07:26:18Z,15595095,NCT04757272,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-15,NA,NA,2021-02-16,2021-02-15,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-18,Actual,"March 13, 2020",Actual,2020-03-13,February 2021,2021-02-28,"July 10, 2020",Actual,2020-07-10,"July 10, 2020",Actual,2020-07-10,28 Days,Observational [Patient Registry],NA,,Clinical Characteristics and In-hospital Death of a Chilean COVID-19 Prospective Cohort,Clinical Characteristics and In-hospital Death During the First 100 Days of the COVID-19 Pandemic in Chile: A Prospective Cohort Study From a University Hospital,Completed,NA,NA,395,Actual,University of Chile,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Anonymized data will be shared upon request,2021-10-17T07:26:11Z,2021-10-17T07:26:11Z,15595014,NCT04758039,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-06,NA,NA,2021-02-13,2021-02-13,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-13,2021-02-16,Actual,"January 29, 2021",Actual,2021-01-29,February 2021,2021-02-28,"August 29, 2021",Anticipated,2021-08-29,"July 29, 2021",Anticipated,2021-07-29,NA,Interventional,NA,,Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2,Mucolytic Agents and Ventilator-associated Pneumonia in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2,Recruiting,NA,N/A,40,Anticipated,"Clinical Hospital Center, Split",,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:26:28Z,2021-10-17T07:26:28Z,15595234,NCT04755972,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-02,NA,NA,2021-04-23,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-27,Actual,"April 20, 2021",Actual,2021-04-20,April 2021,2021-04-30,December 2022,Anticipated,2022-12-31,March 2022,Anticipated,2022-03-31,NA,Interventional,AX-COVID,,Annexin A5 in Patients With Severe COVID-19 Disease,"Annexin A5 in Patients With Severe COVID-19 Disease: A Single Centre, Randomized, Double-blind, Placebo-controlled Pilot Trial",Recruiting,NA,Phase 2,60,Anticipated,Lawson Health Research Institute,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,To be evaluated on individual basis,NA,NA,Yes,Information and data sharing will be considered on individual basis at conclusion of the study.,2021-10-17T07:27:34Z,2021-10-17T07:27:34Z,15596162,NCT04748757,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-20,NA,NA,2021-02-09,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"November 6, 2020",Actual,2020-11-06,February 2021,2021-02-28,"November 30, 2025",Anticipated,2025-11-30,"November 1, 2025",Anticipated,2025-11-01,36 Months,Observational [Patient Registry],NA,,"Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity","National Pandemic Cohort Network - High-resolution Platform (HAP) Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity",Recruiting,NA,NA,750,Anticipated,"Charite University, Berlin, Germany",,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Saliva, Urin, Oropharyngeal / Nasopharyngeal swab / Bronchoalveolar lavage (BAL) /
      Endotracheal aspirate (ENTA), whole blood
    ",NA,NA,NA,No,"Given a concrete inquiry and prior consent by the study participants in question, IPD (individual participant data) can be made available on a case by case basis.",2021-10-17T07:27:46Z,2021-10-17T07:27:46Z,15596374,NCT04747366,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-03,NA,NA,2021-09-28,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-05,Actual,"May 25, 2021",Actual,2021-05-25,September 2021,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Prothioneâ„¢ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19),"A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Prothioneâ„¢ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,231,Actual,"Prothione, LLC",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:28:25Z,2021-10-17T07:28:25Z,15596985,NCT04742725,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-01,NA,NA,2021-02-02,2021-02-01,2021-02-03,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-04,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,NA,,Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19,Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19,Recruiting,NA,NA,90,Anticipated,Ain Shams University,,NA,6,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:29:22Z,2021-10-17T07:29:22Z,15597718,NCT04736901,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-01,NA,NA,2021-02-03,2021-02-02,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-05,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,NA,,Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients,Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients,Recruiting,NA,NA,150,Anticipated,Ain Shams University,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:29:01Z,2021-10-17T07:29:01Z,15597483,NCT04738760,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-05,NA,NA,2021-02-05,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-08,Actual,"January 26, 2021",Actual,2021-01-26,February 2021,2021-02-28,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,Steam-COVID,,Steam Inhalations in COVID-19 Patients,Steam Inhalations in Asymptomatic and Paucisymptomatic COVID-19 Patients,Recruiting,NA,N/A,200,Anticipated,Meyer Children's Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:28:19Z,2021-10-17T07:28:19Z,15596903,NCT04743349,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-03,NA,NA,2021-02-03,2021-02-03,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"July 1, 2021",Anticipated,2021-07-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,NA,,New Immune-inflammation Index for Predicting Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection,New Immune-inflammation Index for Predicting Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection,Recruiting,NA,NA,50,Anticipated,Ain Shams University,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:28:56Z,2021-10-17T07:28:56Z,15597410,NCT04739345,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-28,NA,NA,2021-10-05,2021-01-29,2021-02-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-07,Actual,"January 12, 2021",Actual,2021-01-12,January 2021,2021-01-31,"November 30, 2021",Anticipated,2021-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,SPRINTER,,Study to Assess Efficacy and Safety of Inhaled Interferon-Î² Therapy for COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19",Recruiting,NA,Phase 3,610,Anticipated,Synairgen Research Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:29:57Z,2021-10-17T07:29:57Z,15598175,NCT04732949,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-31,NA,NA,2021-02-01,2021-02-01,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"March 1, 2021",Anticipated,2021-03-01,NA,Observational,NA,,Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome,Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome,Recruiting,NA,NA,84,Anticipated,Ain Shams University,,NA,2,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:29:42Z,2021-10-17T07:29:42Z,15597965,NCT04734678,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-15,NA,NA,2021-01-26,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"January 8, 2021",Actual,2021-01-08,January 2021,2021-01-31,October 2022,Anticipated,2022-10-31,October 2022,Anticipated,2022-10-31,NA,Interventional,NA,,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Recruiting,NA,N/A,5350,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:30:57Z,2021-10-17T07:30:57Z,15598980,NCT04726371,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-25,NA,NA,2021-01-28,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"August 25, 2020",Actual,2020-08-25,January 2021,2021-01-31,"March 31, 2022",Anticipated,2022-03-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,,Evaluation of a Synbiotic Formula in Patient With COVID-19,Evaluation of a Synbiotic Formula in Patient With COVID-19,Recruiting,NA,N/A,20,Anticipated,Chinese University of Hong Kong,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:30:23Z,2021-10-17T07:30:23Z,15598524,NCT04730284,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-26,NA,NA,2021-08-02,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"January 22, 2021",Actual,2021-01-22,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,September 2021,Anticipated,2021-09-30,NA,Observational,NA,,"MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey","Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey",Recruiting,NA,NA,1500,Anticipated,HealthTree Foundation,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,Visit the HealthTree Foundation's online patient portal: HealthTree Cure Hub For Multiple Myeloma,http://healthtree.org,Yes,"The HealthTree foundation values responsible and ethical sharing of data from clinical trials. De-identified patient responses to the questionnaire will be aggregated and shared back with the patient. Additionally, portions of the de-identified results will be shared with the research community through publications (abstracts, reports, manuscripts).",2021-10-17T07:30:49Z,2021-10-17T07:30:49Z,15598866,NCT04727294,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-05,NA,NA,2021-04-21,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-23,Actual,"April 20, 2021",Anticipated,2021-04-20,September 2020,2020-09-30,"January 1, 2022",Anticipated,2022-01-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,COVID-19,,Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva,Efficacy of Three Antimicrobial Mouthwashes in Reducing SARS-CoV-2 Viral Load in the Saliva of Patients Diagnosed With COVID-19: A Pilot Study,Recruiting,NA,N/A,40,Anticipated,Queen Mary University of London,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Aggregated/collective data regarding the efficacy of the different mouthwashes will be shared with the scientific community as a de-identified/coded information,2021-10-17T07:31:23Z,2021-10-17T07:31:23Z,15599369,NCT04723446,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-21,NA,NA,2021-08-27,2021-01-25,2021-01-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"July 1, 2020",Actual,2020-07-01,August 2021,2021-08-31,"December 15, 2020",Actual,2020-12-15,"December 15, 2020",Actual,2020-12-15,NA,Observational,SONIC-19,,Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome,Comparison of Non-invasive Oxygenation Strategies in ICU Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome,Completed,NA,NA,300,Actual,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:31:08Z,2021-10-17T07:31:08Z,15599151,NCT04725084,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-13,NA,NA,2021-01-22,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"September 25, 2020",Actual,2020-09-25,January 2021,2021-01-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay,Completed,NA,N/A,101,Actual,Lucira Health Inc,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:31:45Z,2021-10-17T07:31:45Z,15599710,NCT04720794,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-06,NA,NA,2021-01-13,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-14,Actual,"December 23, 2020",Actual,2020-12-23,January 2021,2021-01-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Observational,CoVEHPI,,Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI),Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI): A Prospective Cohort Study,Recruiting,NA,NA,4504,Anticipated,Clalit Health Services,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:33:30Z,2021-10-17T07:33:30Z,15601169,NCT04709003,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-15,NA,NA,2021-04-09,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,"December 9, 2020",Actual,2020-12-09,January 2021,2021-01-31,"March 30, 2021",Actual,2021-03-30,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay Among Asymptomatic Subjects,Completed,NA,N/A,304,Actual,Lucira Health Inc,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:31:50Z,2021-10-17T07:31:50Z,15599769,NCT04720235,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-14,NA,NA,2021-08-25,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"July 16, 2020",Actual,2020-07-16,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa Due to SARS-CoV2 (TSUNAMI Study): a Multicenter Open Label Randomized Control Trial,Completed,NA,N/A,474,Actual,Istituto Superiore di SanitÃ ,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:32:26Z,2021-10-17T07:32:26Z,15600220,NCT04716556,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-29,NA,NA,2021-01-12,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"November 26, 2020",Actual,2020-11-26,January 2021,2021-01-31,"December 1, 2023",Anticipated,2023-12-01,"December 1, 2023",Anticipated,2023-12-01,NA,Interventional,SeroCOV,,Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Protocol for the Collection of Clinical Samples for Evaluation and Implementation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Recruiting,NA,N/A,385,Anticipated,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:33:40Z,2021-10-17T07:33:40Z,15601337,NCT04707833,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-20,NA,NA,2021-04-30,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-06,Actual,"June 22, 2020",Actual,2020-06-22,April 2021,2021-04-30,"October 11, 2020",Actual,2020-10-11,"October 11, 2020",Actual,2020-10-11,NA,Observational,NA,,Migrant Workers' Responses to the COVID-19 Pandemic,Responses of International Migrant Workers to Large-Scale Dormitory Outbreaks of COVID-19: A Population Survey,Completed,NA,NA,1011,Actual,Yale-NUS College,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Due to stipulations by the Institutional Review Board, data cannot be shared.",2021-10-17T07:32:08Z,2021-10-17T07:32:08Z,15599983,NCT04718519,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-16,NA,NA,2021-03-15,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-18,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,1 Year,Observational [Patient Registry],KIDCOV,,KIDney Injury in Times of COVID-19 (KIDCOV),The KIDCOV Study: ASSESSMENT of SARS-CoV-2 Without HOSPITALIZATION as a RISK FACTOR for ACUTE KIDNEY INJURY,Recruiting,NA,NA,2000,Anticipated,"University of California, San Francisco",,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Participation will involve completion of questionnaires with return of urine samples in
      mailed collection kits at 2, 6, and 12 months after their date of PCR test.
    ",NA,NA,NA,No,"Research records will be kept confidential to the extent permitted by law. Subjects will be identified by a code, and personal information from study records will not be released without the subject's permission. Study subjects will not be identified in any publication that may result from this study. However, the records may be reviewed under guidelines of the Federal Privacy Act by site monitors to assure the accuracy and completeness of study data. The investigators will make sure patient health information is removed from all the bio-samples and data obtained. The investigators will adhere to the NIH and HHS policies regarding the sharing of data and resources with the scientific community, publications, and intellectual property rights, and sharing of biomedical research resources.",2021-10-17T07:33:59Z,2021-10-17T07:33:59Z,15601628,NCT04705766,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-31,NA,NA,2021-01-11,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"November 14, 2020",Actual,2020-11-14,January 2021,2021-01-31,"January 15, 2021",Anticipated,2021-01-15,"January 15, 2021",Anticipated,2021-01-15,NA,Interventional,NA,,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),"Active, not recruiting",NA,Phase 1,50,Actual,Quantinosis.ai LLC,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"We will publish based on summary data, but make individual participant data available upon request. There are no plans to publish individual participant data.",2021-10-17T07:33:54Z,2021-10-17T07:33:54Z,15601537,NCT04706416,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-29,NA,NA,2021-01-12,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"April 16, 2020",Actual,2020-04-16,December 2020,2020-12-31,"June 10, 2021",Anticipated,2021-06-10,"June 10, 2021",Anticipated,2021-06-10,NA,Interventional,ImmuCoV,,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Recruiting,NA,N/A,80,Anticipated,"University Hospital, Rouen",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:33:40Z,2021-10-17T07:33:40Z,15601341,NCT04707820,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-08,NA,NA,2021-05-12,2021-01-11,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-13,Actual,"March 16, 2021",Actual,2021-03-16,May 2021,2021-05-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,Isavu-CAPA,,Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis,Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients,Recruiting,NA,Phase 3,162,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:33:41Z,2021-10-17T07:33:41Z,15601358,NCT04707703,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-24,NA,NA,2021-05-20,2020-12-25,2020-12-29,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-24,Actual,"November 15, 2020",Actual,2020-11-15,May 2021,2021-05-31,"November 15, 2021",Anticipated,2021-11-15,"November 15, 2021",Anticipated,2021-11-15,NA,Interventional,NA,,Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients,Efficacy of Inhaled Nitroglycerin in Moderate to Severe Cases of COVID-19 Patients,Recruiting,NA,N/A,30,Anticipated,University of Lahore,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:36:43Z,2021-10-17T07:36:43Z,15604153,NCT04686760,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-07,NA,NA,2021-01-08,2021-01-08,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"January 4, 2021",Actual,2021-01-04,January 2021,2021-01-31,"January 3, 2023",Anticipated,2023-01-03,"January 3, 2023",Anticipated,2023-01-03,NA,Observational,periCOVID,,Understanding COVID-19 Infection in Pregnant Women and Their Babies,Understanding COVID-19 Infection in Pregnant Women and Their Babies,Recruiting,NA,NA,1200,Anticipated,"St George's, University of London",,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:34:20Z,2021-10-17T07:34:20Z,15601967,NCT04703270,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-29,NA,NA,2021-01-26,2021-01-04,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-29,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,August 2021,Anticipated,2021-08-31,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,NA,,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Recruiting,NA,N/A,50,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,when to published,NA,NA,Yes,all IPD that underlie results in a publication,2021-10-17T07:35:32Z,2021-10-17T07:35:32Z,15603041,NCT04695301,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-19,NA,NA,2020-12-30,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"July 23, 2020",Actual,2020-07-23,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"December 10, 2020",Actual,2020-12-10,NA,Interventional,NA,,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach,Completed,NA,N/A,200,Actual,University of Lahore,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,"statistical analysis, results",2021-10-17T07:36:08Z,2021-10-17T07:36:08Z,15603636,NCT04690920,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-30,NA,NA,2021-09-30,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"February 11, 2021",Actual,2021-02-11,"September 27, 2021",2021-09-27,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,NA,Observational,NA,,Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases,The Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases; An Observational Prospective Study,Recruiting,NA,NA,350,Anticipated,National Institutes of Health Clinical Center (CC),,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:36:09Z,2021-10-17T07:36:09Z,15603647,NCT04690816,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-17,NA,NA,2021-05-03,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-04,Actual,"January 8, 2021",Actual,2021-01-08,May 2021,2021-05-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,RES-Q-HR,,Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Recruiting,NA,Phase 2,1094,Anticipated,"Heinrich-Heine University, Duesseldorf",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:37:30Z,2021-10-17T07:37:30Z,15604803,NCT04681430,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-22,NA,NA,2020-12-24,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-28,Actual,"November 2, 2020",Actual,2020-11-02,December 2020,2020-12-31,"January 10, 2021",Anticipated,2021-01-10,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,,Role of Mega Dose of Vitamin C in Critical COVID-19 Patients,Efficacy of Mega Dose Vitamin C in Critically Ill COVID-19 Patients,Recruiting,NA,N/A,15,Anticipated,University of Lahore,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:37:20Z,2021-10-17T07:37:20Z,15604666,NCT04682574,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-16,NA,NA,2021-10-01,2020-12-16,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"March 30, 2021",Actual,2021-03-30,May 2021,2021-05-31,"July 28, 2022",Anticipated,2022-07-28,"July 28, 2022",Anticipated,2022-07-28,NA,Interventional,NA,,Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients,"A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 3,300,Anticipated,"Shenyang Tonglian Group CO., Ltd",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:38:51Z,2021-10-17T07:38:51Z,15606011,NCT04672564,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-17,NA,NA,2021-04-27,2020-12-17,2020-12-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"March 1, 2020",Actual,2020-03-01,April 2021,2021-04-30,"July 31, 2021",Anticipated,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,NA,Observational,NA,,Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients,Utility of Empiric Antibiotics on Admission for Non-intubated Patients With Novel Coronavirus Diseases 2019 (COVID-19): A Retrospective Cohort Study of Electronic Health Records,"Active, not recruiting",NA,NA,100000,Anticipated,National Institutes of Health Clinical Center (CC),,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:38:34Z,2021-10-17T07:38:34Z,15605744,NCT04674410,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-14,NA,NA,2021-07-30,2020-12-18,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,"July 8, 2021",Actual,2021-07-08,"June 5, 2021",Actual,2021-06-05,NA,Interventional,NA,,COVID-19 Long-Haulers Study,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]",Completed,NA,Phase 2,56,Actual,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:37:54Z,2021-10-17T07:37:54Z,15605129,NCT04678830,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-12,NA,NA,2021-02-01,2020-12-19,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"March 1, 2021",Anticipated,2021-03-01,December 2020,2020-12-31,"August 1, 2021",Anticipated,2021-08-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Recruiting,NA,N/A,40,Anticipated,European University of Madrid,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:37:55Z,2021-10-17T07:37:55Z,15605139,NCT04678700,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-16,NA,NA,2021-02-17,2020-12-16,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"February 8, 2021",Actual,2021-02-08,January 2021,2021-01-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,Community Collaboration to Combat COVID-19 (C-FORWARD),Community Collaboration to Combat COVID-19,Enrolling by invitation,NA,N/A,3000,Anticipated,Johns Hopkins University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:38:44Z,2021-10-17T07:38:44Z,15605904,NCT04673292,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-25,NA,NA,2021-03-26,2020-12-10,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-03-29,Actual,"January 7, 2021",Actual,2021-01-07,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,NA,,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,"A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants","Active, not recruiting",NA,Phase 2,600,Anticipated,"Arcturus Therapeutics, Inc.",,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-10-17T07:39:27Z,2021-10-17T07:39:27Z,15606541,NCT04668339,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-13,NA,NA,2021-08-23,2020-12-16,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"December 2, 2020",Actual,2020-12-02,August 2021,2021-08-31,"August 20, 2021",Actual,2021-08-20,"August 20, 2021",Actual,2021-08-20,1 Day,Observational [Patient Registry],NA,,Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina,"Long-term Persistence of Immunoglobulin G Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Vulnerable Neighbourhood in Buenos Aires, Argentina",Completed,NA,NA,189,Actual,Hospital Italiano de Buenos Aires,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      blod samples for antibodies detection against dengue
    ",NA,NA,NA,Undecided,NA,2021-10-17T07:38:44Z,2021-10-17T07:38:44Z,15605905,NCT04673279,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-09,NA,NA,2021-05-09,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"March 29, 2021",Actual,2021-03-29,May 2021,2021-05-31,"May 1, 2021",Actual,2021-05-01,"April 25, 2021",Actual,2021-04-25,NA,Observational,IC-COVID-19,,Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2,Expert Statements on Infection Control in Intensive Care Unit for Severe Acute Respiratory Syndrome Coronavirus 2,Completed,NA,NA,35,Actual,NMC Specialty Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:39:48Z,2021-10-17T07:39:48Z,15606871,NCT04665960,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-02,NA,NA,2021-07-26,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"January 1, 2021",Actual,2021-01-01,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,CX4945,,Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19),"Phase II, Randomized, Investigator Initiated Trial to Evaluate Safety and to Explore Clinical Benefit of Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,40,Anticipated,University of Arizona,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Study results will be published on clinicaltrials.gov.,2021-10-17T07:39:29Z,2021-10-17T07:39:29Z,15606553,NCT04668209,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-11,NA,NA,2021-04-10,2020-12-13,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-04-10,2021-04-13,Actual,"May 22, 2020",Actual,2020-05-22,April 2021,2021-04-30,"January 25, 2021",Actual,2021-01-25,"January 25, 2021",Actual,2021-01-25,NA,Observational,CATCOVID-AIR,,Noninvasive Respiratory Support in COVID-19 (CATCOVID-AIR),Noninvasive Respiratory Support Outside the Intensive Care Unit in COVID-19 Pneumonia: a Multicentric Study (CATCOVID-AIR),Completed,NA,NA,367,Actual,Hospital Universitari Vall d'Hebron Research Institute,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:39:29Z,2021-10-17T07:39:29Z,15606555,NCT04668196,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-06,NA,NA,2021-03-12,2020-12-06,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"December 8, 2020",Actual,2020-12-08,December 2020,2020-12-31,"March 8, 2021",Actual,2021-03-08,"March 8, 2021",Actual,2021-03-08,NA,Interventional,NA,,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Hospitalization or Outpatient ManagEment of Patients With Suspected or Confirmed SRAS-CoV-2 Infection: the Revised HOME-CoV Score Study.,Completed,NA,N/A,1300,Actual,"University Hospital, Angers",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:41:02Z,2021-10-17T07:41:02Z,15608042,NCT04657471,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-01,NA,NA,2020-12-08,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"September 24, 2020",Actual,2020-09-24,December 2020,2020-12-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Adolescents With COVID-19/MIS-C at HCFMUSP,Prospective Studies in School-aged Children and Adolescents With COVID-19 Treated at HCFMUSP,Enrolling by invitation,NA,N/A,100,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:40:43Z,2021-10-17T07:40:43Z,15607773,NCT04659486,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-08,NA,NA,2021-03-19,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-19,2021-03-23,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"July 14, 2021",Anticipated,2021-07-14,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,NOSOCOVID,,NOSOcomial COVID-19 in ICU (NOSOCOVID),"Evaluation of a SARS-CoV-2 Infectious Risk Management Protocol on the Transmission of Nosocomial COVID in Intensive Care Unit""",Recruiting,NA,NA,600,Anticipated,Nantes University Hospital,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:40:44Z,2021-10-17T07:40:44Z,15607796,NCT04659356,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-30,NA,NA,2020-12-07,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-07,2020-12-09,Actual,"April 19, 2020",Actual,2020-04-19,December 2020,2020-12-31,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,12 Months,Observational [Patient Registry],NA,,ASCO Survey on COVID-19 in Oncology (ASCO) Registry,ASCO Survey on Coronavirus Disease 2019 (COVID-19) in Oncology (ASCO) Registry,Recruiting,NA,NA,2000,Anticipated,American Society of Clinical Oncology,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Late 2021,"Completion of a satisfactory Research Project Proposal Application, as discussed on the ASCO Data Library website (https://www.asco.org/research-guidelines/center-research-analytics-centra/asco-data-library)",http://www.asco.org/research-guidelines/center-research-analytics-centra/asco-data-library,Yes,"ASCO will make deidentified Registry data available to researchers (both those at Registry sites and those not involved with the Registry) for further analysis. The timing of data release will depend on the number of cases reported to the registry, and entry of the outcome information. ASCO will review requests for Registry data from individuals and entities that submit a research proposal that complies with ASCO's requirements for data access. ASCO will promote access to information for projects that address the needs of patients with cancer, including marginalized populations and communities. ASCO will promote authenticity, quality, reliability and integrity of information and analyses. ASCO will promote fair access and efficiency in the use and sharing of ASCO Information within the bounds of this Policy.",2021-10-17T07:40:46Z,2021-10-17T07:40:46Z,15607828,NCT04659135,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-14,NA,NA,2021-09-23,2020-12-01,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"April 9, 2021",Actual,2021-04-09,April 2021,2021-04-30,"July 31, 2022",Anticipated,2022-07-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,AirFLO2,,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,Recruiting,NA,N/A,50,Anticipated,Duke University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:42:09Z,2021-10-17T07:42:09Z,15609007,NCT04649775,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-02,NA,NA,2020-12-02,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-03,Actual,"May 27, 2020",Actual,2020-05-27,December 2020,2020-12-31,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,NA,Phase 4,54,Actual,Bryn Mawr Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:41:45Z,2021-10-17T07:41:45Z,15608654,NCT04652648,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-30,NA,NA,2021-09-13,2020-12-01,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-16,Actual,"March 1, 2020",Actual,2020-03-01,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2021",Actual,2021-06-30,1 Day,Observational [Patient Registry],NA,,Surfactant Protein Genetic Variants in COVID-19 Infection,Surfactant Protein Genetic Variants in COVID-19 Infection,"Active, not recruiting",NA,NA,300,Actual,Milton S. Hershey Medical Center,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      DNA will be stored for the future studies.
    ",NA,NA,NA,No,De-identified data will be available to other researchers.,2021-10-17T07:42:05Z,2021-10-17T07:42:05Z,15608942,NCT04650191,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-26,NA,NA,2020-12-11,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"December 4, 2020",Anticipated,2020-12-04,December 2020,2020-12-31,"December 30, 2021",Anticipated,2021-12-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,,"Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans","Phase 3 Multi-Site, Randomised, Placebo Controlled, Double Blind, Single Dose Study of TY027 for Early Treatment of COVID-19",Recruiting,NA,Phase 3,1305,Anticipated,Tychan Pte Ltd.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:42:11Z,2021-10-17T07:42:11Z,15609036,NCT04649515,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-13,NA,NA,2021-05-05,2020-11-20,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"November 14, 2020",Actual,2020-11-14,May 2021,2021-05-31,"November 26, 2021",Anticipated,2021-11-26,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,,The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,The Doctors for Coronavirus Prevention Project Thanksgiving /Christmas Messaging Campaign,"Active, not recruiting",NA,N/A,20000000,Anticipated,"National Bureau of Economic Research, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,The pre-analysis plan will be posted publicly. The ability to share IPD will be based on discussions with our partner organization.,2021-10-17T07:42:58Z,2021-10-17T07:42:58Z,15609716,NCT04644328,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-13,NA,NA,2020-11-18,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"August 1, 2020",Actual,2020-08-01,November 2020,2020-11-30,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,30 Days,Observational [Patient Registry],RECIPE,,Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era,Restoring Non-Emergent Cardiovascular Care in the Peri-COVID 19 Era,Recruiting,NA,NA,1000,Anticipated,Pinnacle Health Cardiovascular Institute,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:44:11Z,2021-10-17T07:44:11Z,15610839,NCT04636021,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-23,NA,NA,2021-08-30,2020-11-23,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-02,Actual,"December 10, 2020",Actual,2020-12-10,August 2021,2021-08-31,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,NA,Interventional,NA,,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19),"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ABBV-47D11 and ABBV-2B04 as Monotherapy or Combination Therapy in Adults With COVID-19",Completed,NA,Phase 1,25,Actual,AbbVie,,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:43:00Z,2021-10-17T07:43:00Z,15609777,NCT04644120,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-24,NA,NA,2021-02-07,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-07,2021-02-10,Actual,"October 30, 2020",Actual,2020-10-30,February 2021,2021-02-28,"October 30, 2021",Anticipated,2021-10-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Anakinra in the Management of COVID-19 Infection,Efficacy of Anakinra in the Management of Patients With COVID-19 Infection in Qatar: A Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,80,Anticipated,Hamad Medical Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:43:04Z,2021-10-17T07:43:04Z,15609856,NCT04643678,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-09,NA,NA,2021-03-15,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-18,Actual,"August 29, 2020",Actual,2020-08-29,March 2021,2021-03-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,SAINT-PERU,,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Recruiting,NA,Phase 2,186,Anticipated,Universidad Peruana Cayetano Heredia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:44:12Z,2021-10-17T07:44:12Z,15610850,NCT04635943,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-12,NA,NA,2020-11-13,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-17,Actual,"June 22, 2020",Actual,2020-06-22,November 2020,2020-11-30,"April 22, 2021",Anticipated,2021-04-22,"March 22, 2021",Anticipated,2021-03-22,NA,Observational,EpiSARS2,,Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration,Prevalence and Risk Factors of COVID-19 Infection in the Upper Silesian Agglomeration Population in 2020,Recruiting,NA,NA,6000,Anticipated,Medical University of Silesia,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      5 ml venous blood sample
    ",NA,NA,NA,No,NA,2021-10-17T07:45:33Z,2021-10-17T07:45:33Z,15611942,NCT04627623,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-13,NA,NA,2021-10-01,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"February 22, 2021",Actual,2021-02-22,September 2021,2021-09-30,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,"Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects","Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",Recruiting,NA,Phase 3,308,Anticipated,Rigel Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:45:14Z,2021-10-17T07:45:14Z,15611678,NCT04629703,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-06,NA,NA,2021-07-30,2020-11-17,2020-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"August 5, 2020",Actual,2020-08-05,November 2020,2020-11-30,"December 28, 2021",Anticipated,2021-12-28,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,NA,,Use of Angiotensin-(1-7) in COVID-19,Randomized Clinical Trial Phase I/II for the Use of Angiotensin-(1-7) in the Treatment of Severe Infection by Sars-CoV-2,Recruiting,NA,Phase 1/Phase 2,130,Anticipated,Erasme University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:44:31Z,2021-10-17T07:44:31Z,15611160,NCT04633772,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-10,NA,NA,2021-04-27,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"October 24, 2020",Actual,2020-10-24,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,,"COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)","COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)",Recruiting,NA,NA,3000,Anticipated,"University Hospital, Basel, Switzerland",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Biological material is appropriately stored in a restricted area only accessible to
      authorized personnel. Until completion of the study, the material will be stored in the
      biobank ""SERO-BL-COVID-19"".
    ",NA,NA,NA,NA,NA,2021-10-17T07:45:55Z,2021-10-17T07:45:55Z,15612279,NCT04625257,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-23,NA,NA,2021-01-19,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"November 4, 2020",Actual,2020-11-04,January 2021,2021-01-31,"February 4, 2024",Anticipated,2024-02-04,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,LidoCovid,,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Recruiting,NA,Phase 3,100,Anticipated,"University Hospital, Strasbourg, France",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:48:12Z,2021-10-17T07:48:12Z,15614358,NCT04609865,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-03,NA,NA,2021-04-12,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-14,Actual,"December 18, 2020",Actual,2020-12-18,April 2021,2021-04-30,"December 15, 2021",Anticipated,2021-12-15,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,NA,,A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19",Recruiting,NA,Phase 1,60,Anticipated,"Sironax USA, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:46:20Z,2021-10-17T07:46:20Z,15612703,NCT04622332,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-02,NA,NA,2020-11-02,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"July 10, 2020",Actual,2020-07-10,November 2020,2020-11-30,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Nasal Photodisinfection COVID Proof of Concept Study,Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract,Recruiting,NA,N/A,100,Anticipated,Sunnybrook Health Sciences Centre,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:47:17Z,2021-10-17T07:47:17Z,15613535,NCT04615936,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-29,NA,NA,2021-01-05,2020-10-29,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-05,2021-01-06,Actual,"November 5, 2020",Actual,2020-11-05,January 2021,2021-01-31,"September 24, 2021",Anticipated,2021-09-24,"September 24, 2021",Anticipated,2021-09-24,NA,Observational,CONTACT,,"A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois","EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois: CONTACT",Recruiting,NA,NA,1250,Anticipated,AbbVie,,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,Samples With DNA,"
      Whole blood sample
    ",NA,NA,NA,Undecided,NA,2021-10-17T07:47:59Z,2021-10-17T07:47:59Z,15614166,NCT04611230,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-06,NA,NA,2021-02-08,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"December 20, 2020",Actual,2020-12-20,February 2021,2021-02-28,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,NA,Interventional,NA,,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,"A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting",Completed,NA,Phase 4,3,Actual,"St. Francis Hospital, New York",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:46:29Z,2021-10-17T07:46:29Z,15612825,NCT04621461,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-03,NA,NA,2020-11-05,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-06,Actual,"July 27, 2020",Actual,2020-07-27,November 2020,2020-11-30,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,1 Year,Observational [Patient Registry],RE-CoV-ERY,,Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome Caused by COVID-19,Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-CoV-2 (COVID-19),Recruiting,NA,NA,100,Anticipated,"University Hospital, Toulouse",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:46:47Z,2021-10-17T07:46:47Z,15613092,NCT04619368,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-24,NA,NA,2021-01-13,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-14,Actual,"October 27, 2020",Actual,2020-10-27,January 2021,2021-01-31,"July 15, 2021",Anticipated,2021-07-15,"March 15, 2021",Anticipated,2021-03-15,NA,Interventional,Nano-COVID19,,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Two Phases Clinical Trial to Evaluate Safety and Efficacy of Methotrexate Associated to LDL Like Nanoparticles (LDE-MTX) in the Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease.,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,University of Sao Paulo General Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:48:05Z,2021-10-17T07:48:05Z,15614283,NCT04610567,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-27,NA,NA,2021-02-03,2020-10-27,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"October 8, 2020",Actual,2020-10-08,February 2021,2021-02-28,"December 1, 2020",Actual,2020-12-01,"November 20, 2020",Actual,2020-11-20,NA,Observational,COVID-19,,Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019,Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus: a Dilemma,Completed,NA,NA,8,Actual,Hospital Italiano de Buenos Aires,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:48:13Z,2021-10-17T07:48:13Z,15614375,NCT04609774,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2020-10-26,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"June 26, 2019",Actual,2019-06-26,October 2020,2020-10-31,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Observational,ICUcovid,,Perceived Stress Among ICU Medical Staff During COVID-19 Crisis,Perceived Stress and Needs Among Medical Staff in ICU During COVID-19 Crisis,Completed,NA,NA,60,Actual,University of Liege,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:49:00Z,2021-10-17T07:49:00Z,15614996,NCT04604769,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-27,NA,NA,2020-10-27,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"October 9, 2020",Actual,2020-10-09,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,ARBs CORONA II,,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,NA,Phase 3,1372,Anticipated,University of British Columbia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:48:42Z,2021-10-17T07:48:42Z,15614794,NCT04606563,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-21,NA,NA,2020-10-28,2020-10-21,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-30,Actual,"September 19, 2020",Actual,2020-09-19,October 2020,2020-10-31,"October 1, 2021",Anticipated,2021-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,VTE-COVID-19,,Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate,Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate,Recruiting,NA,NA,50,Anticipated,Aalborg University Hospital,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Exhaled breath condensate (EBC) Blood samples
    ",NA,NA,NA,No,NA,2021-10-17T07:49:53Z,2021-10-17T07:49:53Z,15615835,NCT04598620,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-19,NA,NA,2021-05-04,2020-10-22,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-06,Actual,"October 28, 2020",Actual,2020-10-28,October 2020,2020-10-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),"Online RCT Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Coronavirus-related Catastrophizing in Adults",Recruiting,NA,N/A,624,Anticipated,The University of Queensland,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Immediately following publication up and for a further 10 years .,"Investigators whose proposed use of the data has been approved by an independent review committee. Initial contact should be directed to the contact person for scientific enquiries (Mr Jonathan Davies, jonathan.davies@uq.edu.au).
Note: Requestors will need to sign a data access agreement.",https://sites.google.com/view/uqcovidmeditation,Yes,"All of the individual trial-related participant data collected during the trial, after de-identification.",2021-10-17T07:49:21Z,2021-10-17T07:49:21Z,15615356,NCT04602312,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-03,NA,NA,2021-08-18,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-24,Actual,"June 9, 2020",Actual,2020-06-09,August 2021,2021-08-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,NA,,Functional Recovery of Hospitalised Patients With COVID-19: The COREG Extension Study,Functional Recovery of Older Hospitalised Patients With COVID-19: a Prospective and Retrospective Cohort Study Extension to the Coronavirus Registry (COREG),Recruiting,NA,NA,211,Anticipated,McMaster University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:49:22Z,2021-10-17T07:49:22Z,15615365,NCT04602260,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-20,NA,NA,2021-04-14,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-19,Actual,"November 2, 2020",Actual,2020-11-02,April 2021,2021-04-30,"April 9, 2021",Actual,2021-04-09,"April 9, 2021",Actual,2021-04-09,NA,Interventional,COVID-RT-01,,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2),Completed,NA,N/A,22,Actual,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:49:53Z,2021-10-17T07:49:53Z,15615841,NCT04598581,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-19,2021-07-29,NA,2021-08-11,2020-10-20,2020-10-22,Actual,2021-08-11,2021-08-12,Actual,NA,NA,NA,2021-08-11,2021-08-12,Actual,"September 16, 2020",Actual,2020-09-16,August 2021,2021-08-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)","A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of ""VIRACIDE"" in the Management of Corona Virus Disease 2019 (COVID-19)",Completed,NA,N/A,118,Actual,"The Herb, Inc",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:50:17Z,2021-10-17T07:50:17Z,15616143,NCT04596085,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-12,NA,NA,2021-06-21,2020-10-13,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"November 19, 2020",Actual,2020-11-19,June 2021,2021-06-30,November 2022,Anticipated,2022-11-30,November 2021,Anticipated,2021-11-30,NA,Observational,PRISM,,COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C,An Observational Cohort Study to Determine Late Outcomes and Immunological Responses After Infection With SARS-CoV-2 in Children With and Without Multisystem Inflammatory Syndrome (MIS-C),Recruiting,NA,NA,250,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood, Nasal Swabs, Saliva, Stools, Urine
    ",NA,NA,NA,NA,NA,2021-10-17T07:51:25Z,2021-10-17T07:51:25Z,15617114,NCT04588363,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-05,NA,NA,2020-10-19,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Pilot Trial for the Benefit of Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,NA,Phase 2,60,Anticipated,Gadjah Mada University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:50:33Z,2021-10-17T07:50:33Z,15616390,NCT04594330,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-07,NA,NA,2021-06-29,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"October 9, 2020",Actual,2020-10-09,December 2020,2020-12-31,"December 4, 2020",Actual,2020-12-04,"December 4, 2020",Actual,2020-12-04,NA,Observational,NA,,ImmuneSenseâ„¢ COVID-19 Study,ImmuneSenseâ„¢ COVID-19 Study,Completed,NA,NA,180,Actual,Adaptive Biotechnologies,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:52:09Z,2021-10-17T07:52:09Z,15617703,NCT04583982,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-09,NA,NA,2021-04-12,2020-10-09,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-15,Actual,"December 18, 2020",Actual,2020-12-18,April 2021,2021-04-30,September 2023,Anticipated,2023-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,MOR,,Mouth Rinses for Inactivation of COVID-19,Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus,Recruiting,NA,Phase 2,480,Anticipated,"University of North Carolina, Chapel Hill",,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,following publication up to 1 year,"Deidentified individual data that supports the results will be shared beginning following publication up to 1 year provided the investigator who proposes to use the data has approval from an IRB, IEC, or REB as applicable, and an executed data use/sharing agreement with UNC.",NA,Yes,"Deidentified individual data that supports the results will be shared beginning following publication up to 1 year provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-10-17T07:52:01Z,2021-10-17T07:52:01Z,15617592,NCT04584684,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-13,NA,NA,2021-01-20,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"October 22, 2020",Actual,2020-10-22,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","An Open Study of the Safety, Tolerability and Immunogenicity of the ""Gam-COVID-Vac""Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years","Active, not recruiting",NA,Phase 2,110,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:51:35Z,2021-10-17T07:51:35Z,15617260,NCT04587219,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-07,NA,NA,2020-10-10,2020-10-08,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-10,2020-10-14,Actual,"October 4, 2020",Actual,2020-10-04,October 2020,2020-10-31,"October 3, 2022",Anticipated,2022-10-03,"October 3, 2021",Anticipated,2021-10-03,2 Months,Observational [Patient Registry],NA,,"Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients","Studies on the Differential Expression of Cytokines, Transcriptome and miRNA in the Context of COVID-19 Infection in Egyptian Community",Recruiting,NA,NA,40,Anticipated,Tanta University,,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:52:13Z,2021-10-17T07:52:13Z,15617753,NCT04583566,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-25,NA,NA,2021-04-19,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-20,Actual,"May 15, 2020",Actual,2020-05-15,April 2021,2021-04-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,NA,N/A,1200,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:54:13Z,2021-10-17T07:54:13Z,15619465,NCT04570488,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-05,NA,NA,2021-09-01,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"October 2, 2020",Actual,2020-10-02,September 2021,2021-09-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,MATIS,,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia,Recruiting,NA,Phase 1/Phase 2,456,Anticipated,Imperial College London,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,To be determined,2021-10-17T07:52:26Z,2021-10-17T07:52:26Z,15617980,NCT04581954,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-01,NA,NA,2020-10-14,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"September 4, 2020",Actual,2020-09-04,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,RELEASE,,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,A Phase I/II Dose-escalation Multi Center Study to Evaluate the Safety of Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in coronaviruS pnEumonia and/or Lymphopenia,Recruiting,NA,Phase 1/Phase 2,58,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:53:06Z,2021-10-17T07:53:06Z,15618536,NCT04578210,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-28,NA,NA,2020-12-28,2020-09-29,2020-10-01,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-30,Actual,"October 30, 2020",Actual,2020-10-30,December 2020,2020-12-31,"December 28, 2020",Actual,2020-12-28,"December 28, 2020",Actual,2020-12-28,NA,Interventional,NA,,UVA Light Device to Treat COVID-19,Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Pilot Study,Completed,NA,N/A,5,Actual,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:53:57Z,2021-10-17T07:53:57Z,15619234,NCT04572399,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-27,NA,NA,2021-06-21,2020-09-30,2020-10-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-24,Actual,"October 1, 2020",Actual,2020-10-01,June 2021,2021-06-30,"June 30, 2023",Anticipated,2023-06-30,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,Covid19Reh,,Cardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19) Patients,Would Cardiorespiratory Exercise and Chinese Herbal Medicine Facilitate Rehabilitation Among Post-discharge Patients With COVID-19? Clinical Efficacy and Mechanisms,Recruiting,NA,N/A,172,Anticipated,Hong Kong Baptist University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,1 year after the completion of study.,All researchers can get the information by sending requests to the study contact person.,NA,Yes,All individual participant data collected during the trial will be deidentified and available for anyone who wish to access the data immediately following publication.,2021-10-17T07:53:57Z,2021-10-17T07:53:57Z,15619239,NCT04572360,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-06,NA,NA,2021-09-14,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-20,Actual,"October 29, 2020",Actual,2020-10-29,September 2021,2021-09-30,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Observational,NA,,Understanding Immunity to the Flu Vaccine in COVID-19 Patients,Understanding Immunity to the Flu Vaccine in COVID-19 Patients,Completed,NA,NA,37,Actual,Stanford University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,Samples With DNA,"
      Blood samples
    ",NA,NA,NA,No,NA,2021-10-17T07:52:47Z,2021-10-17T07:52:47Z,15618333,NCT04579588,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-30,NA,NA,2020-10-29,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-02,Actual,"October 14, 2020",Actual,2020-10-14,September 2020,2020-09-30,"October 10, 2021",Anticipated,2021-10-10,"May 10, 2021",Anticipated,2021-05-10,NA,Observational,NA,,T Cells Response to SARS COV 2 Peptides,"Prospective, One Center, Four Groups, Open, Comparative, Controlled Study to Explore T Cells Response to SARS COV 2 Peptides by Metabolic Activity Method in Convalesce and Healthy Individuals Versus Antibody Response",Recruiting,NA,NA,400,Anticipated,Savicell Diagnostics Ltd,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      peripheral Blood samples (27ml) once from each participant
    ",NA,NA,NA,Undecided,NA,2021-10-17T07:53:49Z,2021-10-17T07:53:49Z,15619121,NCT04573348,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-01,NA,NA,2021-09-30,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"October 15, 2020",Actual,2020-10-15,"September 28, 2021",2021-09-28,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,NA,Observational,NA,,Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health,Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health,Recruiting,NA,NA,1540,Anticipated,National Institutes of Health Clinical Center (CC),,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:53:51Z,2021-10-17T07:53:51Z,15619149,NCT04573062,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-14,NA,NA,2021-05-25,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-28,Actual,"September 1, 2020",Actual,2020-09-01,May 2021,2021-05-31,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,CONFIDENT,,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation: the CONFIDENT Trial,Recruiting,NA,Phase 2,500,Anticipated,University of Liege,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:55:57Z,2021-10-17T07:55:57Z,15620966,NCT04558476,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-28,NA,NA,2021-03-17,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"June 20, 2020",Actual,2020-06-20,September 2020,2020-09-30,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,MELCOVID,,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,"A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)",Completed,NA,Phase 2,18,Actual,Pharmamel S.L.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:54:26Z,2021-10-17T07:54:26Z,15619681,NCT04568863,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-22,NA,NA,2020-09-22,2020-09-22,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-25,Actual,"September 15, 2020",Actual,2020-09-15,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"November 1, 2020",Anticipated,2020-11-01,NA,Observational,NA,,Corona Virus Infection Among Liver Transplant Recipients,Corona Virus Infection Among Liver Transplant Recipients: A Multicenter Study,Recruiting,NA,NA,150,Anticipated,Assiut University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:54:55Z,2021-10-17T07:54:55Z,15620050,NCT04565782,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-22,NA,NA,2021-07-15,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-22,Actual,"April 19, 2020",Actual,2020-04-19,July 2021,2021-07-31,"October 2, 2020",Actual,2020-10-02,"October 2, 2020",Actual,2020-10-02,NA,Interventional,NA,,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,"Nitazoxanide for Moderate to Severe COVID-19 Pneumonia: a Multicenter, Randomized, Placebo-controlled, Double-Blind Clinical Trial",Completed,NA,Phase 2,500,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-10-17T07:55:35Z,2021-10-17T07:55:35Z,15620620,NCT04561219,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-19,NA,NA,2021-05-06,2020-09-19,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-07,Actual,"July 2, 2020",Actual,2020-07-02,September 2020,2020-09-30,"September 1, 2021",Anticipated,2021-09-01,"April 1, 2021",Actual,2021-04-01,NA,Observational,NA,,COVID-19 and Lactating Mothers,COVID-19 and Lactating Mothers,"Active, not recruiting",NA,NA,100,Anticipated,University of Rochester,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:55:59Z,2021-10-17T07:55:59Z,15620984,NCT04558320,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-16,NA,NA,2021-01-26,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"August 19, 2020",Actual,2020-08-19,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 18, 2020",Actual,2020-12-18,NA,Interventional,NA,,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:57:09Z,2021-10-17T07:57:09Z,15621958,NCT04550351,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-15,NA,NA,2020-10-02,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-05,Actual,"September 25, 2020",Actual,2020-09-25,October 2020,2020-10-31,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,2 Years,Observational [Patient Registry],COVID-Reims,,CoViD-19 Patient in Reims University Hospital in March to April 2020,Follow-up CoViD-19 Patients Hospitalized in Reims University Hospital Between the 01/03/2020 and 30/04/2020,Recruiting,NA,NA,499,Anticipated,CHU de Reims,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      blood samples
    ",NA,NA,NA,NA,NA,2021-10-17T07:56:39Z,2021-10-17T07:56:39Z,15621563,NCT04553575,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-23,NA,NA,2020-12-17,2020-09-15,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-21,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"December 2, 2020",Actual,2020-12-02,"December 2, 2020",Actual,2020-12-02,NA,Observational,NA,,"imPulseâ„¢ Una Full-spectrum, Over Clothing E-stethoscope",SARS-CoV-2/COVID-19 Study of the Audible and Inaudible Vibroacoustic E-stethoscope - imPulseâ„¢ Una,Completed,NA,NA,34,Actual,"Level 42 AI, Inc.",,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:56:18Z,2021-10-17T07:56:18Z,15621235,NCT04556149,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-09,NA,NA,2020-11-01,2020-09-15,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-01,2020-11-03,Actual,"June 8, 2020",Actual,2020-06-08,November 2020,2020-11-30,"September 5, 2020",Actual,2020-09-05,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19,Completed,NA,Phase 2,392,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-10-17T07:56:51Z,2021-10-17T07:56:51Z,15621696,NCT04552483,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,NA,NA,2021-10-06,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"April 15, 2020",Actual,2020-04-15,October 2021,2021-10-31,"July 15, 2020",Actual,2020-07-15,"July 15, 2020",Actual,2020-07-15,NA,Observational,CONSCIENCE,,Prevalence of COVID-19 (Coronavirus Disease 19) in Pregnant Women on Labor in a Public Hospital in Chile (COroNavirus diSease Covid-19 pandEmic iN ChilE),"Analysis of Prevalence, Pregnancy Outcomes and Sociodemographic Conditions in Women at Labour With and Without Coronavirus 19 Disease COVID-19 in a Public Hospital in Chile",Completed,NA,NA,720,Actual,"Hospital San Juan de Dios, Santiago",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:56:57Z,2021-10-17T07:56:57Z,15621781,NCT04551690,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-08,NA,NA,2021-09-15,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"September 29, 2020",Actual,2020-09-29,September 2021,2021-09-30,"August 31, 2021",Actual,2021-08-31,"August 31, 2021",Actual,2021-08-31,NA,Observational,NA,,COVID-19-Related Health and Practices Among Dental Hygienists,COVID-19-Related Health and Practices Among Dental Hygienists,Completed,NA,NA,6976,Actual,American Dental Association,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:58:20Z,2021-10-17T07:58:20Z,15622869,NCT04542915,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-10,NA,NA,2021-03-02,2020-09-10,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"April 29, 2020",Actual,2020-04-29,March 2021,2021-03-31,"February 4, 2021",Actual,2021-02-04,"February 4, 2021",Actual,2021-02-04,NA,Interventional,NA,,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)",Completed,NA,Phase 2,200,Actual,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:57:38Z,2021-10-17T07:57:38Z,15622321,NCT04547127,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-09,NA,NA,2021-01-15,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-20,Actual,"May 1, 2020",Actual,2020-05-01,January 2021,2021-01-31,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,,Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19,CSP #2030 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19,"Active, not recruiting",NA,NA,10000,Anticipated,VA Office of Research and Development,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,None Retained,"
      No biospecimens will be collected
    ",Following publication of the primary manuscript and completion of study objectives,"Data access will contingent upon approval by a review committee and appropriate oversight bodies, such as an IRB and VA R&D Committee. Requestors may be required to sign a Cooperative Studies Program data use agreement.",NA,Yes,Participant-level study data will be made available to VA investigators for secondary analyses.,2021-10-17T07:57:59Z,2021-10-17T07:57:59Z,15622599,NCT04545047,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-08,2020-11-12,NA,2020-12-07,2020-09-08,2020-09-09,Actual,2020-11-24,2020-12-03,Actual,NA,NA,NA,2020-12-07,2020-12-09,Actual,"March 31, 2020",Actual,2020-03-31,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"July 15, 2020",Actual,2020-07-15,NA,Observational,NA,,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Open Observational Study of Efficacy and Safety of Polyoxidonium in Complex Therapy of Hospitalized Patients With COVID-19,Completed,NA,NA,81,Actual,NPO Petrovax,"There was no control or comparison group, polyoxidonium was used in the treatment of all patients, it is not possible to compare the results of treatment of patients with and without Polyoxidonium. The study used various treatment regimens for COVID-19 (antiviral agents, antimalarial agents, anticoagulants), depending on the base of the study, so it is impossible to fully determine whether these agents influenced the effectiveness of Polyoxidonium.",NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:58:26Z,2021-10-17T07:58:26Z,15622951,NCT04542226,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-21,NA,NA,2021-04-27,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"April 11, 2018",Actual,2018-04-11,April 2021,2021-04-30,"January 11, 2021",Actual,2021-01-11,"June 4, 2020",Actual,2020-06-04,NA,Observational,NA,,The Impact of Premorbid Illnesses on the Risk of ICU Admission and Short-term Outcome,The Impact of Premorbid Illnesses on the Risk of ICU Admission and Short-term Outcome,Completed,NA,NA,9905,Actual,Uppsala University,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:58:23Z,2021-10-17T07:58:23Z,15622916,NCT04542538,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-03,NA,NA,2021-07-27,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"June 1, 2021",Actual,2021-06-01,September 2020,2020-09-30,"November 30, 2022",Anticipated,2022-11-30,"November 30, 2022",Anticipated,2022-11-30,NA,Interventional,NA,,COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents,Multilevel Participatory Intervention to Reduce Barriers and Promote Social and Behavioral Facilitators of COVID-19 Testing Among African Americans and Latinx Public Housing Residents,Recruiting,NA,N/A,310,Anticipated,Charles Drew University of Medicine and Science,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:58:25Z,2021-10-17T07:58:25Z,15622934,NCT04542395,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-03,NA,NA,2021-01-22,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"November 1, 2020",Actual,2020-11-01,September 2020,2020-09-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,,COVID-19 Risk Reduction Among African American Parishioners,"Multilevel, Multidisciplinary, Faith-Based Participatory Interventions to Reduce COVID-19 Related-Risks Among Underserved African Americans",Recruiting,NA,N/A,265,Anticipated,Charles Drew University of Medicine and Science,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:58:25Z,2021-10-17T07:58:25Z,15622940,NCT04542343,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-01,NA,NA,2020-11-23,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV003),"A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine",Recruiting,NA,Phase 3,10300,Anticipated,University of Oxford,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:59:21Z,2021-10-17T07:59:21Z,15623782,NCT04536051,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2021-05-05,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"June 11, 2020",Actual,2020-06-11,June 2020,2020-06-30,"August 30, 2021",Anticipated,2021-08-30,"December 30, 2020",Actual,2020-12-30,NA,Interventional,NA,,Salivary SARS-CoV-2 Load of Covid-19 Patients After Oral Antimicrobial Solutions and Dentifrices,AvaliaÃ§Ã£o da Carga do vÃ­rus SARS-CoV-2 na Cavidade Oral e na Saliva apÃ³s desinfecÃ§Ã£o Com soluÃ§Ãµes Antimicrobianas Orais e dentifrÃ­cios.,Enrolling by invitation,NA,N/A,202,Anticipated,Hospital Israelita Albert Einstein,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:59:05Z,2021-10-17T07:59:05Z,15623517,NCT04537962,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-21,NA,NA,2021-05-20,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-21,Actual,"May 18, 2021",Actual,2021-05-18,May 2021,2021-05-31,April 2022,Anticipated,2022-04-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS,"Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial",Recruiting,NA,Phase 2,82,Anticipated,"Cantonal Hosptal, Baselland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:59:18Z,2021-10-17T07:59:18Z,15623743,NCT04536350,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-28,NA,NA,2021-01-25,2020-08-31,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"November 14, 2020",Actual,2020-11-14,January 2021,2021-01-31,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,DW-MSC,,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled",Completed,NA,Phase 1,9,Actual,Ina-Respond,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:59:22Z,2021-10-17T07:59:22Z,15623804,NCT04535856,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-26,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"March 2, 2020",Actual,2020-03-02,August 2020,2020-08-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2020",Anticipated,2020-09-30,14 Days,Observational [Patient Registry],NA,,CORE Study COVID-19,Clinical Characterization Protocol for Severe Emerging Infections: Coronavirus,Recruiting,NA,NA,2000,Anticipated,D'Or Institute for Research and Education,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:00:12Z,2021-10-17T08:00:12Z,15624424,NCT04531202,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-28,NA,NA,2020-11-07,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"September 1, 2020",Actual,2020-09-01,November 2020,2020-11-30,"October 9, 2020",Actual,2020-10-09,"October 1, 2020",Actual,2020-10-01,10 Days,Observational [Patient Registry],NA,,Taste and Smell Impairment in Critically Ill COVID-19 Patients,Taste and Smell Impairment in Critically Ill COVID-19 Patients,Completed,NA,NA,40,Actual,Sisli Hamidiye Etfal Training and Research Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:59:53Z,2021-10-17T07:59:53Z,15624234,NCT04532632,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-20,NA,NA,2021-08-04,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"October 5, 2020",Actual,2020-10-05,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,"July 15, 2021",Actual,2021-07-15,NA,Interventional,NA,,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,"Active, not recruiting",NA,Phase 4,3,Actual,West Virginia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:19Z,2021-10-17T08:00:19Z,15624553,NCT04530448,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-06,NA,NA,2021-04-19,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-20,Actual,"September 4, 2020",Actual,2020-09-04,August 2020,2020-08-31,"May 15, 2021",Anticipated,2021-05-15,"February 15, 2021",Actual,2021-02-15,NA,Interventional,NA,,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19","Active, not recruiting",NA,Phase 2,45,Actual,Verona Pharma plc,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Verona Pharma will not be sharing individual deidentified participant data or other relevant study documents.,2021-10-17T08:00:46Z,2021-10-17T08:00:46Z,15624962,NCT04527471,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-24,NA,NA,2021-05-05,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"December 16, 2020",Actual,2020-12-16,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,CHIP,,COVID-19 Health Professional Impact Study,"A Pilot Assessment of the COVID-19 Antibody Status and Associated Factors, in Individuals Employed by a Large Acute NHS Trust During the Coronavirus Pandemic","Active, not recruiting",NA,N/A,1504,Actual,The Royal Wolverhampton Hospitals NHS Trust,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Results will be published in journal,2021-10-17T08:00:46Z,2021-10-17T08:00:46Z,15624966,NCT04527432,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-17,NA,NA,2021-09-20,2020-08-24,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"December 15, 2020",Actual,2020-12-15,September 2021,2021-09-30,"November 30, 2021",Anticipated,2021-11-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,VitCov,,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study","High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study","Active, not recruiting",NA,N/A,80,Actual,"Cantonal Hosptal, Baselland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:01:04Z,2021-10-17T08:01:04Z,15625190,NCT04525820,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-18,NA,NA,2021-09-12,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-12,2021-09-20,Actual,"April 6, 2020",Actual,2020-04-06,September 2021,2021-09-30,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Observational,TARGET-VIP,,Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia,Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia,"Active, not recruiting",NA,NA,1124,Actual,National Medical Research Center for Therapy and Preventive Medicine,,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:01:43Z,2021-10-17T08:01:43Z,15625701,NCT04522076,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-20,NA,NA,2021-09-25,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-25,2021-09-28,Actual,"September 1, 2020",Actual,2020-09-01,September 2021,2021-09-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NH-Shingrix,,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents: A Randomized, Doubled-Blinded, Comparative Group Observational Study",Recruiting,NA,Early Phase 1,250,Anticipated,University of Oklahoma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:01:32Z,2021-10-17T08:01:32Z,15625550,NCT04523246,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-17,NA,NA,2021-09-23,2020-08-21,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"November 12, 2020",Actual,2020-11-12,September 2021,2021-09-30,"September 30, 2022",Anticipated,2022-09-30,"September 22, 2021",Actual,2021-09-22,NA,Observational,MOIST,,MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients,MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients,"Active, not recruiting",NA,NA,215,Actual,University of Alberta,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:01:12Z,2021-10-17T08:01:12Z,15625252,NCT04525404,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-20,NA,NA,2021-08-01,2020-08-20,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-06,Actual,"February 20, 2020",Actual,2020-02-20,June 2020,2020-06-30,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Observational,NA,,Prediction Models for Diagnosis and Prognosis of Severe COVID-19,Prediction Models for Diagnosis and Prognosis of Severe COVID-19,Completed,NA,NA,617,Actual,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:01:13Z,2021-10-17T08:01:13Z,15625273,NCT04525287,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-18,NA,NA,2020-08-18,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"August 18, 2020",Actual,2020-08-18,August 2020,2020-08-31,"August 18, 2021",Anticipated,2021-08-18,"February 17, 2021",Anticipated,2021-02-17,NA,Observational,iGenes-COVID19,,Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events,Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events,Recruiting,NA,NA,60,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood with complete thrombophilic profile testing and RAAS components assessment through PCR
      (multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic
      genotypes)
    ",NA,NA,NA,Yes,NA,2021-10-17T08:02:07Z,2021-10-17T08:02:07Z,15626031,NCT04519398,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-15,NA,NA,2021-02-08,2020-08-15,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"June 1, 2020",Actual,2020-06-01,August 2020,2020-08-31,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2021",Anticipated,2021-09-30,3 Months,Observational [Patient Registry],NA,,Renal Biomarkers in AKI and COVID-19,Acute Kidney Injury In Subjects With Severe Acute Respiratory Syndrome Due to SARS-CoV2 Infection,Recruiting,NA,NA,90,Anticipated,Instituto Nacional de Enfermedades Respiratorias,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,Samples With DNA,"
      The SARS-CoV-2 RNA will be obtained from 200 microliters of urine, by standard methods
    ",NA,NA,NA,NA,NA,2021-10-17T08:02:23Z,2021-10-17T08:02:23Z,15626267,NCT04517630,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-11,NA,NA,2020-08-13,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-13,2020-08-17,Actual,"August 11, 2020",Actual,2020-08-11,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Characteristics in Post Covid-19 Patients,Clinical Respiratory Investigation in Post Covid-19 Patients,Recruiting,NA,N/A,20,Anticipated,Universidade Metodista de Piracicaba,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:02:49Z,2021-10-17T08:02:49Z,15626641,NCT04514705,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-12,NA,NA,2021-02-02,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"July 12, 2020",Actual,2020-07-12,February 2021,2021-02-28,"November 30, 2020",Actual,2020-11-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,FAMICOV,,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,NA,N/A,500,Actual,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:03:14Z,2021-10-17T08:03:14Z,15627005,NCT04511949,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-24,NA,NA,2020-08-12,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-13,Actual,"June 30, 2020",Actual,2020-06-30,August 2020,2020-08-31,April 2021,Anticipated,2021-04-30,October 2020,Anticipated,2020-10-31,6 Months,Observational [Patient Registry],NA,,COVID-19 in Immunosuppressed Children,COVID-19 in Immunosuppressed Children,Recruiting,NA,NA,200,Anticipated,D'Or Institute for Research and Education,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:03:18Z,2021-10-17T08:03:18Z,15627069,NCT04511429,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-11,NA,NA,2020-08-11,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"March 17, 2020",Actual,2020-03-17,August 2020,2020-08-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,ARBS CORONA I,,Host Response Mediators in Coronavirus (COVID-19) Infection,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?,Recruiting,NA,NA,500,Anticipated,University of British Columbia,,NA,4,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:03:26Z,2021-10-17T08:03:26Z,15627161,NCT04510623,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-11,NA,NA,2021-09-07,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"October 23, 2020",Actual,2020-10-23,September 2021,2021-09-30,"August 17, 2021",Actual,2021-08-17,"August 17, 2021",Actual,2021-08-17,NA,Interventional,CanCovDia,,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial,Completed,NA,Phase 3,116,Actual,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:03:27Z,2021-10-17T08:03:27Z,15627177,NCT04510493,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-24,NA,NA,2020-08-04,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-05,Actual,"June 27, 2020",Actual,2020-06-27,August 2020,2020-08-31,"October 1, 2020",Anticipated,2020-10-01,"August 30, 2020",Anticipated,2020-08-30,NA,Observational,NA,,Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians in the Covid-19 Pandemic,Evaluation of Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians During the Covid-19 Pandemic,Recruiting,NA,NA,310,Anticipated,Dokuz Eylul University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:04:57Z,2021-10-17T08:04:57Z,15628420,NCT04500652,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-07,NA,NA,2021-08-24,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"May 26, 2020",Actual,2020-05-26,August 2021,2021-08-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Observational,AI-COV-19,,Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms,Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms and Imaging,Recruiting,NA,NA,2000,Anticipated,Imperial College London,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,within study duration,Researchers of the study,NA,Yes,"This is a study using retrospective, pseudo-anonymised data that were acquired as part of routine clinical care for the patients. There are no direct risks to the patients' health. The main issues revolve around data security and storage. In order to address this, members of the direct care team who are not members of the research team will perform the pseudo-anonymisation of the data and pass a set of pseudo-anonymised data to the research team with no access to the pseudo-anonymisation code. The research team will therefore be unable to identify the patients from those data. The pseudo-anonymised data will also be securely stored to further minimise risks.",2021-10-17T08:03:28Z,2021-10-17T08:03:28Z,15627188,NCT04510441,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2020-08-14,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"May 1, 2023",Anticipated,2023-05-01,"May 1, 2023",Anticipated,2023-05-01,NA,Observational,C-MORE,,Capturing MultiORgan Effects of COVID-19,"Assessing the Effects of Coronavirus Disease (COVID-19) on Multiple Organ Systems and Impact on Quality of Life, Functional Capacity and Mental Health",Recruiting,NA,NA,616,Anticipated,University of Oxford,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      10 ml of blood stored
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:03:32Z,2021-10-17T08:03:32Z,15627238,NCT04510025,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-03,NA,NA,2021-04-05,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-06,Actual,"August 1, 2020",Actual,2020-08-01,June 2020,2020-06-30,"March 31, 2021",Actual,2021-03-31,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVRehab,,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19","The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19: An Explorative Study",Completed,NA,N/A,48,Actual,Radboud University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Only upon asking.,2021-10-17T08:04:10Z,2021-10-17T08:04:10Z,15627744,NCT04505761,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-10,NA,NA,2020-11-21,2020-08-10,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-21,2020-11-24,Actual,"April 15, 2020",Actual,2020-04-15,November 2020,2020-11-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,1 Year,Observational [Patient Registry],COREG,,The McMaster Multi-Regional COVID-19 Hospital Case Registry,A Rapid Research Platform to Inform Prevention & Improve the Clinical Management of COVID-19 Illness for Priority Older Adult Groups: The McMaster Multi-regional Hospital Coronavirus Registry,Recruiting,NA,NA,1500,Anticipated,McMaster University,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Entire registry,NA,NA,Yes,WHO-ISARIC COVID-19 database (https://isaric.tghn.org/covid-19-clinical-research-resources/).,2021-10-17T08:03:41Z,2021-10-17T08:03:41Z,15627355,NCT04508959,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-29,NA,NA,2021-05-11,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-12,Actual,"September 8, 2020",Actual,2020-09-08,May 2021,2021-05-31,"January 8, 2021",Actual,2021-01-08,"January 8, 2021",Actual,2021-01-08,NA,Interventional,NA,,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),"BARCONA: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)",Completed,NA,Phase 2,40,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Data will become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Sripal.Bangalore@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices) will be shared upon reasonable request.",2021-10-17T08:05:53Z,2021-10-17T08:05:53Z,15629256,NCT04494646,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-31,NA,NA,2020-07-31,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"May 8, 2020",Actual,2020-05-08,July 2020,2020-07-31,"December 1, 2021",Anticipated,2021-12-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,COVEN,,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19) - COVEN Study,Recruiting,NA,N/A,128,Anticipated,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:05:27Z,2021-10-17T08:05:27Z,15628860,NCT04497454,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,NA,NA,2020-07-29,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-30,Actual,"March 7, 2020",Actual,2020-03-07,July 2020,2020-07-31,"July 21, 2020",Actual,2020-07-21,"July 20, 2020",Actual,2020-07-20,NA,Observational,NA,,HYPONATREMIA IN COVID-19 PATIENTS,HYPONATREMIA AND INFLAMMATION AND CLINICAL OUTCOMES IN HOSPITALIZED COVID-19 PATIENTS,Completed,NA,NA,250,Actual,Hospital Nacional Profesor Alejandro Posadas,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:06:07Z,2021-10-17T08:06:07Z,15629440,NCT04493268,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-24,NA,NA,2021-03-08,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"July 23, 2020",Actual,2020-07-23,March 2021,2021-03-31,"December 30, 2021",Anticipated,2021-12-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,ULSC,,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,"Restem, LLC.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:05:56Z,2021-10-17T08:05:56Z,15629290,NCT04494386,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,NA,NA,2021-08-18,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-19,Actual,"July 1, 2020",Actual,2020-07-01,August 2021,2021-08-31,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Observational,EMN-COVID,,COVID-19 Infection and Multiple Myeloma,COVID-19 INFECTION IN MULTIPLE MYELOMA PATIENTS: AN EUROPEAN OBSERVATIONAL STUDY,Recruiting,NA,NA,500,Anticipated,European Myeloma Network,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:06:15Z,2021-10-17T08:06:15Z,15629562,NCT04492371,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-28,NA,NA,2021-08-24,2020-07-28,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"July 15, 2020",Actual,2020-07-15,August 2021,2021-08-31,"December 15, 2021",Anticipated,2021-12-15,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,EPI-COVID-POP,,COVID-19 Seroprevalence Study in French Guiana,COVID-19 Seroprevalence Study in French Guiana,Recruiting,NA,N/A,1500,Anticipated,Institut Pasteur,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:06:29Z,2021-10-17T08:06:29Z,15629747,NCT04490850,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-22,NA,NA,2021-03-04,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-08,Actual,"July 22, 2020",Actual,2020-07-22,March 2021,2021-03-31,"July 22, 2021",Anticipated,2021-07-22,"July 22, 2021",Anticipated,2021-07-22,NA,Observational,NA,,Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19,Clinical Outcome of Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19 Cytokine Release Syndrome,Recruiting,NA,NA,860,Anticipated,King Faisal Specialist Hospital & Research Center,,NA,3,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:07:08Z,2021-10-17T08:07:08Z,15630272,NCT04486521,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-23,NA,NA,2020-12-11,2020-07-23,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-16,Actual,"November 18, 2020",Actual,2020-11-18,December 2020,2020-12-31,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,DAMPEN-CI,,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection,Recruiting,NA,Phase 2,80,Anticipated,Emory University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Data will be made available for sharing at the conclusion of the study and will be available for one year.,Data will be available for sharing with academic or pharmaceutical investigators for analyses including comparison of DAMPEN-CI results with those from other drug trials in similar patient cohorts. Researchers wishing to use data should email the investigators of DAMPEN-Cl. A summary of the research plan will be required prior to release of the DAMPEN-CI data.,NA,Yes,"The researchers plan to share individual participant data including participant status ordinal score at baseline and end of treatment, study drug allocation, duration of treatment, and survival status at Day 60.",2021-10-17T08:06:56Z,2021-10-17T08:06:56Z,15630132,NCT04487886,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-13,NA,NA,2020-07-16,2020-07-16,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-21,Actual,"September 15, 2020",Anticipated,2020-09-15,July 2020,2020-07-31,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NEUROSIVIR,,"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831","A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers",Recruiting,NA,Phase 1,45,Anticipated,"NeuroActiva, Inc.",,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,90 days after the completion of the study,to be determined,NA,Yes,We plan to share the Study Protocol,2021-10-17T08:08:04Z,2021-10-17T08:08:04Z,15631089,NCT04480333,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-02,NA,NA,2020-07-23,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-24,Actual,July 2020,Anticipated,2020-07-31,June 2020,2020-06-30,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Observational,CONFI-DIAB,,Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes,Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes: a Monocentric Cross-sectional Study,Recruiting,NA,NA,700,Anticipated,"Central Hospital, Nancy, France",,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:07:18Z,2021-10-17T08:07:18Z,15630416,NCT04485351,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-16,NA,NA,2021-04-01,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-06,Actual,"July 24, 2020",Actual,2020-07-24,April 2021,2021-04-30,"September 17, 2021",Anticipated,2021-09-17,"July 17, 2021",Anticipated,2021-07-17,NA,Interventional,NICOR,,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,A Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 Patients,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Tomsk National Research Medical Center of the Russian Academy of Sciences,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:08:32Z,2021-10-17T08:08:32Z,15631475,NCT04476992,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-16,NA,NA,2021-04-16,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-04-16,2021-04-19,Actual,"July 16, 2020",Actual,2020-07-16,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,TOCIDEX,,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,NA,Phase 2,660,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:08:32Z,2021-10-17T08:08:32Z,15631481,NCT04476979,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-09,NA,NA,2021-06-18,2020-07-15,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-18,2021-06-22,Actual,"June 29, 2020",Actual,2020-06-29,June 2021,2021-06-30,"June 15, 2021",Actual,2021-06-15,"June 15, 2021",Actual,2021-06-15,NA,Observational,NA,,Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU,Psychological Distress Symptoms in Family Members of Patients With COVID-19 Respiratory Failure in Intensive Care Units,Completed,NA,NA,330,Actual,"University of Colorado, Denver",,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:08:32Z,2021-10-17T08:08:32Z,15631491,NCT04476914,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-16,NA,NA,2021-06-22,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-24,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,"June 22, 2021",Actual,2021-06-22,"June 22, 2021",Actual,2021-06-22,NA,Observational,NA,,Long-Term Experience and Health Effects of COVID-19,"A Longitudinal, Long-Term, Observational Study of COVID-19 Experience and Health Effects",Completed,NA,NA,64,Actual,Altura,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:08:24Z,2021-10-17T08:08:24Z,15631383,NCT04477902,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-06,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"June 10, 2020",Actual,2020-06-10,July 2020,2020-07-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,PSICOcs,,Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children,Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children,Recruiting,NA,NA,30000,Anticipated,Hospices Civils de Lyon,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:08:46Z,2021-10-17T08:08:46Z,15631713,NCT04475484,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-12,NA,NA,2020-12-13,2020-07-13,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-12-13,2020-12-17,Actual,"June 10, 2020",Actual,2020-06-10,December 2020,2020-12-31,"December 11, 2020",Actual,2020-12-11,"June 26, 2020",Actual,2020-06-26,1 Day,Observational [Patient Registry],NA,,"Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina","Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) in a Vulnerable Neighbourhood, Buenos Aries Argentina",Completed,NA,NA,873,Actual,Hospital Italiano de Buenos Aires,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,undecided,2021-10-17T08:09:17Z,2021-10-17T08:09:17Z,15632160,NCT04472078,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2021-08-14,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-17,Actual,"July 21, 2020",Actual,2020-07-21,August 2021,2021-08-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,NA,,Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota,Epidemiologic Assessment of SARS-CoV-2 Prevalence in Minnesota,Recruiting,NA,NA,3000,Anticipated,University of Minnesota,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      With the participant's approval, and as approved by IRB, de-identified biological samples
      will be stored and tested for anti- SARS-CoV-2 IgG and IgM. These samples may be used in
      future COVID-19 studies to develop assays or study other features of the disease. These
      leftovers may be used for multiple basic science analysis and potentially for genetic
      testing. The consent process will explain this to prospective participants.

      During the conduct of the study, an individual participant can choose to withdraw consent to
      have biological specimens stored for future research. However, withdrawal of consent with
      regard to biosample storage will not be possible after the study is completed. The consent
      process will explain this to prospective participants.
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:09:07Z,2021-10-17T08:09:07Z,15632030,NCT04473183,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-22,NA,NA,2020-12-02,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"May 21, 2020",Actual,2020-05-21,December 2020,2020-12-31,"December 1, 2020",Actual,2020-12-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,GOTCHA,,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study","GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,NA,Phase 4,10,Actual,Samaritan Health Services,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:09:06Z,2021-10-17T08:09:06Z,15632013,NCT04473274,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2021-07-04,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-04,2021-07-07,Actual,"July 14, 2020",Actual,2020-07-14,July 2021,2021-07-31,"October 15, 2021",Anticipated,2021-10-15,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,I-COVID-PK,,Efficacy of Iodine Complex Against COVID-19 Patients,Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,200,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:09:06Z,2021-10-17T08:09:06Z,15632016,NCT04473261,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2021-02-13,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-13,2021-02-17,Actual,"November 14, 2020",Actual,2020-11-14,February 2021,2021-02-28,"October 30, 2021",Anticipated,2021-10-30,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,SIZI-COVID-PK,,Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients,Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,180,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:09:12Z,2021-10-17T08:09:12Z,15632092,NCT04472585,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-13,NA,NA,2020-10-09,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Actual,"October 9, 2020",Actual,2020-10-09,October 2020,2020-10-31,"December 2, 2021",Anticipated,2021-12-02,November 2021,Anticipated,2021-11-30,NA,Observational,COpregVID,,Evaluating Clinical Parameters of COVID-19 in Pregnancy,Evaluation of Clinical Parameters Following COVID-19 Infection in Pregnancy (COpregVID),Recruiting,NA,NA,116,Anticipated,Chelsea and Westminster NHS Foundation Trust,,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Research team wishes to enable any meta-analyses of COVID-19 trials making appropriate requests. No plan to share IPD has been made at this time.,2021-10-17T08:09:32Z,2021-10-17T08:09:32Z,15632342,NCT04470583,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-09,NA,NA,2021-09-16,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-20,Actual,"July 10, 2020",Actual,2020-07-10,September 2021,2021-09-30,"January 24, 2021",Actual,2021-01-24,"January 24, 2021",Actual,2021-01-24,NA,Observational,NA,,Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients,Arrhythmic Manifestations and Management Strategies in Hospitalized COVID-19 Patients: Proposal for a Multicenter Registry,Completed,NA,NA,666,Actual,Kansas City Heart Rhythm Research Foundation,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:10:38Z,2021-10-17T08:10:38Z,15632966,NCT04465552,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-07,NA,NA,2020-07-10,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-13,Actual,"June 15, 2020",Actual,2020-06-15,July 2020,2020-07-31,"August 30, 2020",Anticipated,2020-08-30,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,NA,,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,NA,Phase 3,100,Anticipated,University of Health Sciences Lahore,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:10:11Z,2021-10-17T08:10:11Z,15632566,NCT04468646,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-01,NA,NA,2020-12-16,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-12-16,2020-12-19,Actual,"April 3, 2020",Actual,2020-04-03,December 2020,2020-12-31,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,NA,Observational,NA,,Characteristics of TraceTogether Users,Characteristics of TraceTogether Users,Completed,NA,NA,505,Actual,Yale-NUS College,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Due to stipulations by the Institutional Review Board, data cannot be shared.",2021-10-17T08:10:11Z,2021-10-17T08:10:11Z,15632577,NCT04468581,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-09,NA,NA,2020-07-10,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-13,Actual,"June 2, 2020",Actual,2020-06-02,July 2020,2020-07-31,"September 25, 2020",Anticipated,2020-09-25,"September 15, 2020",Anticipated,2020-09-15,NA,Observational,NA,,Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR,Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR,Recruiting,NA,NA,150,Anticipated,Neurognos,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:10:15Z,2021-10-17T08:10:15Z,15632618,NCT04468217,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-28,NA,NA,2020-11-10,2020-07-12,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Actual,"July 17, 2020",Actual,2020-07-17,November 2020,2020-11-30,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19",Completed,NA,Phase 1,68,Actual,Sanofi,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T08:09:58Z,2021-10-17T08:09:58Z,15632452,NCT04469621,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-08,NA,NA,2020-12-01,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"July 12, 2020",Actual,2020-07-12,December 2020,2020-12-31,"December 15, 2021",Anticipated,2021-12-15,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,,Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years","Active, not recruiting",NA,Phase 2,900,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:10:33Z,2021-10-17T08:10:33Z,15632884,NCT04466085,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-23,NA,NA,2021-02-08,2020-07-06,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"July 1, 2020",Actual,2020-07-01,February 2021,2021-02-28,"December 20, 2022",Anticipated,2022-12-20,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NCOVIP,,Northeast COVID-19 and Pregnancy Study Group,Clinical and Laboratory Predictors of COVID-19 Progression and Maternal and Perinatal Outcomes in Infected Pregnant and Postpartum Women in Six Reference Centers in the Northeast of Brazil,Recruiting,NA,NA,180,Anticipated,Instituto Materno Infantil Prof. Fernando Figueira,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      whole blood
    ",NA,NA,NA,NA,NA,2021-10-17T08:11:29Z,2021-10-17T08:11:29Z,15633397,NCT04462367,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-02,NA,NA,2020-11-12,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial","Active, not recruiting",NA,Phase 3,908,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:11:47Z,2021-10-17T08:11:47Z,15633527,NCT04461379,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-23,NA,NA,2020-10-06,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"June 25, 2020",Actual,2020-06-25,August 2020,2020-08-31,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers","A Phase 1 Randomized Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers",Completed,NA,Phase 1,12,Actual,"Pulmoquine Therapeutics, Inc",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is no plan to make IPD available to other researchers.,2021-10-17T08:11:48Z,2021-10-17T08:11:48Z,15633529,NCT04461353,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-02,NA,NA,2021-01-26,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-28,Actual,"June 8, 2020",Actual,2020-06-08,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"December 30, 2020",Actual,2020-12-30,NA,Observational,NA,,Psychiatric Disturbances and COVID-19 Infection,Psychiatric Disturbances in Patients Infected With COVID-19: A Cross Sectional Study,Completed,NA,NA,400,Actual,Cairo University,,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:12:25Z,2021-10-17T08:12:25Z,15633779,NCT04459403,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-18,NA,NA,2021-08-05,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-09,Actual,"June 19, 2020",Actual,2020-06-19,August 2021,2021-08-31,June 2023,Anticipated,2023-06-30,May 2023,Anticipated,2023-05-31,NA,Observational,PHENOTYPE,,PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs,PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs,Recruiting,NA,NA,500,Anticipated,Chelsea and Westminster NHS Foundation Trust,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      -  Blood samples: 20 additional mls taken at each routine follow-up visit.

        -  Endobronchial samples (washings/brushings/biopsy) if a bronchoscopy is deemed necessary
           for the clinical care of the patient
    ",NA,NA,NA,No,NA,2021-10-17T08:12:26Z,2021-10-17T08:12:26Z,15633787,NCT04459351,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-03,NA,NA,2020-10-13,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,A Prospective Open-label Study of the TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,NA,Phase 3,100,Actual,AO GENERIUM,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:12:27Z,2021-10-17T08:12:27Z,15633789,NCT04459325,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,NA,NA,2020-09-28,2020-06-29,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"June 8, 2020",Actual,2020-06-08,September 2020,2020-09-30,"November 30, 2021",Anticipated,2021-11-30,"October 31, 2021",Anticipated,2021-10-31,2 Months,Observational [Patient Registry],NA,,"The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications","The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications",Enrolling by invitation,NA,NA,200,Anticipated,Silesian Centre for Heart Diseases,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Blood, urine
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:13:40Z,2021-10-17T08:13:40Z,15634479,NCT04453748,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2021-05-05,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"June 30, 2020",Actual,2020-06-30,May 2021,2021-05-31,"April 14, 2021",Actual,2021-04-14,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVAX19,,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Completed,NA,Phase 1,40,Actual,Vaxine Pty Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:13:39Z,2021-10-17T08:13:39Z,15634460,NCT04453852,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2021-05-19,2020-06-29,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-24,Actual,"November 1, 2020",Actual,2020-11-01,May 2021,2021-05-31,April 2023,Anticipated,2023-04-30,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,,At Home Monitoring for Patients With Covid19,Covidfree@Home: At Home Monitoring Using Mobile Devices for Patients With Covid19,Recruiting,NA,N/A,1000,Anticipated,"University Health Network, Toronto",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:13:40Z,2021-10-17T08:13:40Z,15634473,NCT04453774,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-25,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 28, 2020",Actual,2020-05-28,June 2020,2020-06-30,September 2021,Anticipated,2021-09-30,May 2021,Anticipated,2021-05-31,NA,Observational,NA,,The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19,The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Coronavirus Disease 2019,Recruiting,NA,NA,100,Anticipated,Portsmouth Hospitals NHS Trust,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Blood sample
    ",NA,NA,NA,No,NA,2021-10-17T08:13:42Z,2021-10-17T08:13:42Z,15634504,NCT04453527,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-26,NA,NA,2020-09-04,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-07,Actual,"October 15, 2020",Anticipated,2020-10-15,July 2020,2020-07-31,"February 15, 2021",Anticipated,2021-02-15,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NATADEX,,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection","Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection",Recruiting,NA,Phase 2/Phase 3,525,Anticipated,"NeuroActiva, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:13:51Z,2021-10-17T08:13:51Z,15634623,NCT04452565,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-23,NA,NA,2020-08-18,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"June 26, 2020",Actual,2020-06-26,August 2020,2020-08-31,"July 24, 2020",Actual,2020-07-24,"July 24, 2020",Actual,2020-07-24,NA,Interventional,COVAL-NANCY,,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) in the Population of the Grand Nancy Metropolitan Area,Completed,NA,N/A,2006,Actual,"Central Hospital, Nancy, France",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:15:07Z,2021-10-17T08:15:07Z,15635114,NCT04448769,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-25,NA,NA,2020-08-31,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 25, 2020",Actual,2020-04-25,August 2020,2020-08-31,"June 20, 2020",Actual,2020-06-20,"June 10, 2020",Actual,2020-06-10,NA,Observational,NA,,"Knowledge, Attitude and Practice of Dental Students About COVID-19","Knowledge, Attitude and Practice About COVID-19 and Awareness of Infection Control to Prevent COVID-19 Transmission in Clinics and Perception About Online Learning During Lock Down Period: A Cross-sectional Study",Completed,NA,NA,215,Actual,Melaka Manipal Medical College,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No personal details of the participant will be shared.,2021-10-17T08:15:04Z,2021-10-17T08:15:04Z,15635064,NCT04449081,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-18,NA,NA,2020-10-21,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"July 10, 2020",Actual,2020-07-10,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age","Active, not recruiting",NA,Phase 1,180,Anticipated,Medicago,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:14:42Z,2021-10-17T08:14:42Z,15634964,NCT04450004,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-25,NA,NA,2021-09-05,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-08,Actual,"July 29, 2020",Actual,2020-07-29,September 2021,2021-09-30,"August 16, 2021",Actual,2021-08-16,"August 16, 2021",Actual,2021-08-16,NA,Interventional,NA,,Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE),"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)",Completed,NA,Phase 2,151,Actual,EMD Serono,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html",2021-10-17T08:15:07Z,2021-10-17T08:15:07Z,15635117,NCT04448756,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-24,NA,NA,2021-04-08,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-12,Actual,"March 26, 2020",Actual,2020-03-26,April 2021,2021-04-30,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Observational,NA,,Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence,"Characterizing SARS-CoV-2 Persistence in Host Reservoirs, Post-viral Sequelae, and Associations With Host and Viral Determinants in a Cohort of Convalescent COVID-19 Cases",Recruiting,NA,NA,325,Anticipated,Columbia University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Saliva, Nasal Swab, Blood, Stool, Semen, Breastmilk
    ",NA,NA,NA,Undecided,"De-identified patient data, including test results, may be shared with other researchers within Columbia University at the discretion of the Principal Investigator, and only when the Institutional Review Board (IRB) approval has been granted to allow for the sharing of such data.",2021-10-17T08:15:14Z,2021-10-17T08:15:14Z,15635193,NCT04448145,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-04-28,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"May 20, 2020",Actual,2020-05-20,April 2021,2021-04-30,"June 20, 2020",Actual,2020-06-20,"June 20, 2020",Actual,2020-06-20,NA,Observational,NA,,The Impact of COVID-19 Outbreak on Trans-population's Health in Italy,Observational Evaluation of the Impact of COVID-19 Outbreak on Transgender Subject's Health and on the Organization of Trans-population Health Care Services,Completed,NA,NA,111,Actual,Unita Complessa di Ostetricia e Ginecologia,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:15:11Z,2021-10-17T08:15:11Z,15635158,NCT04448418,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2020-08-18,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,"February 22, 2022",Anticipated,2022-02-22,"February 22, 2022",Anticipated,2022-02-22,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19","A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,International Vaccine Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,TRUE,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 3 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be anonymized and may be made available upon reasonable request.,2021-10-17T08:15:17Z,2021-10-17T08:15:17Z,15635237,NCT04447781,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-22,NA,NA,2020-07-28,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"July 23, 2020",Actual,2020-07-23,June 2020,2020-06-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,TITAN,,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,"Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19",Recruiting,NA,Phase 2,176,Anticipated,Instituto do Cancer do Estado de SÃ£o Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,no plan to share individual participant data,2021-10-17T08:15:22Z,2021-10-17T08:15:22Z,15635319,NCT04447235,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-19,NA,NA,2021-08-31,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"June 12, 2020",Actual,2020-06-12,August 2021,2021-08-31,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,NA,,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,NA,Phase 1/Phase 2,20,Anticipated,University of Liege,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:15:37Z,2021-10-17T08:15:37Z,15635565,NCT04445454,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-22,NA,NA,2021-01-21,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"April 24, 2020",Actual,2020-04-24,June 2020,2020-06-30,"November 30, 2020",Actual,2020-11-30,"September 3, 2020",Actual,2020-09-03,NA,Observational,CHLORAZ,,An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso,An Observational Study to Assess the Effectiveness of the Standard of Care (Hydroxychloroquine+Azythromicin or Chloroquine+Azythromicin) Recommended by the Ministry of Health for the Treatment of the Coronavirus Infection in Burkina Faso,Completed,NA,NA,153,Actual,Centre Muraz,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      nasopharyngeal swab
    ",NA,NA,NA,NA,NA,2021-10-17T08:15:38Z,2021-10-17T08:15:38Z,15635567,NCT04445441,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2020-12-01,2020-06-21,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"June 22, 2020",Actual,2020-06-22,December 2020,2020-12-31,"September 20, 2021",Anticipated,2021-09-20,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:15:40Z,2021-10-17T08:15:40Z,15635604,NCT04445194,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-15,NA,NA,2020-11-23,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"June 24, 2020",Actual,2020-06-24,November 2020,2020-11-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV","Active, not recruiting",NA,Phase 1/Phase 2,2130,Actual,University of Oxford,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,within 1 year of trial completion,Any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.,NA,Yes,"The data accumulated from this study will be stored at RMPRU/ Wits. In collaboration with UK collaborators, we aim to make the data available, within one year of completion of the study to any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.
De-identified data will be shared. Related trial documents will be available (protocol, ICFs, statistical analysis plan)",2021-10-17T08:15:46Z,2021-10-17T08:15:46Z,15635682,NCT04444674,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-18,NA,NA,2020-06-18,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-19,Actual,"May 29, 2020",Actual,2020-05-29,June 2020,2020-06-30,November 2020,Anticipated,2020-11-30,October 2020,Anticipated,2020-10-31,NA,Observational,COVICARE,,The COVID-19 Disease and CARdiac Events Study,"An Observational Study of Hospitalised Patients With Coronavirus Disease 2019 (COVID-19) to Determine the Degree of Myocardial Injury Using Biomarkers and Echocardiography, and the Impact of This on Cardiovascular Outcomes",Recruiting,NA,NA,100,Anticipated,NHS Lanarkshire,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Venous blood plasma retained for future analysis.
    ",NA,NA,NA,No,NA,2021-10-17T08:16:39Z,2021-10-17T08:16:39Z,15636441,NCT04438993,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-17,NA,NA,2020-06-17,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-18,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"June 30, 2021",Anticipated,2021-06-30,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,NA,Phase 2,20,Anticipated,Jinnah Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,At the end of completion of the study,Available online,NA,Yes,The report will be published and available online.,2021-10-17T08:16:49Z,2021-10-17T08:16:49Z,15636582,NCT04437823,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-10,NA,NA,2020-06-12,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,"June 5, 2020",Actual,2020-06-05,"June 3, 2020",Actual,2020-06-03,NA,Observational,NA,,Epidemiological and Demographic Data From 150 Patients Diagnosed With Coronavirus Disease 2019 Pneumonia,"Epidemiological and Demographic Data From 150 Patients Diagnosed With Coronavirus Disease 2019 Pneumonia in Intensive Care Unit- a Retrospective, Observational Study in Istanbul, Turkey",Completed,NA,NA,150,Actual,Sisli Hamidiye Etfal Training and Research Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:01Z,2021-10-17T08:18:01Z,15637638,NCT04430023,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-12,NA,NA,2021-05-05,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"July 16, 2020",Actual,2020-07-16,May 2021,2021-05-31,"November 28, 2020",Actual,2020-11-28,"November 13, 2020",Actual,2020-11-13,NA,Interventional,ABACCuS,,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Completed,NA,Phase 2,71,Actual,William Beaumont Hospitals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:41Z,2021-10-17T08:17:41Z,15637342,NCT04432272,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-12,NA,NA,2020-06-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"March 15, 2020",Actual,2020-03-15,June 2020,2020-06-30,"May 15, 2020",Actual,2020-05-15,"May 15, 2020",Actual,2020-05-15,NA,Observational,COVIT-EHPAD,,Covid-19 and Vitamin D in Nursing-home,COvid-19 et VITamine d en EHPAD,Completed,NA,NA,96,Actual,"University Hospital, Angers",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:17:17Z,2021-10-17T08:17:17Z,15636968,NCT04435119,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2020-06-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"April 3, 2020",Actual,2020-04-03,June 2020,2020-06-30,"May 15, 2020",Actual,2020-05-15,"May 1, 2020",Actual,2020-05-01,NA,Observational,NA,,Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19),Compassionate Use of Opaganib in Patients With Severe COVID-19,Completed,NA,NA,23,Actual,Shaare Zedek Medical Center,,NA,2,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:17:17Z,2021-10-17T08:17:17Z,15636969,NCT04435106,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-10,NA,NA,2020-10-15,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"July 28, 2020",Actual,2020-07-28,June 2020,2020-06-30,"December 31, 2025",Anticipated,2025-12-31,"July 15, 2025",Anticipated,2025-07-15,NA,Interventional,CovImmune 2,,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement,Recruiting,NA,N/A,1000,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:06Z,2021-10-17T08:18:06Z,15637682,NCT04429594,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-06,NA,NA,2020-11-07,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"June 15, 2020",Actual,2020-06-15,November 2020,2020-11-30,"June 30, 2020",Actual,2020-06-30,"June 25, 2020",Actual,2020-06-25,NA,Observational,Prone Position,,Early Prone Position on Coronavirus Disease 2019 Pneumonia,The Effect of Early Prone Position on Prognosis in Acute Respiratory Failure Due to Coronavirus Disease 2019 Pneumonia,Completed,NA,NA,33,Actual,Sisli Hamidiye Etfal Training and Research Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:19Z,2021-10-17T08:18:19Z,15637910,NCT04427969,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,NA,NA,2020-06-10,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-11,Actual,"May 26, 2020",Actual,2020-05-26,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,October 2020,Anticipated,2020-10-31,NA,Observational,CARDS,,Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19),Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19),Recruiting,NA,NA,60,Anticipated,Royal Marsden NHS Foundation Trust,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:18:25Z,2021-10-17T08:18:25Z,15637988,NCT04427280,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-09,NA,NA,2021-04-06,2020-06-10,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"June 9, 2020",Actual,2020-06-09,September 2020,2020-09-30,"January 20, 2021",Actual,2021-01-20,"November 19, 2020",Actual,2020-11-19,NA,Interventional,NA,,"Safety of TY027, a Treatment for COVID-19, in Humans","Phase 1 First-in-Human, Time Lagged, Randomised, Placebo Controlled, Double Blind, Single Ascending Dose Study of TY027 in Healthy Adult Volunteers",Completed,NA,Phase 1,32,Actual,Tychan Pte Ltd.,,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:06Z,2021-10-17T08:18:06Z,15637703,NCT04429529,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-09,NA,NA,2020-06-09,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"June 5, 2020",Actual,2020-06-05,June 2020,2020-06-30,"July 31, 2021",Anticipated,2021-07-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,,"Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19","Identification of Genetic Factors Determining Disease Course and Preparation of Pharmacogenetic Applications in the New Type of Coronavirus Infection, COVID-19","Active, not recruiting",NA,NA,1000,Anticipated,Szeged University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood, nose and throat swab
    ",NA,NA,NA,No,NA,2021-10-17T08:18:33Z,2021-10-17T08:18:33Z,15638131,NCT04426253,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-05,NA,NA,2020-12-08,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-10,Actual,"May 19, 2020",Actual,2020-05-19,December 2020,2020-12-31,"December 20, 2021",Anticipated,2021-12-20,"July 19, 2021",Anticipated,2021-07-19,NA,Observational,NA,,Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.,Possibilities of Chest Magnetic Resonance Imaging (MRI) in Diagnostics of COVID-19. The Use of MRI to Assess Lung Damage in Patients With Coronavirus Infection,Recruiting,NA,NA,115,Anticipated,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:50Z,2021-10-17T08:18:50Z,15638384,NCT04424355,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-03-16,2020-06-05,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"September 25, 2020",Actual,2020-09-25,"September 25, 2020",Actual,2020-09-25,NA,Interventional,NA,,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,A Randomised Controlled Trial to Compare McGrath Videolaryngoscope Against Direct Laryngoscope for Endotracheal Intubation When Powered Air Purifying Respirator is Worn During the Current Coronavirus Disease 2019 Pandemic,Completed,NA,N/A,28,Actual,Singapore General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:45Z,2021-10-17T08:18:45Z,15638299,NCT04424953,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-07,NA,NA,2020-07-15,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"May 15, 2020",Actual,2020-05-15,July 2020,2020-07-31,"June 5, 2020",Actual,2020-06-05,"June 4, 2020",Actual,2020-06-04,NA,Observational,NA,,HFNC Treatment in COVID-19 Pneumonia,the Effect of HFNC Treatment on Mortality and Length of ICU Stay in Patient With COVID-19 Pneumonia,Completed,NA,NA,43,Actual,Sisli Hamidiye Etfal Training and Research Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:46Z,2021-10-17T08:18:46Z,15638313,NCT04424836,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-08,NA,NA,2020-06-12,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"June 8, 2020",Actual,2020-06-08,June 2020,2020-06-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,1 Year,Observational [Patient Registry],SERO-MARES,,Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19),"Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses and Assymptomatic Carriers Among a Cohort of 2,300 Healthcare Workers at the Consorci Sanitari Del Maresme (CSdM)",Recruiting,NA,NA,2400,Anticipated,Hospital de MatarÃ³,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:38Z,2021-10-17T08:18:38Z,15638192,NCT04425759,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-09,NA,NA,2021-01-15,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"August 1, 2020",Actual,2020-08-01,January 2021,2021-01-31,"December 29, 2020",Actual,2020-12-29,"December 29, 2020",Actual,2020-12-29,NA,Interventional,CRISIS,,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19),Completed,NA,Phase 1/Phase 2,23,Actual,"Clear Creek Bio, Inc.",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:42Z,2021-10-17T08:18:42Z,15638255,NCT04425252,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-05,NA,NA,2020-09-21,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"June 8, 2020",Actual,2020-06-08,September 2020,2020-09-30,"July 20, 2020",Actual,2020-07-20,"July 15, 2020",Actual,2020-07-15,NA,Observational,Covid-19,,Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia,Thrombosis Risk Assessment May Predict Clinical Presentation and Length of Hospital Stay in Covid-19 Pneumonia,Completed,NA,NA,70,Actual,Nisantasi University,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,IPD excluding names and personal identity numbers will be shared when the research is ready to be submitted for publication,2021-10-17T08:19:01Z,2021-10-17T08:19:01Z,15638508,NCT04423315,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-04,NA,NA,2021-02-18,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-18,2021-02-21,Actual,"June 10, 2020",Actual,2020-06-10,February 2021,2021-02-28,August 2021,Anticipated,2021-08-31,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,CoronaCope - Internet-based Cognitive Behavioural Therapy for Adults Suffering From Mental Health Problems Related to the Coronavirus Pandemic,"Active, not recruiting",NA,N/A,120,Anticipated,Linkoeping University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:18:53Z,2021-10-17T08:18:53Z,15638396,NCT04424212,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2020-06-05,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"May 29, 2020",Actual,2020-05-29,May 2020,2020-05-31,"December 1, 2020",Anticipated,2020-12-01,"September 1, 2020",Anticipated,2020-09-01,NA,Observational,QT-COVID-19,,Effects on the Qt Interval of COVID-19 Coronavirus Infection,Observational Study to Evaluate the Effects on the Qt Interval of COVID-19 Coronavirus Infection in Critically Ill Patients,Recruiting,NA,NA,80,Anticipated,Hospital General Universitario Gregorio MaraÃ±on,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:19:08Z,2021-10-17T08:19:08Z,15638606,NCT04422535,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,NA,NA,2020-06-07,2020-06-07,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-07,2020-06-09,Actual,"May 16, 2020",Actual,2020-05-16,June 2020,2020-06-30,"August 23, 2020",Anticipated,2020-08-23,"July 18, 2020",Anticipated,2020-07-18,NA,Interventional,BISCUIT,,BromhexIne And Spironolactone For CoronÐ°VirUs Infection Requiring HospiTalization,Open Label Randomized Clinical Trial BromhexIne And Spironolactone For CoronÐ°VirUs Infection Requiring HospiTalization,Recruiting,NA,Phase 3,80,Anticipated,Lomonosov Moscow State University Medical Research and Educational Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After publishing,any application for access the data will be evaluated by ethical commite of LOMONOSOV MOSCOW STATE UNIVERSITY MEDICAL RESEARCH AND EDUCATIONAL CENTER,NA,Yes,NA,2021-10-17T08:18:53Z,2021-10-17T08:18:53Z,15638406,NCT04424134,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-08,NA,NA,2021-03-07,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-07,2021-03-09,Actual,"June 7, 2020",Actual,2020-06-07,March 2021,2021-03-31,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Observational,NA,,Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers,Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers,Completed,NA,NA,1546,Actual,Egyptian Center for Research and Regenerative Medicine,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:18:55Z,2021-10-17T08:18:55Z,15638421,NCT04424017,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-05,NA,NA,2021-08-16,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"May 6, 2020",Actual,2020-05-06,August 2021,2021-08-31,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,NA,Observational,FRENCH ICU,,Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France,Study of the Increase in ICU Beds Capacity and Caregivers During COVID-19 Pandemic in France : the FRENCH ICU Study,Completed,NA,NA,9860,Actual,Centre Hospitalier Universitaire de NÄ«mes,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:27Z,2021-10-17T08:19:27Z,15638886,NCT04420286,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"July 5, 2020",Anticipated,2020-07-05,June 2020,2020-06-30,"February 20, 2021",Anticipated,2021-02-20,"December 20, 2020",Anticipated,2020-12-20,1 Day,Observational [Patient Registry],NA,,Extracellular Water in Covid 19 Pneumonia,the Determination of Extracellular Water (ECW) Which is Detected by Bioimpedence Method on Severe and Mild Covid 19 Pneumonia Clinical Course,Recruiting,NA,NA,52,Anticipated,Gaziosmanpasa Research and Education Hospital,,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:06Z,2021-10-17T08:20:06Z,15639429,NCT04416009,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-02,NA,NA,2021-05-10,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 16, 2020",Actual,2020-04-16,May 2021,2021-05-31,"September 3, 2020",Actual,2020-09-03,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,NA,Phase 3,142,Actual,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:27Z,2021-10-17T08:19:27Z,15638891,NCT04420247,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-13,NA,NA,2021-03-04,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-05,Actual,"May 20, 2020",Actual,2020-05-20,March 2021,2021-03-31,"July 1, 2021",Anticipated,2021-07-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,A Proposed Alternative to the N-95 Mask Shortage in the COVID-19 Pandemic. A Feasibility Study,"Active, not recruiting",NA,N/A,20,Actual,University of Oklahoma,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:58Z,2021-10-17T08:19:58Z,15639302,NCT04416919,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2021-09-09,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"June 15, 2020",Actual,2020-06-15,June 2021,2021-06-30,"October 1, 2022",Anticipated,2022-10-01,"July 31, 2021",Actual,2021-07-31,NA,Observational,NA,,Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19,"Quality of Life and Long-term Outcomes in Patients With Pneumonia Associated With SARS-Cov2 Infection, Survivors of Intensive Care Units: a Prospective Multicenter Cohort Study","Active, not recruiting",NA,NA,280,Actual,Universidade do Porto,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"The authors encourage interested parties to contact the corresponding author with data sharing requests, including for access to additional unpublished data.",2021-10-17T08:20:02Z,2021-10-17T08:20:02Z,15639363,NCT04416464,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-19,NA,NA,2021-08-17,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"August 6, 2020",Actual,2020-08-06,August 2021,2021-08-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,"Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).","Active, not recruiting",NA,Phase 2,120,Anticipated,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:20:18Z,2021-10-17T08:20:18Z,15639598,NCT04414631,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-29,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"March 22, 2020",Actual,2020-03-22,June 2020,2020-06-30,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,NA,Observational,COVID&PREG,,COVID-19 and Pregnancy Outcomes,COVID-19 and Pregnancy Outcomes: a Portuguese Collaboration Study,Recruiting,NA,NA,300,Anticipated,Universidade Nova de Lisboa,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:20:03Z,2021-10-17T08:20:03Z,15639378,NCT04416373,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2021-03-08,2020-05-29,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"July 2, 2020",Actual,2020-07-02,March 2021,2021-03-31,"December 23, 2020",Actual,2020-12-23,"November 26, 2020",Actual,2020-11-26,NA,Interventional,COVID-19,,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia",Completed,NA,Phase 2,42,Actual,RedHill Biopharma Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:18Z,2021-10-17T08:20:18Z,15639600,NCT04414618,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-23,NA,NA,2020-06-13,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"May 25, 2020",Actual,2020-05-25,June 2020,2020-06-30,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,NA,Observational,CCC,,Cardiac COVID-19 Health Care Workers,Cardiac Involvement in Coronavirus (SARS-Cov-2) Infected Health Care Workers: The CCC Study,Completed,NA,NA,142,Actual,AORTICA Group,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Analysis of immunity polymorphisms including low-resolution HLA typing and genotyping of KIR
      genes
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:20:32Z,2021-10-17T08:20:32Z,15639800,NCT04413071,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-25,NA,NA,2020-12-30,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2021-01-05,Actual,"October 30, 2020",Actual,2020-10-30,December 2020,2020-12-31,"December 25, 2020",Actual,2020-12-25,"December 15, 2020",Actual,2020-12-15,NA,Observational,NA,,Clinical Characteristics of Critically Ill Patients With COVID-19,Clinical Characteristics of Critically Ill Patients With 2019 Novel Coronavirus (COVID-19): Do We Need a New Triage System?,Completed,NA,NA,105,Actual,Nevsehir Public Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:20:29Z,2021-10-17T08:20:29Z,15639743,NCT04413435,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Observational,COVIDIAB-13,,Covid-19 and Diabetes in West of Algeria,Prevalence of Diabetes Among Hospitalized Patients With Covid-19 in West of Algeria. Identification of Diabetes-related Associated Factors Severe Forms,Recruiting,NA,NA,100,Anticipated,"Laboratoire De Recherche Sur Le Diabete, UniversitÃ© de Tlemcen",,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:34Z,2021-10-17T08:20:34Z,15639852,NCT04412746,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-05-09,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"May 26, 2020",Actual,2020-05-26,May 2021,2021-05-31,"May 7, 2021",Actual,2021-05-07,"April 28, 2021",Actual,2021-04-28,NA,Interventional,ACTIVATEII,,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial,Completed,NA,Phase 4,301,Actual,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:22Z,2021-10-17T08:20:22Z,15639640,NCT04414267,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-05-17,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-18,Actual,"May 20, 2020",Actual,2020-05-20,May 2021,2021-05-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,3 Weeks,Observational [Patient Registry],NA,,Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19,Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19,Completed,NA,NA,72,Actual,"Dalarna County Council, Sweden",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:36Z,2021-10-17T08:20:36Z,15639889,NCT04412551,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-24,NA,NA,2021-09-20,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-22,Actual,"June 6, 2020",Actual,2020-06-06,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"June 1, 2021",Actual,2021-06-01,NA,Interventional,TTCOV19,,Timing of Tracheotomy in Covid-19 Patients,"Timing of Tracheotomy in Covid-19 Positive Patients: a Randomized, Controlled Trial",Completed,NA,N/A,150,Actual,"Sahlgrenska University Hospital, Sweden",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:20:38Z,2021-10-17T08:20:38Z,15639916,NCT04412356,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-02,NA,NA,2020-10-23,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"June 2, 2020",Actual,2020-06-02,May 2020,2020-05-31,"October 2, 2020",Actual,2020-10-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,COVIDOCRECHE,,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants","Contamination and Transmission of the SARS-CoV-2 Virus in Exposed, Confined and Community-based Infants: A Cross-sectional, Multicentre, Interventional Seroprevalence Study",Completed,NA,N/A,600,Actual,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:20:24Z,2021-10-17T08:20:24Z,15639679,NCT04413968,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-14,NA,NA,2021-07-23,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"April 28, 2020",Actual,2020-04-28,July 2021,2021-07-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,,Psychological Impact of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders,Psychological Impact and Effect of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders - an Online Survey,Recruiting,NA,NA,1000,Anticipated,Medical University of Graz,,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:20:52Z,2021-10-17T08:20:52Z,15640117,NCT04410835,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,NA,NA,2020-05-28,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"June 5, 2020",Anticipated,2020-06-05,May 2020,2020-05-31,"August 20, 2020",Anticipated,2020-08-20,"July 20, 2020",Anticipated,2020-07-20,NA,Observational,NA,,Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients,Retrospective Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients,Recruiting,NA,NA,156,Anticipated,Gaziosmanpasa Research and Education Hospital,,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:21:15Z,2021-10-17T08:21:15Z,15640441,NCT04408378,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-27,NA,NA,2021-08-06,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-10,Actual,"September 30, 2020",Actual,2020-09-30,August 2021,2021-08-31,"November 30, 2021",Anticipated,2021-11-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,"Study of the P2Et Extract Obtained From Caesalpinia Spinosa in the Symptomatic Treatment of Subjects With COVID-19 at the Hospital Universitario San Ignacio, Colombia.",Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Hospital Universitario San Ignacio,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:20:56Z,2021-10-17T08:20:56Z,15640161,NCT04410510,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-29,NA,NA,2021-10-04,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"May 22, 2020",Actual,2020-05-22,July 2021,2021-07-31,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Observational,PREPARE IBD,,PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic,PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic,"Active, not recruiting",NA,NA,1500,Anticipated,Hull University Teaching Hospitals NHS Trust,,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:20:56Z,2021-10-17T08:20:56Z,15640163,NCT04410484,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-18,NA,NA,2020-05-28,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"December 31, 2023",Anticipated,2023-12-31,"December 30, 2023",Anticipated,2023-12-30,NA,Observational,MICRO-COV,,Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches,Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches,Recruiting,NA,NA,300,Anticipated,University of Zurich,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:59Z,2021-10-17T08:20:59Z,15640194,NCT04410263,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-28,NA,NA,2021-09-27,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"March 31, 2021",Actual,2021-03-31,September 2021,2021-09-30,"February 28, 2022",Anticipated,2022-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,AMPoL,,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19),Recruiting,NA,Phase 2,150,Anticipated,"University of California, San Francisco",,5,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:21:03Z,2021-10-17T08:21:03Z,15640243,NCT04409873,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-28,NA,NA,2021-01-21,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"July 1, 2020",Actual,2020-07-01,January 2021,2021-01-31,"January 12, 2021",Actual,2021-01-12,"January 12, 2021",Actual,2021-01-12,NA,Interventional,NA,,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),"A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)",Completed,NA,Phase 2,124,Actual,CSL Behring,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.,"Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.",NA,Yes,"CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.",2021-10-17T08:21:06Z,2021-10-17T08:21:06Z,15640295,NCT04409509,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-16,NA,NA,2020-06-27,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"June 22, 2020",Actual,2020-06-22,"June 22, 2020",Actual,2020-06-22,NA,Interventional,NA,,Convalescent Plasma Therapy in Patients With COVID-19,Convalescent Plasma Therapy in Patients With COVID-19,Completed,NA,Phase 1,10,Actual,Biofarma,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:21:26Z,2021-10-17T08:21:26Z,15640595,NCT04407208,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-25,NA,NA,2020-05-27,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Observational,NA,,Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure,Awake Proning in Patients With COVID-19-Induced Acute Hypoxemic Respiratory Failure,"Active, not recruiting",NA,NA,29,Actual,Columbia University,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Individual participant data will not be shared owing to privacy protection.,2021-10-17T08:21:17Z,2021-10-17T08:21:17Z,15640471,NCT04408222,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-25,NA,NA,2021-02-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"April 15, 2020",Actual,2020-04-15,February 2021,2021-02-28,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,SOLID,,Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection,Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection,Recruiting,NA,NA,128,Anticipated,FundaciÃ³n GECP,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:21:26Z,2021-10-17T08:21:26Z,15640608,NCT04407143,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-23,NA,NA,2021-03-06,2020-05-23,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-06,2021-03-09,Actual,"May 15, 2020",Actual,2020-05-15,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,,Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.,Investigation of Systemic Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of Coronavirus Disease-19.,Recruiting,NA,NA,25,Anticipated,"National Institute of Cardiology, Laranjeiras, Brazil",,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      ultra frozen plasma samples will be stocked for the evaluation of inflammatory
      anti-inflammatory cytokines
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:21:32Z,2021-10-17T08:21:32Z,15640683,NCT04406545,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-24,NA,NA,2021-03-29,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-03-30,Actual,"May 21, 2020",Actual,2020-05-21,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide,Completed,NA,Phase 4,150,Actual,Materno-Perinatal Hospital of the State of Mexico,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,The Data will be available upon request after a publication is reached.,2021-10-17T08:21:34Z,2021-10-17T08:21:34Z,15640722,NCT04406246,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2021-08-10,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-11,Actual,"May 19, 2020",Actual,2020-05-19,August 2021,2021-08-31,"March 30, 2022",Anticipated,2022-03-30,"March 30, 2022",Anticipated,2022-03-30,NA,Observational,FALCON-C19,,Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19),Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19),Recruiting,NA,NA,1000,Anticipated,Manchester University NHS Foundation Trust,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Throat and nose swabs and/or saliva samples may be taken at multiple time points and stored
      for future testing.

      Whole blood samples may be taken at multiple time points during the study. Samples will be
      processed and the serum stored.

      Finger stick samples may also be taken and stored for future testing.
    ",NA,NA,NA,No,NA,2021-10-17T08:21:17Z,2021-10-17T08:21:17Z,15640481,NCT04408170,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-26,NA,NA,2020-11-19,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-19,2020-11-23,Actual,"June 4, 2020",Actual,2020-06-04,November 2020,2020-11-30,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,,The Use of Disinfectants Among Women in Egypt and the Toxicity by Bleach During the Coronavirus Lock-down.,Disinfection Practices Among Women in Egypt During the Coronavirus Pandemic.,Completed,NA,NA,425,Actual,Helwan University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,The plan to make (IPD) viable has not been decided to maintain the confidentiality and privacy of the information collected in this research project.,2021-10-17T08:21:43Z,2021-10-17T08:21:43Z,15640844,NCT04405284,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,NA,NA,2020-12-14,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-14,2020-12-17,Actual,"November 10, 2020",Actual,2020-11-10,May 2020,2020-05-31,"June 1, 2022",Anticipated,2022-06-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,CORONA,,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,A Prospective Randomized Trial of Prone Positioning Versus Usual Care for Patients With Do-not-intubate Goals of Care and Hypoxemic Respiratory Failure During the Coronavirus SARS-CoV-2 (COVID-19) Pandemic,Recruiting,NA,N/A,596,Anticipated,University of Calgary,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:07Z,2021-10-17T08:22:07Z,15641139,NCT04402879,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-24,NA,NA,2021-01-29,2020-05-26,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-01,Actual,"April 17, 2020",Actual,2020-04-17,January 2021,2021-01-31,"August 1, 2020",Actual,2020-08-01,"June 1, 2020",Actual,2020-06-01,NA,Observational,COVIT-D,,Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency,Cohort Study to Determine the Association Between Vitamin D Deficiency and Severity of the Disease in Patients With Coronarvirus Disease 2019 (COVID-19),Completed,NA,NA,300,Actual,"Hospital San Carlos, Madrid",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:21:57Z,2021-10-17T08:21:57Z,15641010,NCT04403932,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-20,NA,NA,2021-02-08,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"July 22, 2020",Actual,2020-07-22,February 2021,2021-02-28,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,1 Year,Observational [Patient Registry],CCOVID-PREG,,Characteristics of COVID-19 Infection Among PREGnant Women,Characteristics of COVID-19 Infection Among PREGnant Women,Recruiting,NA,NA,100,Anticipated,Inova Health System,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"Since COVID-19 in pregnant women is still a novel topic, we anticipate the need for collaboration with other researchers studying the effects of COVID-19 in pregnant women.
Individual participant data that underlie the results to be reported in our research would be available to be shared after deidentification (text, tables, figures and appendices) for individual participant meta-analysis.
Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our Institution's data warehouse but without investigator support other than deposited metadata.
Time Frame: Beginning 9 months and ending 36 months following article publication.
Information to be shared: Study Protocol, Results.
Access Criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.",2021-10-17T08:22:52Z,2021-10-17T08:22:52Z,15641796,NCT04398264,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-23,NA,NA,2021-01-25,2020-05-23,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"June 3, 2020",Actual,2020-06-03,January 2021,2021-01-31,"February 1, 2021",Anticipated,2021-02-01,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,NA,,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""","Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: ""The Hope Coalition""",Recruiting,NA,Phase 3,1968,Anticipated,Cardresearch,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:05Z,2021-10-17T08:22:05Z,15641106,NCT04403100,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,NA,NA,2020-05-24,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-24,2020-05-27,Actual,"February 1, 2020",Actual,2020-02-01,May 2020,2020-05-31,"June 20, 2020",Anticipated,2020-06-20,"June 6, 2020",Anticipated,2020-06-06,NA,Observational,NA,,The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19,The Clinical Difference Between the Nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the Fatal Cases With Severe COVID-19,Recruiting,NA,NA,100,Anticipated,The First Affiliated Hospital of Guangzhou Medical University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,It is not decided,2021-10-17T08:22:06Z,2021-10-17T08:22:06Z,15641124,NCT04403009,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-20,NA,NA,2021-02-02,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"June 15, 2020",Actual,2020-06-15,February 2021,2021-02-28,"August 15, 2020",Actual,2020-08-15,"July 15, 2020",Actual,2020-07-15,NA,Observational,COVID-PSL,,"Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)","Observational Study in Diagnosed Patients Covid-19, Supported on an Outpatient Basis.",Completed,NA,NA,450,Actual,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:07Z,2021-10-17T08:22:07Z,15641136,NCT04402905,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"May 17, 2020",Actual,2020-05-17,"May 16, 2020",Actual,2020-05-16,NA,Observational,NA,,Ozone Therapy in the Prevention of COVID-19 Infection,The Effectiveness of Ozone Therapy in the Prevention of COVID-19 Infection,Completed,NA,NA,71,Actual,Marmara University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:35Z,2021-10-17T08:22:35Z,15641555,NCT04400006,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-22,NA,NA,2021-08-30,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"May 28, 2020",Actual,2020-05-28,August 2021,2021-08-31,"February 19, 2021",Actual,2021-02-19,"February 19, 2021",Actual,2021-02-19,NA,Interventional,NA,,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,"A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19",Completed,NA,Phase 1/Phase 2,65,Actual,"Apellis Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:22:15Z,2021-10-17T08:22:15Z,15641285,NCT04402060,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-19,NA,NA,2020-07-06,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"June 13, 2020",Actual,2020-06-13,July 2020,2020-07-31,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,NA,N/A,20,Anticipated,Beyond Air Inc.,,2,NA,NA,NA,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:57Z,2021-10-17T08:22:57Z,15641877,NCT04397692,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-19,NA,NA,2020-08-28,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-08-31,Actual,"April 21, 2020",Actual,2020-04-21,May 2020,2020-05-31,"October 21, 2020",Anticipated,2020-10-21,"October 21, 2020",Anticipated,2020-10-21,NA,Observational,ECMO-SARS,,Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19,Extracorporeal Membrane Oxygenation (ECMO) as a Therapeutic Option in Severe Form of COVID-19: a Nationwide Cohort Study,Recruiting,NA,NA,300,Anticipated,Rennes University Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:22:58Z,2021-10-17T08:22:58Z,15641891,NCT04397588,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-17,NA,NA,2021-01-08,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"May 6, 2020",Actual,2020-05-06,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,ACHIEVE,,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial,Completed,NA,Phase 2,90,Actual,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:22:55Z,2021-10-17T08:22:55Z,15641837,NCT04398004,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-20,NA,NA,2021-07-08,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-09,Actual,"April 9, 2020",Actual,2020-04-09,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,June 2022,Anticipated,2022-06-30,NA,Observational,NA,,Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19,"Characterization of ARDS, Critical Illness Myopathy and Their Long-term Consequences in Patients With Covid-19 Disease: Effects of Inflammation, Mitochondrial Dysfunction and Plasma Concentrations of Various Sedative Drugs",Recruiting,NA,NA,50,Anticipated,"University Hospital Inselspital, Berne",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:23:03Z,2021-10-17T08:23:03Z,15641950,NCT04397172,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-18,NA,NA,2020-10-21,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"June 4, 2020",Actual,2020-06-04,May 2020,2020-05-31,"October 1, 2020",Actual,2020-10-01,"October 1, 2020",Actual,2020-10-01,NA,Observational,WHO,,EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19,"The Impact of EXercise TRAining, Physical Activity and Sedentary Lifestyle on Clinical Outcomes in Surviving Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2: Cross-sectional Study",Completed,NA,NA,1574,Actual,University of Sao Paulo General Hospital,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Starting in June 2020. All the data will be available permanently.,Data will be available to other researchers after the end of the study. Data will be available for statistical analyses. The personal data of volunteers will not be identified. The principal investigator will be responsible for requests and criteria for information that will be shared.,https://osf.io/crv6t/,Yes,All data will be shared publicly through the tool Open Science Framework.,2021-10-17T08:23:11Z,2021-10-17T08:23:11Z,15642039,NCT04396353,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,NA,2021-06-08,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-10,Actual,"June 21, 2020",Actual,2020-06-21,May 2020,2020-05-31,"May 30, 2021",Actual,2021-05-30,"March 26, 2021",Actual,2021-03-26,NA,Interventional,ACTION,,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial,Completed,NA,Phase 4,615,Actual,Brazilian Clinical Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.,2021-10-17T08:23:28Z,2021-10-17T08:23:28Z,15642284,NCT04394377,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-15,NA,NA,2021-03-21,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-23,Actual,"May 15, 2020",Actual,2020-05-15,March 2021,2021-03-31,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Interventional,COVAYDE,,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19,Completed,NA,N/A,13,Actual,HÃ´pital de Verdun,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:21Z,2021-10-17T08:23:21Z,15642191,NCT04395144,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-16,NA,NA,2021-03-31,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"April 3, 2020",Actual,2020-04-03,March 2021,2021-03-31,"September 1, 2020",Actual,2020-09-01,"May 1, 2020",Actual,2020-05-01,NA,Observational,COVIDsFlt1,,sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?,sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?,Completed,NA,NA,72,Actual,CHU de Reims,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,"
      blood
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:23:30Z,2021-10-17T08:23:30Z,15642302,NCT04394195,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-18,NA,NA,2021-09-16,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-17,Actual,"May 5, 2020",Actual,2020-05-05,September 2021,2021-09-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?,Recruiting,NA,Phase 1,40,Anticipated,Hampshire Hospitals NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:33Z,2021-10-17T08:23:33Z,15642382,NCT04393792,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-13,NA,NA,2020-10-26,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"August 31, 2020",Actual,2020-08-31,May 2020,2020-05-31,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,COVIDSPERM,,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,NA,N/A,20,Anticipated,Universitair Ziekenhuis Brussel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:54Z,2021-10-17T08:23:54Z,15642621,NCT04391829,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-26,NA,NA,2021-02-16,2020-05-15,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-18,Actual,"May 5, 2020",Actual,2020-05-05,February 2021,2021-02-28,"February 16, 2021",Actual,2021-02-16,"February 16, 2021",Actual,2021-02-16,1 Day,Observational [Patient Registry],NA,,Serologic Testing of Household Contacts of Confirmed Cases of COVID-19,Observational Trial Evaluating the Serologic Status of Household Contacts of Patients Diagnosed With COVID-19,Completed,NA,NA,96,Actual,Hospital Universitario Dr. Jose E. Gonzalez,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood samples will be obtained by capillary puncture or venipuncture for rapid testing of
      antibodies against SARS-CoV-2 (IVD COVID-19 IgM/IgG test kit, Singclean).

      Samples will be stored in the laboratory, and discarded at the discretion of the researcher.
    ",NA,NA,NA,NA,NA,2021-10-17T08:23:39Z,2021-10-17T08:23:39Z,15642466,NCT04393142,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-14,NA,NA,2021-07-13,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-14,Actual,"April 12, 2021",Actual,2021-04-12,July 2021,2021-07-31,February 2022,Anticipated,2022-02-28,November 2021,Anticipated,2021-11-30,NA,Interventional,CaTT,,COVID-19 and Anti-CD14 Treatment Trial,"Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,300,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:58Z,2021-10-17T08:23:58Z,15642693,NCT04391309,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-25,NA,NA,2021-05-22,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"November 30, 2020",Actual,2020-11-30,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,Clinical Use of Stem Cells for the Treatment of Covid-19,What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study),Completed,NA,Phase 1/Phase 2,30,Actual,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:42Z,2021-10-17T08:23:42Z,15642502,NCT04392778,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,2021-06-15,NA,2021-07-15,2020-05-15,2020-05-18,Actual,2021-07-15,2021-07-19,Actual,NA,NA,NA,2021-07-15,2021-07-19,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"August 11, 2020",Actual,2020-08-11,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,Safety population,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers",Completed,NA,Phase 1,130,Actual,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:47Z,2021-10-17T08:23:47Z,15642571,NCT04392219,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-15,NA,NA,2021-03-16,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-18,Actual,"May 31, 2020",Actual,2020-05-31,March 2021,2021-03-31,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,DICER,,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Completed,NA,Phase 2,100,Actual,University of Michigan,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:59Z,2021-10-17T08:23:59Z,15642707,NCT04391179,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),Aerosol Inhalation of the Exosomes Derived From Allogenic COVID-19 T Cell in the Treatment of Early Stage Novel Coronavirus Pneumonia,"Active, not recruiting",NA,Phase 1,60,Anticipated,TC Erciyes University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:24:14Z,2021-10-17T08:24:14Z,15642947,NCT04389385,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-15,NA,NA,2021-03-18,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-23,Actual,"May 20, 2020",Actual,2020-05-20,March 2021,2021-03-31,"December 1, 2020",Actual,2020-12-01,"July 10, 2020",Actual,2020-07-10,NA,Observational,NA,,Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic,Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic,Completed,NA,NA,108,Actual,Vanderbilt University Medical Center,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:23:59Z,2021-10-17T08:23:59Z,15642708,NCT04391166,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-10,NA,NA,2020-08-14,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Effectiveness of Prone Positioning Combined With High-flow Nasal Cannula for Patients With COVID-19 Induced ARDS,Recruiting,NA,N/A,248,Anticipated,Hospital Universitari Vall d'Hebron Research Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will be shared when first 200 patients (counting the 5 studies participating in the meta-trial) will be included and at the end of inclusion,NA,NA,Yes,"Data will be shared to perform a meta-trial including other studies that assess the effectiveness of prone position in COVID-19 patients supported with nasal high flow.
No patient identifying data will be transferred to the data repository. The data set will use pseudoanonymised data. The consent process for the study will highlight that this is a meta-trial and that both aggregated and individual data without personal identifying features will be used to formulate the results from the study. Local regulation for the management of patient data needs to be adhered to as part of agreement for involvement in the study.
Data will be shared during the study at two points, Time 1 An interim analysis at 200 patients in which aggregated outcome data for the primary outcome and severe adverse effects will be analyzed
Time 2 Final analysis outlining salient clinical feature of patients for each group, outcomes",2021-10-17T08:23:59Z,2021-10-17T08:23:59Z,15642713,NCT04391140,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-07-20,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"May 4, 2020",Actual,2020-05-04,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"March 21, 2021",Actual,2021-03-21,NA,Interventional,NA,,Study to Evaluate the Effect of a Probiotic in COVID-19,The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection,Completed,NA,N/A,41,Actual,Bioithas SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:05Z,2021-10-17T08:24:05Z,15642795,NCT04390477,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,2020-12-09,NA,2020-12-10,2020-05-14,2020-05-15,Actual,2020-12-10,2020-12-17,Actual,NA,NA,NA,2020-12-10,2020-12-17,Actual,"July 31, 2020",Actual,2020-07-31,December 2020,2020-12-31,"October 9, 2020",Actual,2020-10-09,"September 17, 2020",Actual,2020-09-17,NA,Interventional,SAINT,,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,Completed,NA,Phase 2,24,Actual,"Clinica Universidad de Navarra, Universidad de Navarra",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:09Z,2021-10-17T08:24:09Z,15642860,NCT04390022,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2020-08-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"March 31, 2020",Actual,2020-03-31,August 2020,2020-08-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19),Completed,NA,N/A,15,Actual,"University Hospital, Basel, Switzerland",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:10Z,2021-10-17T08:24:10Z,15642868,NCT04389944,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2020-05-12,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"February 20, 2020",Actual,2020-02-20,February 2020,2020-02-29,"May 30, 2020",Anticipated,2020-05-30,"May 20, 2020",Anticipated,2020-05-20,NA,Observational,NA,,Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention,"Department of Chinese Medicine, Branch of Linsen, Chinese Medicine, and Kunming, Taipei City Hospital, Taipei, Taiwan Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan.",Recruiting,NA,NA,300,Anticipated,Taipei City Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:24:20Z,2021-10-17T08:24:20Z,15643046,NCT04388644,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2020-05-14,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 10, 2020",Anticipated,2020-05-10,May 2020,2020-05-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,12 Months,Observational [Patient Registry],COVID-19,,Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.,Detection Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Male Genitourinary System and Its Impact on Male Reproductive Health: an Observational Clinical Study.,Recruiting,NA,NA,200,Anticipated,Tongji Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      whole bloodï¼Œserumï¼Œurine, prostate fluid, and semen
    ",Data will be available with 6 months of study completion.,Data access requests will be reviewed by the external independent review panel and Tongji hospital. Requester will be required to sign a Data Access Agreement.,NA,Yes,De-identified individual participant data for all primary and secondary outcome measure will be available.,2021-10-17T08:24:20Z,2021-10-17T08:24:20Z,15643047,NCT04388631,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-13,NA,NA,2021-03-14,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-14,2021-03-16,Actual,"June 15, 2020",Actual,2020-06-15,March 2021,2021-03-31,"November 30, 2021",Anticipated,2021-11-30,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,,Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia,Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia,Recruiting,NA,NA,250,Anticipated,Princess Nourah Bint Abdulrahman University,,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:24:20Z,2021-10-17T08:24:20Z,15643051,NCT04388618,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-06-01,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"April 21, 2020",Actual,2020-04-21,June 2021,2021-06-30,September 2022,Anticipated,2022-09-30,September 2021,Anticipated,2021-09-30,20 Months,Observational [Patient Registry],ASPIRE,,Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic,Assessing the Safety of Pregnancy In the CoRonavirus pandEmic: a Nationwide Prospective Study,Recruiting,NA,NA,11000,Anticipated,"University of California, San Francisco",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      At-home blood spot kits will be used for serology surveillance. Tests will occur weekly
      during the first trimester and monthly during the second and third trimesters of pregnancy.
      Covid-19 antibody serology and cytokine testing will be assayed using these blood spot cars.
    ",NA,NA,NA,Yes,NA,2021-10-17T08:24:20Z,2021-10-17T08:24:20Z,15643054,NCT04388605,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-12,NA,NA,2021-10-04,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 24, 2020",Actual,2020-08-24,October 2021,2021-10-31,"October 4, 2021",Actual,2021-10-04,"July 13, 2021",Actual,2021-07-13,NA,Observational,COVIDOR,,"Epidemiological Study of the Covid-19 Presto Test - The ""COVIDOR"" Study","Epidemiological Study of the Covid-19 Presto Test Among Agents of the Local Authorities of CCTVL, Region Centre Val de Loire and Orleans MÃ©tropole. Correlation of IgM Level According to Contact With the Public",Completed,NA,NA,3228,Actual,OrlÃ©ans MÃ©tropole Service de MÃ©decine PrÃ©ventive,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      blood drop to test IgM and IgG by an immunoserology rapid screening autotest and antigenic
      test
    ",NA,NA,NA,Undecided,"Blood sample to be taken after self-bite. A consent form is given to the officer.
A drop of blood is deposited on a coverslip, 2 drops of reagents allow migration to the gel.
Reading in 15 minutes
strip: negative result
bands: positive result
An authorized person, subject to medical confidentiality, reports the result in the medical file and informs the agent of the result.
He is given a paper document signed by the SMP with the procedure to follow.",2021-10-17T08:24:25Z,2021-10-17T08:24:25Z,15643133,NCT04387968,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-13,NA,NA,2020-06-17,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-19,Actual,"May 13, 2020",Actual,2020-05-13,June 2020,2020-06-30,"June 17, 2020",Actual,2020-06-17,"June 12, 2020",Actual,2020-06-12,NA,Observational,MC-19,,Determinants of COVID-19 Pneumonia (MC-19),Major Determinants of COVID-19 Associated Pneumonia,Completed,NA,NA,520,Actual,Catholic University of the Sacred Heart,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      plasma samples
    ",NA,NA,NA,NA,NA,2021-10-17T08:24:26Z,2021-10-17T08:24:26Z,15643153,NCT04387799,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-08,NA,NA,2020-10-05,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,April 2021,Anticipated,2021-04-30,"September 10, 2020",Actual,2020-09-10,NA,Interventional,NA,,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,NA,N/A,400,Anticipated,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:24:59Z,2021-10-17T08:24:59Z,15643589,NCT04384458,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-09,NA,NA,2021-02-22,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"September 8, 2020",Actual,2020-09-08,December 2020,2020-12-31,"July 31, 2021",Anticipated,2021-07-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Zofin (Organicell Flow) for Patients With COVID-19,"A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Moderate to SARS Related to COVID-19 Infection vs Placebo",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Organicell Regenerative Medicine,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:00Z,2021-10-17T08:25:00Z,15643592,NCT04384445,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-10,NA,NA,2020-05-12,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"June 1, 2020",Anticipated,2020-06-01,May 2020,2020-05-31,"September 1, 2020",Anticipated,2020-09-01,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,NA,Early Phase 1,150,Anticipated,"Ministry of Health, Saudi Arabia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:24:45Z,2021-10-17T08:24:45Z,15643416,NCT04385836,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,NA,NA,2020-05-08,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"March 13, 2020",Actual,2020-03-13,May 2020,2020-05-31,"April 14, 2020",Actual,2020-04-14,"April 14, 2020",Actual,2020-04-14,NA,Observational,NA,,Outcomes in Hospitalized Older Patients With COVID-19,COVIDAge Study- Hospital Des Trois-ChÃªne,Completed,NA,NA,230,Actual,"University Hospital, Geneva",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:24:52Z,2021-10-17T08:24:52Z,15643499,NCT04385212,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2020-07-31,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,"A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",Completed,NA,N/A,33,Actual,Taoyuan General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The study outcome will be shared with the experts and persons interested in this field.,2021-10-17T08:25:00Z,2021-10-17T08:25:00Z,15643602,NCT04384380,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-09,NA,NA,2021-05-26,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"May 4, 2020",Actual,2020-05-04,May 2021,2021-05-31,"August 1, 2020",Actual,2020-08-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,,Convalescent Plasma for Patients With COVID-19,The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease,Completed,NA,Phase 2,30,Actual,Henry Ford Health System,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:24:52Z,2021-10-17T08:24:52Z,15643502,NCT04385199,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-06-28,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"May 6, 2020",Actual,2020-05-06,June 2021,2021-06-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,COSiN,,Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales,Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales,Recruiting,NA,NA,200,Anticipated,Kirby Institute,,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Access to samples and data is governed by the Protocol Steering Committee. Requests can be made to the Committee (via the Principal Investigators).,2021-10-17T08:25:07Z,2021-10-17T08:25:07Z,15643688,NCT04383652,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2020-12-02,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"May 8, 2020",Actual,2020-05-08,December 2020,2020-12-31,"December 1, 2030",Anticipated,2030-12-01,"December 1, 2030",Anticipated,2030-12-01,NA,Interventional,NA,,Novel Regimens in COVID-19 Treatment,Nitazoxanide in Treatment of COVID-19,Recruiting,NA,Phase 3,160,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:15Z,2021-10-17T08:25:15Z,15643784,NCT04382846,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-03-26,2020-05-07,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-03-29,Actual,"June 15, 2020",Actual,2020-06-15,March 2021,2021-03-31,"February 28, 2022",Anticipated,2022-02-28,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,NA,,"CoV-ICU Score, Intensive Care Unit, SARS-CoV-2",CoV-ICU Score: Who Will Need Intensive Care in the Course of Corona Virus Disease?,Recruiting,NA,NA,100,Anticipated,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:25:09Z,2021-10-17T08:25:09Z,15643706,NCT04383483,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2020-06-10,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-11,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,CÃ³rdobaTrail,,Inhaled Ibuprofen to Treat COVID-19,"Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.",Recruiting,NA,N/A,40,Anticipated,QuÃ­mica Luar SRL,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:25:16Z,2021-10-17T08:25:16Z,15643790,NCT04382768,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2020-05-18,2020-05-06,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"March 22, 2020",Actual,2020-03-22,March 2020,2020-03-31,"March 21, 2021",Anticipated,2021-03-21,"March 21, 2021",Anticipated,2021-03-21,NA,Observational,ImmunoCOVID,,Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.,Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.,Enrolling by invitation,NA,NA,1500,Anticipated,University Hospital Southampton NHS Foundation Trust,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:18Z,2021-10-17T08:25:18Z,15643819,NCT04382508,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2020-11-30,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-01,Actual,"June 15, 2020",Actual,2020-06-15,November 2020,2020-11-30,"October 8, 2020",Actual,2020-10-08,"October 8, 2020",Actual,2020-10-08,30 Days,Observational [Patient Registry],NA,,Covid-19 Triage Using Camera-based AI,Covid-19 Triage Using Camera-based AI,Completed,NA,NA,214,Actual,Vastra Gotaland Region,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,It will be made available upon final publication,A complete de-identified data set will be made made publicly available in a data repository. The exact data-repository is not yet decided.,NA,Yes,De-identified data from patients observations,2021-10-17T08:25:09Z,2021-10-17T08:25:09Z,15643709,NCT04383457,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-05,NA,NA,2020-05-10,2020-05-06,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"February 1, 2020",Actual,2020-02-01,May 2020,2020-05-31,"May 1, 2020",Actual,2020-05-01,"April 30, 2020",Actual,2020-04-30,NA,Observational,NA,,Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT,Egyptian Initial Experience About 2019 Novel Corona Virus Disease (COVID-19): Single-center Study Analysis of 48 Patients in Alexandria-Egypt Regarding Radiological Patterns and Co-morbid Lung Diseases,Completed,NA,NA,48,Actual,Alexandria University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"The investigators will recommend further large group future researches for some notices in the study, but preferably not be biased",2021-10-17T08:25:18Z,2021-10-17T08:25:18Z,15643824,NCT04382469,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-08-05,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-12,Actual,"May 8, 2020",Actual,2020-05-08,August 2021,2021-08-31,"December 1, 2021",Anticipated,2021-12-01,"July 21, 2021",Actual,2021-07-21,NA,Interventional,SAVIORII,,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII)","Active, not recruiting",NA,N/A,60,Anticipated,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:19Z,2021-10-17T08:25:19Z,15643837,NCT04382391,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-02-15,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"April 29, 2020",Actual,2020-04-29,February 2021,2021-02-28,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Efficacy and Safety of PolyoxidoniumÂ® in Hospitalized Patients With Coronavirus Disease COVID-19,"A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of PolyoxidoniumÂ®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).","Active, not recruiting",NA,Phase 2/Phase 3,394,Actual,NPO Petrovax,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:25:31Z,2021-10-17T08:25:31Z,15643968,NCT04381377,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-08-23,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"May 6, 2020",Actual,2020-05-06,August 2021,2021-08-31,"July 29, 2021",Actual,2021-07-29,"July 29, 2021",Actual,2021-07-29,NA,Interventional,ROCO,,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19,Completed,NA,N/A,107,Actual,University of Bern,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:35Z,2021-10-17T08:25:35Z,15644027,NCT04380909,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-07-13,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-14,Actual,"April 24, 2020",Actual,2020-04-24,July 2021,2021-07-31,"June 24, 2021",Actual,2021-06-24,"April 9, 2021",Actual,2021-04-09,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease",Completed,NA,Phase 2,212,Actual,"Janssen Pharmaceutica N.V., Belgium",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-10-17T08:25:35Z,2021-10-17T08:25:35Z,15644018,NCT04380961,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-07,NA,NA,2021-08-25,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-31,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"December 21, 2020",Actual,2020-12-21,"November 5, 2020",Actual,2020-11-05,NA,Interventional,NA,,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Completed,NA,Phase 2,50,Actual,MGC Pharmaceuticals d.o.o,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:24Z,2021-10-17T08:25:24Z,15643883,NCT04382040,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-05,NA,NA,2021-09-27,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"May 11, 2020",Actual,2020-05-11,September 2021,2021-09-30,"May 11, 2025",Anticipated,2025-05-11,"December 11, 2021",Anticipated,2021-12-11,NA,Observational,NA,,Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19,"Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study",Recruiting,NA,NA,500,Anticipated,Center for Integrated Care,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Start with publication for a year.,Site Principal Investigator to review written requests from HIPPA-trained investigators.,NA,Yes,"Confidential, de-identified,demographic and health symptoms will be collected as part of this study.",2021-10-17T08:25:36Z,2021-10-17T08:25:36Z,15644031,NCT04380870,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-30,NA,NA,2020-06-10,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"May 22, 2020",Actual,2020-05-22,"May 22, 2020",Actual,2020-05-22,NA,Interventional,LDCTiP,,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,NA,N/A,230,Actual,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:51Z,2021-10-17T08:25:51Z,15644202,NCT04379531,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2020-09-13,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-09-13,2020-09-16,Actual,"November 1, 2020",Anticipated,2020-11-01,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"November 20, 2020",Anticipated,2020-11-20,NA,Observational,NA,,Haemoglobin Concentration on COVID-19,An Important Index on Severity of Coronavirus Disease: Erythrocyte Haemoglobin Concentration,Recruiting,NA,NA,200,Anticipated,Nevsehir Public Hospital,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:26:07Z,2021-10-17T08:26:07Z,15644444,NCT04377607,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-01,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 8, 2020",Anticipated,2020-05-08,"May 7, 2020",Anticipated,2020-05-07,NA,Interventional,NA,,Social Media and Covid19 Pandemic,The Role of Social Media as an Information Source in Covid19 Pandemic,Enrolling by invitation,NA,N/A,212,Anticipated,Acibadem University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,if requested to.,2021-10-17T08:25:58Z,2021-10-17T08:25:58Z,15644292,NCT04378738,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-05,NA,NA,2020-08-25,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-26,Actual,"May 7, 2020",Actual,2020-05-07,August 2020,2020-08-31,"August 5, 2020",Actual,2020-08-05,"July 28, 2020",Actual,2020-07-28,NA,Observational,EpiCoV-Brazil,,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,Completed,NA,NA,1589,Actual,University of Sao Paulo General Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"The investigators haven't developed a plan for sharing, but would be open to share unidentified data for research or public health purposes",2021-10-17T08:25:59Z,2021-10-17T08:25:59Z,15644313,NCT04378582,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2021-01-28,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-02-02,Actual,"July 15, 2020",Actual,2020-07-15,January 2021,2021-01-31,"July 15, 2022",Anticipated,2022-07-15,"April 15, 2022",Anticipated,2022-04-15,NA,Observational,NA,,Quality of Life and Long-term Outcomes After Hospitalization for COVID-19,Assessment of Health-related Quality of Life and Long-term Outcomes After Hospitalization for COVID-19: A Multicenter Prospective Cohort Study,Recruiting,NA,NA,1000,Anticipated,Hospital Moinhos de Vento,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"The authors encourage interested parties to contact the corresponding author with data sharing requests, including for access to additional unpublished data.",2021-10-17T08:26:15Z,2021-10-17T08:26:15Z,15644560,NCT04376658,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2020-05-08,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"March 15, 2020",Actual,2020-03-15,April 2020,2020-04-30,"August 31, 2021",Anticipated,2021-08-31,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,NA,,Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);,Health-related Quality of Life (HRQOL) and Physical Performance in Individuals After COVID-19 Induced Hospitalisation and the Impact of a Standard Care Follow-up Program: a Longitudinal Observational Cohort Study,Recruiting,NA,NA,60,Anticipated,Kantonsspital Winterthur KSW,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:26:23Z,2021-10-17T08:26:23Z,15644667,NCT04375709,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-30,NA,NA,2020-07-14,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-16,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"July 10, 2020",Actual,2020-07-10,"July 10, 2020",Actual,2020-07-10,NA,Observational,NA,,"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior","COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior",Completed,NA,NA,18251,Actual,Milton S. Hershey Medical Center,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:08Z,2021-10-17T08:26:08Z,15644447,NCT04377581,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2021-07-07,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"June 6, 2020",Actual,2020-06-06,July 2021,2021-07-31,"June 8, 2021",Actual,2021-06-08,"May 10, 2021",Actual,2021-05-10,NA,Interventional,iNSPIRE,,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE),Completed,NA,Phase 2,46,Actual,AbbVie,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.",Requests for access to individual participant data from ibrutinib clinical studies conducted by AbbVie can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu,http://yoda.yale.edu/,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2021-10-17T08:26:26Z,2021-10-17T08:26:26Z,15644708,NCT04375397,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,NA,NA,2020-05-07,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"June 5, 2021",Anticipated,2021-06-05,"June 5, 2021",Anticipated,2021-06-05,NA,Interventional,HPI-COVID-19,,Host-pathogen Interactions During SARS-CoV-2 Infection,Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19),Recruiting,NA,N/A,450,Anticipated,Hospices Civils de Lyon,,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:17Z,2021-10-17T08:26:17Z,15644580,NCT04376476,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-19,NA,NA,2020-05-01,2020-05-01,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-06,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"March 30, 2021",Anticipated,2021-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma,Recruiting,NA,Phase 3,240,Anticipated,West Virginia University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:20Z,2021-10-17T08:26:20Z,15644623,NCT04376034,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2021-06-28,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"May 25, 2020",Actual,2020-05-25,June 2021,2021-06-30,"September 25, 2022",Anticipated,2022-09-25,"September 25, 2022",Anticipated,2022-09-25,NA,Interventional,HARMONICOV,,Human Ab Response & immunoMONItoring of COVID-19 Patients,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,NA,N/A,75,Anticipated,Rennes University Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:26:46Z,2021-10-17T08:26:46Z,15645015,NCT04373200,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-01,NA,NA,2021-08-17,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"May 4, 2020",Actual,2020-05-04,August 2021,2021-08-31,"March 30, 2021",Actual,2021-03-30,"August 30, 2020",Actual,2020-08-30,NA,Observational,NA,,C-reactive Protein Levels Among Individuals With COVID-19,Triage Strategies Based on C-reactive Protein Levels Among Individuals With COVID-19: A Prospective Cohort Study,Completed,NA,NA,1006,Actual,Frederiksberg University Hospital,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Blood sample
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:26:41Z,2021-10-17T08:26:41Z,15644928,NCT04373798,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-01,NA,NA,2021-06-11,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-16,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"June 25, 2021",Anticipated,2021-06-25,"June 25, 2021",Anticipated,2021-06-25,NA,Interventional,PIONEER,,Early Intervention in COVID-19: Favipiravir Verses Standard Care,A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir and StaNdard Care vErsEs Standard CaRe,"Active, not recruiting",NA,Phase 3,502,Actual,Chelsea and Westminster NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Research team wishes to enable any meta-analyses of COVID-19 trials making appropriate requests. No plan to share IPD has been made at this time.,2021-10-17T08:26:41Z,2021-10-17T08:26:41Z,15644934,NCT04373733,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-03,NA,NA,2020-09-12,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"May 4, 2020",Actual,2020-05-04,September 2020,2020-09-30,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial,Completed,NA,Phase 2,58,Actual,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:26:29Z,2021-10-17T08:26:29Z,15644751,NCT04375098,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2020-08-20,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"May 5, 2020",Actual,2020-05-05,August 2020,2020-08-31,"April 5, 2021",Anticipated,2021-04-05,"April 5, 2021",Anticipated,2021-04-05,NA,Interventional,NA,,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial,"Active, not recruiting",NA,Phase 2,29,Anticipated,University of Virginia,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:26:33Z,2021-10-17T08:26:33Z,15644837,NCT04374565,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-02,NA,NA,2020-07-01,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-07,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,"August 29, 2021",Anticipated,2021-08-29,"May 5, 2021",Anticipated,2021-05-05,NA,Interventional,REP-COVID,,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,NA,Phase 2,116,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:26:33Z,2021-10-17T08:26:33Z,15644840,NCT04374539,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-30,NA,NA,2021-04-06,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-09,Actual,"April 8, 2020",Actual,2020-04-08,April 2021,2021-04-30,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,,"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19","Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19",Recruiting,NA,NA,1000,Anticipated,Stanford University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood sample and optional nasopharyngeal swab, cheek swab with saliva collection, nasal swab,
      stool sample, blood microsample, and endotracheal aspirate (sputum samples)
    ",NA,NA,NA,No,NA,2021-10-17T08:26:47Z,2021-10-17T08:26:47Z,15645021,NCT04373148,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2021-07-30,2020-04-29,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-03,Actual,"September 1, 2020",Actual,2020-09-01,July 2021,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,(COVID-19),,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Unplanned Shifting the Traditional Classroom-Based to Online Distance Learning as a Result of (COVID-19) Social Distancing Measures: Nursing Students' Perception and Achievement,Enrolling by invitation,NA,N/A,180,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,the study will be available to interested researchers by Publication in the indexed journal at the end of the study completion,2021-10-17T08:26:51Z,2021-10-17T08:26:51Z,15645067,NCT04372693,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2020-04-30,2020-04-27,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"October 22, 2020",Anticipated,2020-10-22,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,PredictCovidT,,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,NA,N/A,115,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:19Z,2021-10-17T08:27:19Z,15645505,NCT04369456,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,NA,NA,2020-04-30,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Observational,NA,,Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients,Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients,Recruiting,NA,NA,30,Anticipated,Semmelweis University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:26:52Z,2021-10-17T08:26:52Z,15645084,NCT04372576,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,NA,NA,2020-06-11,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-16,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"August 1, 2021",Anticipated,2021-08-01,"May 1, 2021",Anticipated,2021-05-01,12 Months,Observational [Patient Registry],NA,,HUNgarian COronaVirus Disease-19 Epidemiological Research,Hungarian CoronaVirus Disease-19 Epidemiological Research,Recruiting,NA,NA,11200,Anticipated,Semmelweis University Heart and Vascular Center,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:27:14Z,2021-10-17T08:27:14Z,15645412,NCT04370067,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,NA,NA,2021-08-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"August 12, 2020",Actual,2020-08-12,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,,COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings,"COVID-19 in People Living With HIV: Evaluation of Risk Factors and Outcomes in Resource-limited Settings. A Pooled Substudy of ADVANCE, DÂ²EFT, DolPHIN2 and NAMSAL","Active, not recruiting",NA,NA,596,Actual,Kirby Institute,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:26:58Z,2021-10-17T08:26:58Z,15645177,NCT04371835,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,NA,NA,2021-09-02,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"May 5, 2020",Actual,2020-05-05,"August 31, 2021",2021-08-31,"June 1, 2025",Anticipated,2025-06-01,"June 1, 2025",Anticipated,2025-06-01,NA,Observational,NA,,Genetics of COVID-19 Susceptibility and Manifestations,Genetics of COVID-19 Susceptibility and Manifestations,Recruiting,NA,NA,2500,Anticipated,National Institutes of Health Clinical Center (CC),,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:27:01Z,2021-10-17T08:27:01Z,15645227,NCT04371432,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,2021-05-28,NA,2021-07-24,2020-04-28,2020-05-01,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"May 13, 2020",Actual,2020-05-13,July 2021,2021-07-31,"May 26, 2020",Actual,2020-05-26,"May 24, 2020",Actual,2020-05-24,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Completed,NA,N/A,14267,Actual,"National Bureau of Economic Research, Inc.","Participants' behavior was not directly observed, outcomes were measured immediately postintervention in May 2020, and online recruitment may not be representative.",17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Generally, social scientists post code and de-identified data when the findings are published","To be determined, if published alongside the paper data and code may be gated.",NA,Yes,"Generally, economists will post code and de-identified data when the findings are published",2021-10-17T08:27:01Z,2021-10-17T08:27:01Z,15645229,NCT04371419,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2021-07-01,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"April 27, 2020",Actual,2020-04-27,July 2021,2021-07-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NA,,"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children","Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children",Recruiting,NA,NA,400,Anticipated,St. Jude Children's Research Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:27:03Z,2021-10-17T08:27:03Z,15645243,NCT04371315,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-04-30,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"April 14, 2021",Anticipated,2021-04-14,"April 14, 2021",Anticipated,2021-04-14,NA,Observational,NA,,Observational Study of COVID-19 Treatment Efficacy,Observational Study of COVID-19 Treatment Efficacy,Enrolling by invitation,NA,NA,1000,Anticipated,OSF Healthcare System,,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:27:15Z,2021-10-17T08:27:15Z,15645426,NCT04369989,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"December 27, 2020",Anticipated,2020-12-27,"August 27, 2020",Anticipated,2020-08-27,NA,Interventional,NA,,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,NA,Phase 2,200,Anticipated,Medical University of Vienna,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:27:20Z,2021-10-17T08:27:20Z,15645519,NCT04369365,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,24 Months,Observational [Patient Registry],NA,,Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement,Prospective Registry for Multimodal Assessment of Neuromuscular Pathology Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection,Recruiting,NA,NA,500,Anticipated,University Hospital Tuebingen,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:27:37Z,2021-10-17T08:27:37Z,15645799,NCT04367350,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-23,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 23, 2020",Actual,2020-04-23,"April 23, 2020",Actual,2020-04-23,NA,Interventional,PIC-19,,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol,Completed,NA,Phase 2,5,Actual,University of Milan,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:29Z,2021-10-17T08:27:29Z,15645665,NCT04368377,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2021-02-09,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"April 1, 2020",Actual,2020-04-01,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 30, 2021",Anticipated,2021-12-30,7 Days,Observational [Patient Registry],IMSEQ,,COVID-19 Immune Repertoire Sequencing,COVID-19 Immune Repertoire Sequencing,Recruiting,NA,NA,100,Anticipated,"Institute of Tropical Medicine, Belgium",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:27:31Z,2021-10-17T08:27:31Z,15645695,NCT04368143,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-28,NA,NA,2021-06-09,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-11,Actual,"April 18, 2020",Actual,2020-04-18,June 2021,2021-06-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,1 Year,Observational [Patient Registry],NA,,ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers,SARS-CoV-2 Seroprevalence Among Healthcare Workers: ARMOR Study Demonstration Project,Recruiting,NA,NA,1000,Anticipated,Columbia University,,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:27:33Z,2021-10-17T08:27:33Z,15645734,NCT04367857,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2021-03-24,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-26,Actual,"April 28, 2020",Actual,2020-04-28,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,,"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19",ScreenNC: A Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the SARS-CoV-2 Infection,Enrolling by invitation,NA,NA,10000,Anticipated,"University of North Carolina, Chapel Hill",,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Blood; virus from nasal or oral swab
    ",NA,NA,NA,No,NA,2021-10-17T08:27:34Z,2021-10-17T08:27:34Z,15645749,NCT04367740,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"March 26, 2020",Actual,2020-03-26,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,PROBIOZOVID,,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora,Recruiting,NA,Phase 2,152,Anticipated,Azienda Policlinico Umberto I,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:49Z,2021-10-17T08:27:49Z,15645946,NCT04366089,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2020-06-05,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 14, 2020",Actual,2020-05-14,"May 14, 2020",Actual,2020-05-14,NA,Interventional,COVID'HEMOS,,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,NA,N/A,99,Actual,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:35Z,2021-10-17T08:27:35Z,15645764,NCT04367662,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2021-01-28,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"May 4, 2020",Actual,2020-05-04,January 2021,2021-01-31,"October 29, 2020",Actual,2020-10-29,"October 29, 2020",Actual,2020-10-29,NA,Observational,COVIDSMELL,,Study of the Pathogenesis of Olfactory Disorders in COVID-19,Study of the Pathogenesis of Olfactory Disorders in COVID-19,Completed,NA,NA,26,Actual,Institut Pasteur,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Nasal swabs
    ",NA,NA,NA,No,NA,2021-10-17T08:27:41Z,2021-10-17T08:27:41Z,15645847,NCT04366934,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2020-12-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-10,Actual,"May 4, 2020",Actual,2020-05-04,December 2020,2020-12-31,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,ROCOCO,,Serology COVID-19 From the Cornwall Hospital Union,Serology COVID-19 From the Cornwall Hospital Union,Completed,NA,N/A,2587,Actual,Centre Hospitalier de Cornouaille,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:28:12Z,2021-10-17T08:28:12Z,15646300,NCT04363593,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2020-07-01,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-02,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,BRACE-CORONA,,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection (COVID-19). A Randomized Trial,Recruiting,NA,N/A,700,Anticipated,D'Or Institute for Research and Education,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:28:00Z,2021-10-17T08:28:00Z,15646109,NCT04364893,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2021-08-30,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"April 17, 2020",Actual,2020-04-17,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"March 29, 2021",Actual,2021-03-29,NA,Interventional,NA,,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients,"Active, not recruiting",NA,Phase 2,384,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Mila.Ortigoza@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"IPD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared.",2021-10-17T08:28:01Z,2021-10-17T08:28:01Z,15646125,NCT04364737,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"February 10, 2020",Actual,2020-02-10,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,April 2020,Anticipated,2020-04-30,NA,Interventional,PEAC,,Protective Effect of Aspirin on COVID-19 Patients,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,NA,Phase 2/Phase 3,128,Anticipated,Xijing Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:27:56Z,2021-10-17T08:27:56Z,15646042,NCT04365309,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2021-06-17,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"May 13, 2020",Actual,2020-05-13,March 2021,2021-03-31,"June 30, 2022",Anticipated,2022-06-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,CYNKCOVID,,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19,"Active, not recruiting",NA,Phase 1/Phase 2,86,Actual,Celularity Incorporated,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:58Z,2021-10-17T08:27:58Z,15646069,NCT04365101,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-23,NA,NA,2021-09-09,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-13,Actual,"April 21, 2020",Actual,2020-04-21,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,LIINC,,Long-term Impact of Infection With Novel Coronavirus (COVID-19),Long-term Impact of Infection With Novel Coronavirus (LIINC): An Observational Study,Recruiting,NA,NA,800,Anticipated,"University of California, San Francisco",,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Whole blood, peripheral blood mononuclear cells, plasma, serum, and saliva.
    ",NA,NA,NA,No,NA,2021-10-17T08:28:24Z,2021-10-17T08:28:24Z,15646489,NCT04362150,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2021-07-28,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"May 21, 2020",Actual,2020-05-21,February 2021,2021-02-28,"August 31, 2021",Anticipated,2021-08-31,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,,The COVID-19 ICU PRAYER Study,Impact of Multi-Denominational Prayer on Morbidity and Mortality of Patients Admitted to the Intensive Care Unite With Corona Virus Infection,Recruiting,NA,N/A,1000,Anticipated,Kansas City Heart Rhythm Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:27Z,2021-10-17T08:28:27Z,15646532,NCT04361838,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-23,NA,NA,2020-08-31,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 27, 2020",Actual,2020-04-27,August 2020,2020-08-31,"June 1, 2021",Anticipated,2021-06-01,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,HCQPreP,,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,NA,Phase 3,1700,Anticipated,Louisiana State University Health Sciences Center in New Orleans,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:13Z,2021-10-17T08:28:13Z,15646321,NCT04363450,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,NA,NA,2020-04-23,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,CytokCOVID19,,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19),Recruiting,NA,N/A,40,Anticipated,Hospital Clinic of Barcelona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:29Z,2021-10-17T08:28:29Z,15646577,NCT04361526,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2020-07-07,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"May 6, 2020",Actual,2020-05-06,July 2020,2020-07-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,,Atrium COVID-19 Syndromic and Serologic Surveillance,"A Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records",Enrolling by invitation,NA,NA,450000,Anticipated,Atrium Health,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:33Z,2021-10-17T08:28:33Z,15646630,NCT04361123,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-23,NA,NA,2020-05-06,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 26, 2020",Actual,2020-04-26,May 2020,2020-05-31,"June 14, 2020",Anticipated,2020-06-14,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,COMBATCOVID19,,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study),Recruiting,NA,Phase 2,70,Anticipated,Maimonides Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:13Z,2021-10-17T08:28:13Z,15646322,NCT04363437,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-20,NA,NA,2020-12-30,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"April 23, 2020",Actual,2020-04-23,December 2020,2020-12-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Observational,NA,,Evaluation of Antibody Tests for COVID-19,Evaluation of Commerical Antibody Tests for COVID-19,Completed,NA,NA,461,Actual,Washington University School of Medicine,,NA,4,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples Without DNA,"
      Plasma or serum.
    ",NA,NA,NA,NA,NA,2021-10-17T08:28:34Z,2021-10-17T08:28:34Z,15646654,NCT04360954,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2021-06-10,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-11,Actual,"June 16, 2020",Actual,2020-06-16,December 2020,2020-12-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,LAPTRANSCOV,,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients,Recruiting,NA,N/A,60,Anticipated,Centre Hospitalier RenÃ© Dubos,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:28:30Z,2021-10-17T08:28:30Z,15646595,NCT04361396,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-23,NA,NA,2020-04-26,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"October 1, 2031",Anticipated,2031-10-01,"April 20, 2030",Anticipated,2030-04-20,NA,Observational,ACCESS,,ACCESS A Master Digital Surveillance Protocol for COVID-19,"ACCESS (American COVID-19 Collaborative, Enabling Seamless Science) Master Digital Surveillance and Associated Clinical Trials Protocol for COVID-19",Recruiting,NA,NA,1000000,Anticipated,Medable Inc.,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Please reach out to the study team for data sharing policies and procedures. Only de-identified and aggregate data may be considered for sharing.,2021-10-17T08:28:15Z,2021-10-17T08:28:15Z,15646353,NCT04363268,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2021-04-28,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"April 8, 2020",Actual,2020-04-08,April 2021,2021-04-30,"December 30, 2022",Anticipated,2022-12-30,"July 1, 2022",Anticipated,2022-07-01,NA,Observational,COVID19 LTFU,,Long Term Outcomes of Patients With COVID-19,Long Term Outcomes of Patients With COVID-19,Recruiting,NA,NA,500,Anticipated,University of Chicago,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:37Z,2021-10-17T08:28:37Z,15646702,NCT04360538,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-20,NA,NA,2020-04-20,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-24,Actual,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,September 2022,Anticipated,2022-09-30,May 2022,Anticipated,2022-05-31,NA,Observational,STOP COVID 19,,Sequencing and Tracking of Phylogeny in COVID-19 Study,Sequencing and Tracking of Phylogeny in COVID-19 Study,Recruiting,NA,NA,500,Anticipated,Portsmouth Hospitals NHS Trust,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:28:43Z,2021-10-17T08:28:43Z,15646796,NCT04359849,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-20,NA,NA,2021-09-02,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"April 16, 2020",Actual,2020-04-16,September 2021,2021-09-30,"July 31, 2025",Anticipated,2025-07-31,"April 30, 2024",Anticipated,2024-04-30,NA,Observational,NA,,A Study to Explore the Role of Gut Flora in COVID-19 Infection,A Non-Interventional Pilot Study to Explore the Role of Gut Flora in COVID-19 Infection,Recruiting,NA,NA,250,Anticipated,ProgenaBiome,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Stool samples.
    ",NA,NA,NA,No,NA,2021-10-17T08:28:43Z,2021-10-17T08:28:43Z,15646800,NCT04359836,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-22,NA,NA,2021-06-28,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-07-01,Actual,"April 23, 2020",Actual,2020-04-23,June 2021,2021-06-30,March 2025,Anticipated,2025-03-31,September 2022,Anticipated,2022-09-30,NA,Observational,NA,,St. Jude Tracking of Viral and Host Factors Associated With COVID-19,SJTRC-St. Jude Tracking of Viral and Host Factors Associated With COVID-19: A Prospective Adaptive Cohort Study,Recruiting,NA,NA,1517,Anticipated,St. Jude Children's Research Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      blood and nasal samples
    ",NA,NA,NA,NA,NA,2021-10-17T08:28:17Z,2021-10-17T08:28:17Z,15646388,NCT04362995,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-20,NA,NA,2021-07-20,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"April 27, 2020",Actual,2020-04-27,July 2021,2021-07-31,"May 10, 2021",Actual,2021-05-10,"May 10, 2021",Actual,2021-05-10,NA,Observational,COVID-19_EIT,,Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients,The Effect of Prone Positioning on Lung Aeration and Ventilation-perfusion Matching in Mechanically Ventilated Patients With Coronavirus Disease Related Acute Respiratory Distress Syndrome,Completed,NA,NA,29,Actual,"University Hospital, Geneva",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:47Z,2021-10-17T08:28:47Z,15646855,NCT04359407,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-20,NA,NA,2021-02-12,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"April 15, 2020",Actual,2020-04-15,February 2021,2021-02-28,"April 15, 2022",Anticipated,2022-04-15,"April 15, 2022",Anticipated,2022-04-15,NA,Interventional,SAVE,,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),"suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial",Recruiting,NA,Phase 2,1000,Anticipated,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:05Z,2021-10-17T08:29:05Z,15647135,NCT04357366,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-17,NA,NA,2020-12-21,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-21,2020-12-23,Actual,"April 16, 2020",Actual,2020-04-16,December 2020,2020-12-31,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,AVoCaDO,,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial",Completed,NA,Phase 1/Phase 2,20,Actual,Hunter Holmes Mcguire Veteran Affairs Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:02Z,2021-10-17T08:29:02Z,15647080,NCT04357782,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,NA,NA,2021-05-24,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-24,2021-05-26,Actual,"April 27, 2020",Actual,2020-04-27,May 2021,2021-05-31,"May 1, 2021",Actual,2021-05-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,COP-COVID-19,,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia",Completed,NA,Phase 2,31,Actual,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:28:53Z,2021-10-17T08:28:53Z,15646943,NCT04358783,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-21,NA,NA,2020-12-17,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"April 9, 2020",Actual,2020-04-09,December 2020,2020-12-31,"April 27, 2020",Actual,2020-04-27,"April 27, 2020",Actual,2020-04-27,NA,Observational,PSY_CO_CHU,,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,Completed,NA,NA,1784,Actual,Centre Hospitalier Universitaire de NÄ«mes,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:28:54Z,2021-10-17T08:28:54Z,15646956,NCT04358640,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2020-11-02,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study,Completed,NA,N/A,122,Actual,UniversitÃ  degli Studi dell'Insubria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Data will be available at the end of the study, once statistical analyses is conducted",Contact Principal Investigator,NA,Yes,"We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.",2021-10-17T08:29:05Z,2021-10-17T08:29:05Z,15647141,NCT04357327,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2020-04-21,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,COPLA,,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,NA,Phase 2,10,Anticipated,Centro de HematologÃ­a y Medicina Interna,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:07Z,2021-10-17T08:29:07Z,15647171,NCT04357106,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-11,NA,NA,2021-08-02,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"July 29, 2020",Actual,2020-07-29,August 2021,2021-08-31,"February 28, 2022",Anticipated,2022-02-28,"January 29, 2022",Anticipated,2022-01-29,NA,Interventional,COVERAGEFrance,,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France),Recruiting,NA,Phase 2/Phase 3,820,Anticipated,"University Hospital, Bordeaux",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:29:12Z,2021-10-17T08:29:12Z,15647248,NCT04356495,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-17,NA,NA,2020-06-08,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"June 2, 2020",Actual,2020-06-02,June 2020,2020-06-30,"March 2, 2022",Anticipated,2022-03-02,"October 2, 2021",Anticipated,2021-10-02,NA,Observational,CAPACoV19,,Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation,Long Term Physical Functional Performance in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation: a Multicentric Observational Study,Recruiting,NA,NA,300,Anticipated,CHU de Reims,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:13Z,2021-10-17T08:29:13Z,15647270,NCT04356378,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2021-02-25,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-01,Actual,"April 25, 2020",Actual,2020-04-25,February 2021,2021-02-28,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1/Phase 2,24,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:19Z,2021-10-17T08:29:19Z,15647373,NCT04355728,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-09-21,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"April 21, 2020",Actual,2020-04-21,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia,Completed,NA,Phase 4,120,Actual,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:20Z,2021-10-17T08:29:20Z,15647392,NCT04355637,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,NA,NA,2021-09-02,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"April 21, 2020",Actual,2020-04-21,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,6 Months,Observational [Patient Registry],NA,,Renal Outcome in Patients With COVID-19,Renal Outcome in Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,NA,900,Anticipated,University of Giessen,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:29:36Z,2021-10-17T08:29:36Z,15647641,NCT04353583,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-12,NA,NA,2021-10-14,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"March 31, 2020",Actual,2020-03-31,October 2021,2021-10-31,"May 31, 2021",Actual,2021-05-31,"May 1, 2021",Actual,2021-05-01,NA,Observational,TARUS,,The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic,The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic: TARUS,Completed,NA,NA,3797,Actual,Ariel University,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:29:34Z,2021-10-17T08:29:34Z,15647600,NCT04353934,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-17,NA,NA,2020-09-29,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 11, 2020",Actual,2020-05-11,September 2020,2020-09-30,"September 28, 2020",Actual,2020-09-28,"August 23, 2020",Actual,2020-08-23,NA,Observational,NA,,Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.,AntikÃ¶rperseroprÃ¤valenz Und Hintergrundinfektionsrate Von SARS-CoV-2 in Einem Ã¶sterreichischen SchlÃ¼sselkollektiv an Arbeitnehmer*Innen,Completed,NA,NA,3301,Actual,AUVA,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,IPD will be encrypted and anonymised.,2021-10-17T08:29:27Z,2021-10-17T08:29:27Z,15647492,NCT04354779,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2020-12-17,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-21,Actual,"August 3, 2020",Actual,2020-08-03,December 2020,2020-12-31,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Observational,CALYPSO,,WGS Analysis of COVID-19 Positive Patients,Whole-Genome Sequencing Analysis of COVID-19 Positive Patients,Enrolling by invitation,NA,NA,5000,Anticipated,Vanda Pharmaceuticals,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:29:38Z,2021-10-17T08:29:38Z,15647661,NCT04353401,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2020-12-08,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-10,Actual,"April 20, 2020",Actual,2020-04-20,December 2020,2020-12-31,"August 31, 2026",Anticipated,2026-08-31,"December 31, 2025",Anticipated,2025-12-31,NA,Observational,ReCovER,,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,Recruiting,NA,NA,500,Anticipated,University of Cologne,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:51Z,2021-10-17T08:29:51Z,15647860,NCT04351854,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-07-29,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"March 23, 2020",Actual,2020-03-23,July 2021,2021-07-31,"July 1, 2020",Actual,2020-07-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,194,Actual,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:39Z,2021-10-17T08:29:39Z,15647670,NCT04353336,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-08-23,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"April 9, 2020",Actual,2020-04-09,August 2021,2021-08-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Observational,NA,,A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19,A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City,Recruiting,NA,NA,10000,Anticipated,"University Hospital, Basel, Switzerland",,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:56Z,2021-10-17T08:29:56Z,15647902,NCT04351503,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-15,NA,NA,2021-03-01,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-03,Actual,"May 5, 2020",Actual,2020-05-05,March 2021,2021-03-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,"A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia","Active, not recruiting",NA,Phase 3,520,Actual,"Humanigen, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:29:59Z,2021-10-17T08:29:59Z,15647946,NCT04351152,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-10-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"June 10, 2020",Actual,2020-06-10,October 2021,2021-10-31,"July 17, 2021",Actual,2021-07-17,"July 17, 2021",Actual,2021-07-17,NA,Interventional,COVI-PRONE,,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE),Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Completed,NA,N/A,400,Actual,St. Joseph's Healthcare Hamilton,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:04Z,2021-10-17T08:30:04Z,15647999,NCT04350723,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-16,NA,NA,2020-06-11,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-16,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,MeCOVID,,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.,Recruiting,NA,Phase 2/Phase 3,450,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:29:40Z,2021-10-17T08:29:40Z,15647702,NCT04353128,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,2021-08-10,NA,2021-08-17,2020-04-11,2020-04-15,Actual,2021-08-17,2021-08-18,Actual,NA,NA,NA,2021-08-17,2021-08-18,Actual,"May 6, 2020",Actual,2020-05-06,August 2021,2021-08-31,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,NA,Observational,NA,,Seroprevalence of SARS-Cov-2 Antibodies in Children,Seroprevalence of SARS-Cov-2 Antibodies in Children - a Prospective Multicentre Cohort Study,Completed,NA,NA,992,Actual,"Queen's University, Belfast",The limitations of this study are that all of the children in this study had only mild disease making comparison between severe and mild disease impossible. The children were also recruited from healthcare workers and the prevalence of antibodies is likely to be lower in the general population.,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Blood plasma
    ",NA,NA,NA,NA,NA,2021-10-17T08:30:35Z,2021-10-17T08:30:35Z,15648405,NCT04347408,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-04-28,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"August 13, 2020",Actual,2020-08-13,April 2021,2021-04-30,"June 1, 2022",Anticipated,2022-06-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,NA,,Early Extubation for Patients With Acute Hypoxemic Respiratory Failure,Early Extubation for Patients With Acute Hypoxemic Respiratory Failure,Recruiting,NA,N/A,108,Anticipated,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:17Z,2021-10-17T08:30:17Z,15648169,NCT04349332,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2021-09-02,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"April 10, 2020",Actual,2020-04-10,September 2021,2021-09-30,"January 19, 2021",Actual,2021-01-19,"January 19, 2021",Actual,2021-01-19,NA,Observational,BLAST COVID-19,,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Completed,NA,NA,20614,Actual,William Beaumont Hospitals,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,Samples With DNA,"
      Whole blood and serum
    ",NA,NA,NA,No,NA,2021-10-17T08:30:18Z,2021-10-17T08:30:18Z,15648180,NCT04349202,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2020-12-23,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"April 17, 2020",Actual,2020-04-17,December 2020,2020-12-31,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,Coronavirus,,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Completed,NA,Phase 2,202,Actual,Karyopharm Therapeutics Inc,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:30:19Z,2021-10-17T08:30:19Z,15648200,NCT04349098,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2020-04-15,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 12, 2020",Actual,2020-04-12,April 2020,2020-04-30,"May 13, 2020",Anticipated,2020-05-13,"May 13, 2020",Anticipated,2020-05-13,NA,Interventional,Ruxo-Sim-20,,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.,Recruiting,NA,Phase 2,94,Anticipated,FundaciÃ³n de investigaciÃ³n HM,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:30:23Z,2021-10-17T08:30:23Z,15648262,NCT04348695,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,NA,NA,2021-10-05,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"April 20, 2020",Actual,2020-04-20,October 2021,2021-10-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,BADAS,,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,"Active, not recruiting",NA,Phase 4,1800,Anticipated,Texas A&M University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,There is not a plan to make IPD available.,2021-10-17T08:30:26Z,2021-10-17T08:30:26Z,15648295,NCT04348370,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-11,NA,NA,2020-11-09,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,HNS-COVID-PK,,Honey & Nigella Sativa Trial Against COVID-19,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan",Completed,NA,Phase 3,313,Actual,Sheikh Zayed Federal Postgraduate Medical Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:35Z,2021-10-17T08:30:35Z,15648412,NCT04347382,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2021-03-24,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-26,Actual,"August 10, 2020",Actual,2020-08-10,March 2021,2021-03-31,"November 30, 2020",Actual,2020-11-30,"October 10, 2020",Actual,2020-10-10,NA,Interventional,COVID-19,,Telerehabilitation for Patients Diagnosed With Coronavirus,Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home,Completed,NA,N/A,30,Actual,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:38Z,2021-10-17T08:30:38Z,15648451,NCT04346927,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2021-07-30,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"April 15, 2020",Actual,2020-04-15,April 2021,2021-04-30,"October 15, 2021",Anticipated,2021-10-15,"August 24, 2021",Anticipated,2021-08-24,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,394,Anticipated,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:30:36Z,2021-10-17T08:30:36Z,15648422,NCT04347239,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-10,NA,NA,2020-07-29,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,CCAP,,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,"Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial",Recruiting,NA,Phase 3,1100,Anticipated,Hvidovre University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:30:53Z,2021-10-17T08:30:53Z,15648645,NCT04345289,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-09,NA,NA,2020-06-05,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 15, 2020",Actual,2020-04-15,June 2020,2020-06-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,N/A,10,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:30:41Z,2021-10-17T08:30:41Z,15648495,NCT04346589,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"May 1, 2020",Anticipated,2020-05-01,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,ProCov,,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov),Recruiting,NA,N/A,25,Anticipated,Centre Hospitalier Intercommunal Aix-Pertuis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:03Z,2021-10-17T08:31:03Z,15648798,NCT04344106,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,2020-09-01,NA,2020-09-22,2020-04-08,2020-04-13,Actual,2020-09-15,2020-09-17,Actual,NA,NA,NA,2020-09-22,2020-09-24,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,"August 13, 2020",Actual,2020-08-13,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:10Z,2021-10-17T08:31:10Z,15648881,NCT04343261,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-13,NA,NA,2021-03-03,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-05,Actual,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"March 3, 2021",Actual,2021-03-03,"November 20, 2020",Actual,2020-11-20,NA,Observational,NIAID,,Collection of Anti-SARS-CoV-2 Immune Plasma,A Pilot Study for Collection of Anti-SARS-CoV-2 Immune Plasma,Completed,NA,NA,151,Actual,National Institutes of Health Clinical Center (CC),,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Serum, plasma
    ",NA,NA,NA,NA,NA,2021-10-17T08:30:56Z,2021-10-17T08:30:56Z,15648681,NCT04344977,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-09,NA,NA,2021-07-01,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"April 1, 2020",Actual,2020-04-01,July 2021,2021-07-31,"August 1, 2022",Anticipated,2022-08-01,"August 1, 2020",Actual,2020-08-01,NA,Observational,STOP-COVID,,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,"Active, not recruiting",NA,NA,5154,Actual,Brigham and Women's Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:31:05Z,2021-10-17T08:31:05Z,15648814,NCT04343898,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,NA,NA,2021-07-02,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-06,Actual,"March 25, 2020",Actual,2020-03-25,July 2021,2021-07-31,"March 12, 2021",Actual,2021-03-12,"March 12, 2021",Actual,2021-03-12,NA,Observational,NA,,Acquiring Convalescent Specimens for COVID-19 Antibodies,Acquiring Convalescent Specimens to Isolate and Identify Potent Monoclonal Antibodies Against COVID-19,Completed,NA,NA,15,Actual,Columbia University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Whole blood from which peripheral blood mononuclear cells (PBMCs) and plasma will be
      processed.
    ",NA,NA,NA,NA,NA,2021-10-17T08:31:19Z,2021-10-17T08:31:19Z,15649014,NCT04342195,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2021-09-28,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"April 4, 2020",Actual,2020-04-04,September 2021,2021-09-30,October 2021,Anticipated,2021-10-31,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,,University of Utah COVID-19 Hydrochloroquine Trial,Hydroxychloroquine for Outpatients With Confirmed COVID-19,"Active, not recruiting",NA,Phase 2,368,Actual,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:20Z,2021-10-17T08:31:20Z,15649017,NCT04342169,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-08,NA,NA,2021-02-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"December 30, 2020",Actual,2020-12-30,NA,Interventional,COVIDAtoZ,,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Completed,NA,N/A,214,Actual,The Cleveland Clinic,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:31:15Z,2021-10-17T08:31:15Z,15648946,NCT04342728,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2021-09-28,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Completed,NA,Phase 2,86,Actual,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:31:07Z,2021-10-17T08:31:07Z,15648843,NCT04343651,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2020-09-23,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"April 11, 2020",Actual,2020-04-11,September 2020,2020-09-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Observational,BIOCOVU,,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Admitted to Emergency Departments During an Epidemic,Recruiting,NA,NA,1000,Anticipated,"University Hospital, Lille",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:31:23Z,2021-10-17T08:31:23Z,15649068,NCT04341792,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,NA,NA,2020-09-02,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"April 15, 2020",Actual,2020-04-15,September 2020,2020-09-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Observational,NA,,Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),Recruiting,NA,NA,500,Anticipated,University of Minnesota,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:31:39Z,2021-10-17T08:31:39Z,15649282,NCT04339998,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2021-01-29,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-01,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"July 25, 2020",Actual,2020-07-25,"May 10, 2020",Actual,2020-05-10,NA,Interventional,CORIMUNO-ANA,,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19",Completed,NA,Phase 2,161,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:31:24Z,2021-10-17T08:31:24Z,15649097,NCT04341584,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2020-10-05,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"April 6, 2020",Actual,2020-04-06,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Observational,BURDENCOV,,"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","""Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers"" ""Impact Psychologique de l'Ã©pidÃ©mie COVID-19 Chez Les Patients, Familles et Soignants de Reanimation"" ""BURDENCOV""",Recruiting,NA,NA,1464,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:31:25Z,2021-10-17T08:31:25Z,15649109,NCT04341519,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2020-12-17,2020-04-07,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"April 3, 2020",Actual,2020-04-03,December 2020,2020-12-31,"July 3, 2020",Actual,2020-07-03,"July 3, 2020",Actual,2020-07-03,28 Days,Observational [Patient Registry],FRENCH CORONA,,French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study,French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study,Completed,NA,NA,1003,Actual,Centre Hospitalier Universitaire de NÄ«mes,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:34Z,2021-10-17T08:31:34Z,15649224,NCT04340466,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-05,NA,NA,2020-09-22,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 17, 2020",Actual,2020-06-17,"June 17, 2020",Actual,2020-06-17,NA,Interventional,HOME-CoV,,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Completed,NA,N/A,3133,Actual,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:50Z,2021-10-17T08:31:50Z,15649434,NCT04338841,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-04,NA,NA,2021-08-05,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-09,Actual,"April 11, 2020",Actual,2020-04-11,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),"A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2/Phase 3,384,Anticipated,I-Mab Biopharma Co. Ltd.,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:28Z,2021-10-17T08:31:28Z,15649160,NCT04341116,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2021-01-08,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"April 2, 2020",Actual,2020-04-02,January 2021,2021-01-31,"January 8, 2021",Actual,2021-01-08,"December 1, 2020",Actual,2020-12-01,NA,Interventional,ESCAPE,,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Completed,NA,Phase 2,102,Actual,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:42Z,2021-10-17T08:31:42Z,15649326,NCT04339712,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,NA,NA,2020-11-26,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"March 1, 2020",Actual,2020-03-01,November 2020,2020-11-30,"April 26, 2020",Actual,2020-04-26,"April 26, 2020",Actual,2020-04-26,NA,Observational,NA,,COVID-19 Risk Stratification,COVID-19 Risk Stratification,Completed,NA,NA,1326,Actual,Brigham and Women's Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Investigators may provide reasonable requests for IPD. These requests will be reviewed by the study team and institution on a case by case basis.,2021-10-17T08:31:45Z,2021-10-17T08:31:45Z,15649359,NCT04339387,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,NA,NA,2020-04-06,2020-04-06,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-07,Actual,"December 23, 2019",Actual,2019-12-23,March 2020,2020-03-31,"March 3, 2020",Actual,2020-03-03,"January 20, 2020",Actual,2020-01-20,NA,Observational,NA,,Clinical and Radiomic Model of COVID-19,A Clinical and Radiological Model to Predict the Prognosis for COVID-19 Patients,Completed,NA,NA,300,Actual,Maastricht University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No share plan,2021-10-17T08:32:05Z,2021-10-17T08:32:05Z,15649592,NCT04337502,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-06,NA,NA,2021-02-08,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"May 8, 2020",Actual,2020-05-08,February 2021,2021-02-28,"February 2, 2021",Actual,2021-02-02,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NOCOVID,,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Completed,NA,Phase 2,143,Actual,Sanotize Research and Development corp.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:01Z,2021-10-17T08:32:01Z,15649543,NCT04337918,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-03,NA,NA,2021-10-01,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"April 3, 2020",Actual,2020-04-03,October 2021,2021-10-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","Active, not recruiting",NA,Phase 1,120,Actual,Inovio Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-10-17T08:32:14Z,2021-10-17T08:32:14Z,15649714,NCT04336410,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,NA,NA,2020-11-06,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"April 1, 2020",Actual,2020-04-01,October 2020,2020-10-31,"June 4, 2020",Actual,2020-06-04,"April 30, 2020",Actual,2020-04-30,1 Month,Observational [Patient Registry],MexCOVID-19,,Outcomes of Patients With COVID-19 in the Intensive Care Unit,Outcomes of Patients With COVID-19 in the Intensive Care Unit: A National Observational Study (Mexico COVID-19 ICU Study),Completed,NA,NA,150,Actual,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,All IPD that underlie could results in a publication.,2021-10-17T08:32:15Z,2021-10-17T08:32:15Z,15649722,NCT04336345,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-03,NA,NA,2020-04-21,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 3, 2020",Anticipated,2020-06-03,NA,Interventional,SRA-COV,,Renin Angiotensin System - CoronaVirus,Renin Angiotensin System - CoronaVirus,Recruiting,NA,N/A,50,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:09Z,2021-10-17T08:32:09Z,15649643,NCT04337008,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-03,NA,NA,2021-10-07,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-15,Estimate,"April 12, 2020",Actual,2020-04-12,October 2021,2021-10-31,"June 10, 2020",Actual,2020-06-10,"May 10, 2020",Actual,2020-05-10,NA,Observational,NA,,"Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine","Determination Of Physical Activity, Sleep And Stress Level Of Pregnant Women In The CovÄ±d-19 Quarantine Period",Completed,NA,NA,100,Actual,Istanbul KÃ¼ltÃ¼r University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:32:11Z,2021-10-17T08:32:11Z,15649673,NCT04336787,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,NA,NA,2021-09-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"June 22, 2020",Actual,2020-06-22,September 2021,2021-09-30,September 2024,Anticipated,2024-09-30,June 2023,Anticipated,2023-06-30,NA,Interventional,HAZDpaC,,A Study of Quintuple Therapy to Treat COVID-19 Infection,"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection",Recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:34Z,2021-10-17T08:32:34Z,15649989,NCT04334512,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2020-04-22,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,"Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study",Recruiting,NA,N/A,750,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:32:37Z,2021-10-17T08:32:37Z,15650024,NCT04334265,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2020-07-17,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"May 11, 2020",Actual,2020-05-11,"May 11, 2020",Actual,2020-05-11,NA,Observational,TOVID-49,,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Completed,NA,NA,132,Actual,"University Hospital, Angers",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:32:41Z,2021-10-17T08:32:41Z,15650077,NCT04333849,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2020-04-22,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"September 15, 2020",Anticipated,2020-09-15,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,"The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",Recruiting,NA,N/A,210,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:32:43Z,2021-10-17T08:32:43Z,15650107,NCT04333589,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-02,NA,NA,2021-09-15,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"April 15, 2020",Actual,2020-04-15,September 2021,2021-09-30,"July 11, 2021",Actual,2021-07-11,"February 25, 2021",Actual,2021-02-25,NA,Interventional,EPICOS,,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,Completed,NA,Phase 3,1002,Actual,Plan Nacional sobre el Sida (PNS),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:31Z,2021-10-17T08:32:31Z,15649939,NCT04334928,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-01,NA,NA,2021-09-20,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"January 6, 2021",Actual,2021-01-06,September 2021,2021-09-30,"July 6, 2022",Anticipated,2022-07-06,"March 6, 2022",Anticipated,2022-03-06,NA,Interventional,NA,,Piclidenoson for Treatment of COVID-19,"Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial",Recruiting,NA,Phase 2,40,Anticipated,Can-Fite BioPharma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"January 2021, indefinitely",To be determined,NA,Yes,To be determined,2021-10-17T08:32:44Z,2021-10-17T08:32:44Z,15650125,NCT04333472,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2020-11-25,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,CP-COVID-19,,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,NA,Phase 2/Phase 3,92,Actual,Universidad del Rosario,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:53Z,2021-10-17T08:32:53Z,15650212,NCT04332835,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2020-09-21,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"March 23, 2020",Actual,2020-03-23,September 2020,2020-09-30,"March 23, 2022",Anticipated,2022-03-23,"March 23, 2022",Anticipated,2022-03-23,NA,Interventional,EPI-COVID-19,,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in Tropical Regions,Recruiting,NA,N/A,1300,Anticipated,Institut Pasteur,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:37Z,2021-10-17T08:33:37Z,15650807,NCT04328129,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,NA,NA,2020-08-12,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-17,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,"July 28, 2020",Actual,2020-07-28,"July 28, 2020",Actual,2020-07-28,NA,Interventional,CP-COVID-19,,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,NA,Phase 2,10,Actual,Universidad del Rosario,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:32:59Z,2021-10-17T08:32:59Z,15650263,NCT04332380,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,NA,NA,2021-09-20,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"April 8, 2020",Actual,2020-04-08,September 2021,2021-09-30,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Observational,NA,,Impact of the Coronavirus (COVID-19) on Patients With Cancer,Impact of the Coronavirus (COVID-19) on Patients With Cancer,Recruiting,NA,NA,50,Anticipated,Stanford University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:33:17Z,2021-10-17T08:33:17Z,15650505,NCT04330521,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2021-04-06,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"April 13, 2020",Actual,2020-04-13,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Observational,COVID-19,,An Observational Study of Patients With Coronavirus Disease 2019,An Observational Study of Patients With Coronavirus Disease 2019,Recruiting,NA,NA,5000,Anticipated,"Target PharmaSolutions, Inc.",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:33:04Z,2021-10-17T08:33:04Z,15650324,NCT04331886,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2020-04-26,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 30, 2020",Actual,2020-03-30,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIMUNO-TOC,,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI),"Active, not recruiting",NA,Phase 2,228,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:33:05Z,2021-10-17T08:33:05Z,15650326,NCT04331808,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2020-10-27,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"March 31, 2020",Actual,2020-03-31,October 2020,2020-10-31,"October 8, 2020",Actual,2020-10-08,"September 24, 2020",Actual,2020-09-24,NA,Interventional,NA,,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Completed,NA,Phase 2/Phase 3,829,Actual,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2021-10-17T08:33:30Z,2021-10-17T08:33:30Z,15650694,NCT04328961,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-27,2021-06-25,NA,2021-06-30,2020-03-30,2020-03-31,Actual,2021-06-25,2021-06-30,Actual,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"July 13, 2020",Actual,2020-07-13,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1483,Actual,University of Minnesota,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:33:34Z,2021-10-17T08:33:34Z,15650746,NCT04328467,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-27,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 30, 2020",Actual,2020-01-30,March 2020,2020-03-31,"April 15, 2020",Anticipated,2020-04-15,"April 2, 2020",Anticipated,2020-04-02,NA,Observational,NA,,Clinical Characteristics and Prognostic Factors of Patients With COVID-19,Clinical Characteristics and Prognostic Factors of Patients With COVID-19 in Chibi Hospital of Hubei Province,Recruiting,NA,NA,120,Anticipated,Shanghai 10th People's Hospital,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:34Z,2021-10-17T08:33:34Z,15650751,NCT04328454,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2021-04-27,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"March 27, 2020",Actual,2020-03-27,April 2021,2021-04-30,"March 30, 2023",Anticipated,2023-03-30,"March 30, 2023",Anticipated,2023-03-30,6 Months,Observational [Patient Registry],COntAGIouS,,In-depth Immunological Investigation of COVID-19.,In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2,Recruiting,NA,NA,100,Anticipated,Universitaire Ziekenhuizen Leuven,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood, plasma, PBMC, BAL, lung tissue
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:33:42Z,2021-10-17T08:33:42Z,15650879,NCT04327570,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2020-10-05,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"March 27, 2021",Anticipated,2021-03-27,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,NA,,Treating COVID-19 With a Bidirectional Oxygenation Valve,The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection,Recruiting,NA,N/A,30,Anticipated,TMC HealthCare,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:33:54Z,2021-10-17T08:33:54Z,15651006,NCT04326452,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,2021-04-28,NA,2021-05-11,2020-03-26,2020-03-31,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 28, 2020",Actual,2020-03-28,May 2021,2021-05-31,"September 2, 2020",Actual,2020-09-02,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,Analysis was performed on randomized population.,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Completed,NA,Phase 3,420,Actual,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T08:33:44Z,2021-10-17T08:33:44Z,15650902,NCT04327388,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-24,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,NA,N/A,30,Anticipated,Mazandaran University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:33:45Z,2021-10-17T08:33:45Z,15650907,NCT04327349,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2020-04-16,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,"ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection",Enrolling by invitation,NA,Phase 3,300,Anticipated,Vanda Pharmaceuticals,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:33:54Z,2021-10-17T08:33:54Z,15651013,NCT04326426,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"September 20, 2020",Anticipated,2020-09-20,"July 20, 2020",Anticipated,2020-07-20,NA,Observational,NA,,Active Monitoring And Determinants of Incidence Infection of COVDI-19,Active Monitoring And Determinants of Incidence Infection of COVDI-19 in a Hospital Population (AMADIICH) Study Protocol,Recruiting,NA,NA,1000,Anticipated,"FundaciÃ³n TeÃ³filo Hernando, Spain",,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:33:54Z,2021-10-17T08:33:54Z,15651017,NCT04326400,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2021-06-23,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-28,Actual,"March 30, 2020",Actual,2020-03-30,June 2021,2021-06-30,"March 30, 2022",Anticipated,2022-03-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,BRACE,,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers (BRACE) Trial,"Active, not recruiting",NA,Phase 3,10078,Anticipated,Murdoch Childrens Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:
Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2021-10-17T08:33:47Z,2021-10-17T08:33:47Z,15650923,NCT04327206,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-24,NA,NA,2020-03-26,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"February 24, 2020",Actual,2020-02-24,March 2020,2020-03-31,"June 17, 2021",Anticipated,2021-06-17,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,,Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong,"Comprehensive Clinical, Virological, Microbiological, Immunological and Laboratory Monitoring of Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,NA,170,Anticipated,Chinese University of Hong Kong,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:33:58Z,2021-10-17T08:33:58Z,15651091,NCT04325919,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2020-07-27,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"March 20, 2020",Actual,2020-03-20,July 2020,2020-07-31,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Actual,2020-07-01,NA,Observational,NA,,Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia,"Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study","Active, not recruiting",NA,NA,80,Anticipated,Istinye University,,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:33:51Z,2021-10-17T08:33:51Z,15650977,NCT04326725,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2020-05-15,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,"October 7, 2021",Anticipated,2021-10-07,"April 7, 2021",Anticipated,2021-04-07,NA,Observational,COVIDx,,Evaluation of Novel Diagnostic Tests for COVID-19,Evaluation of Novel Diagnostic Tests for 2019-nCOV,Recruiting,NA,NA,200,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Throat/Nasal Swab, Nasopharyngeal Swab, Endotracheal tube aspirate and whole blood-serum for
      viral-RNA analysis
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:33:54Z,2021-10-17T08:33:54Z,15651018,NCT04326387,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2021-08-24,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"March 25, 2020",Actual,2020-03-25,August 2021,2021-08-31,"September 25, 2022",Anticipated,2022-09-25,"September 25, 2022",Anticipated,2022-09-25,NA,Observational,NA,,Audio Data Collection for Identification and Classification of Coughing,Audio Data Collection for Identification and Classification of Coughing,"Active, not recruiting",NA,NA,1000,Anticipated,HealthMode Inc.,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:33:55Z,2021-10-17T08:33:55Z,15651028,NCT04326309,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2020-10-08,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-12,Actual,"March 25, 2020",Actual,2020-03-25,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,GARM-COVID19,,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection,Recruiting,NA,Early Phase 1,10,Anticipated,"Black Tie Medical, Inc.",,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,In discussion phase,2021-10-17T08:33:57Z,2021-10-17T08:33:57Z,15651072,NCT04326036,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-26,NA,NA,2021-04-21,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-23,Actual,"April 2, 2020",Actual,2020-04-02,April 2021,2021-04-30,"February 21, 2021",Actual,2021-02-21,"January 26, 2021",Actual,2021-01-26,NA,Interventional,NA,,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Completed,NA,N/A,222,Actual,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:33:58Z,2021-10-17T08:33:58Z,15651092,NCT04325906,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2021-02-23,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-25,Actual,"April 23, 2020",Actual,2020-04-23,March 2020,2020-03-31,September 2021,Anticipated,2021-09-30,June 2021,Anticipated,2021-06-30,2 Months,Observational [Patient Registry],NA,,Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients,Single-Arm Observational Study Designed to Clinically Evaluate Cordio Application in Adult Patients Positive to COVID-19,Recruiting,NA,NA,5000,Anticipated,Cordio Medical,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:05Z,2021-10-17T08:34:05Z,15651236,NCT04325048,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-20,NA,NA,2021-04-08,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-13,Actual,"April 23, 2020",Actual,2020-04-23,March 2021,2021-03-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,1090,Actual,University of Oxford,,19,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:34:09Z,2021-10-17T08:34:09Z,15651289,NCT04324606,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2021-04-29,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-04,Actual,"April 21, 2020",Actual,2020-04-21,April 2021,2021-04-30,"April 30, 2022",Anticipated,2022-04-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,ACTCOVID19,,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",Recruiting,NA,Phase 3,4000,Anticipated,Population Health Research Institute,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:34:10Z,2021-10-17T08:34:10Z,15651308,NCT04324463,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2021-02-22,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"March 10, 2020",Actual,2020-03-10,February 2021,2021-02-28,"December 31, 2020",Actual,2020-12-31,"April 10, 2020",Actual,2020-04-10,NA,Observational,CORONADO,,"""COVID-19 and Diabetes Outcomes""","""Coronavirus SARS-CoV2 and Diabetes Outcomes"" : CORONADO",Completed,NA,NA,5309,Actual,Nantes University Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:34:08Z,2021-10-17T08:34:08Z,15651270,NCT04324736,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2020-04-14,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,CORIMUNO-SARI,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",NA,Phase 2/Phase 3,239,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:34:13Z,2021-10-17T08:34:13Z,15651349,NCT04324073,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2020-03-31,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Observational,CORIMUNO-19,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Recruiting,NA,NA,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T08:34:13Z,2021-10-17T08:34:13Z,15651351,NCT04324047,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-24,NA,NA,2020-10-14,2020-03-24,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"March 20, 2020",Actual,2020-03-20,October 2020,2020-10-31,"March 31, 2024",Anticipated,2024-03-31,"March 31, 2024",Anticipated,2024-03-31,12 Months,Observational [Patient Registry],PRIORITY,,COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),PRIORITY (Pregnancy Coronavirus Outcomes Registry),Enrolling by invitation,NA,NA,2000,Anticipated,"University of California, San Francisco",,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:15Z,2021-10-17T08:34:15Z,15651381,NCT04323839,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-24,NA,NA,2021-04-06,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"June 10, 2020",Actual,2020-06-10,March 2021,2021-03-31,January 2023,Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,CSSC-001,,Convalescent Plasma to Stem Coronavirus (CSSC-001),"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","Active, not recruiting",NA,Phase 2,500,Anticipated,Johns Hopkins University,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Sharing is governed by Johns Hopkins University Institutional Guidelines,2021-10-17T08:34:15Z,2021-10-17T08:34:15Z,15651383,NCT04323800,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2020-11-06,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"March 23, 2020",Actual,2020-03-23,November 2020,2020-11-30,"June 23, 2021",Anticipated,2021-06-23,"March 23, 2021",Anticipated,2021-03-23,30 Days,Observational [Patient Registry],CAPACITY-COVID,,Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY,Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY,Recruiting,NA,NA,1000,Anticipated,UMC Utrecht,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:34:02Z,2021-10-17T08:34:02Z,15651175,NCT04325412,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2020-05-11,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"January 1, 2020",Actual,2020-01-01,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Observational,CovidSurg,,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Recruiting,NA,NA,1000,Anticipated,University of Birmingham,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No individual participant data will be available to other researchers,2021-10-17T08:34:17Z,2021-10-17T08:34:17Z,15651407,NCT04323644,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-19,2020-05-21,NA,2020-06-23,2020-03-24,2020-03-26,Actual,2020-05-28,2020-06-04,Actual,NA,NA,NA,2020-06-23,2020-06-24,Actual,"March 23, 2020",Actual,2020-03-23,June 2020,2020-06-30,"May 10, 2020",Actual,2020-05-10,"May 10, 2020",Actual,2020-05-10,4 Weeks,Observational [Patient Registry],MP-C19,,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Completed,NA,NA,173,Actual,University of Trieste,,NA,2,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,None Retained,"
      Previous specific informed consent, blood samples of some patients treated with
      methylprednisolone were collected, in order to have the possibility to do
    ",NA,NA,NA,No,Anonymised data will be available only to data manager who can visualise clinical chart anytime when is needed,2021-10-17T08:34:17Z,2021-10-17T08:34:17Z,15651411,NCT04323592,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-24,NA,NA,2020-07-09,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"April 20, 2020",Actual,2020-04-20,July 2020,2020-07-31,"December 21, 2020",Anticipated,2020-12-21,"December 20, 2020",Anticipated,2020-12-20,NA,Interventional,ColCOVID-19,,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia,Recruiting,NA,Phase 2,310,Anticipated,Azienda Ospedaliero-Universitaria di Parma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data will be avaliable from July 2020 and documentation will be shared for 10 years,The sponsor recognizes the importance of communicating study data and will disclose and publish the results in a suitable form regardless of outcome. The sponsor will publish the results of this study in scientific journals,NA,Yes,NA,2021-10-17T08:34:27Z,2021-10-17T08:34:27Z,15651570,NCT04322565,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2020-04-18,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"January 15, 2021",Anticipated,2021-01-15,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial",Recruiting,NA,Phase 3,1000,Anticipated,Misr University for Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:20Z,2021-10-17T08:34:20Z,15651452,NCT04323345,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2020-06-24,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-25,Actual,"March 27, 2020",Actual,2020-03-27,June 2020,2020-06-30,"March 20, 2030",Anticipated,2030-03-20,"March 27, 2022",Anticipated,2022-03-27,NA,Observational,NA,,Risk Factors for Community- and Workplace Transmission of COVID-19,Risk Factors for Community- and Workplace Transmission of COVID-19,Recruiting,NA,NA,250000,Anticipated,Oslo University Hospital,,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood and upper repiratory samples will be collected from some participants.
    ",NA,NA,NA,No,"European GDPR regulations severely limits IPD, but the study will share data to the largest extent possible within GDPR.",2021-10-17T08:34:46Z,2021-10-17T08:34:46Z,15651845,NCT04320732,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2021-01-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-20,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"June 14, 2020",Actual,2020-06-14,"June 14, 2020",Actual,2020-06-14,NA,Interventional,NA,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients,Completed,NA,Phase 3,440,Actual,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:40Z,2021-10-17T08:34:40Z,15651751,NCT04321278,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2021-02-09,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"March 21, 2020",Actual,2020-03-21,February 2021,2021-02-28,"March 20, 2022",Anticipated,2022-03-20,"February 9, 2021",Actual,2021-02-09,1 Year,Observational [Patient Registry],BEAT19,,"Behavior, Environment And Treatments for Covid-19",A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19),"Active, not recruiting",NA,NA,100000,Anticipated,xCures,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,De-identified datasets will be made available to qualified researchers in accordance with the study protocol.,2021-10-17T08:34:36Z,2021-10-17T08:34:36Z,15651679,NCT04321811,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2020-09-11,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-16,Actual,"March 23, 2020",Actual,2020-03-23,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,add-on-COV2,,Escin in Patients With Covid-19 Infection,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,University of Catanzaro,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:34:30Z,2021-10-17T08:34:30Z,15651605,NCT04322344,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-18,NA,NA,2020-04-17,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIPREV-LR,,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,NA,Phase 3,1220,Anticipated,Unity Health Toronto,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,TBA,2021-10-17T08:34:41Z,2021-10-17T08:34:41Z,15651763,NCT04321174,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-24,NA,NA,2020-05-20,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"March 9, 2020",Actual,2020-03-09,March 2020,2020-03-31,"June 1, 2021",Anticipated,2021-06-01,"March 1, 2021",Anticipated,2021-03-01,NA,Observational,NA,,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. (CoV-CONTACT-SERO),Recruiting,NA,NA,300,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood samples
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:34:31Z,2021-10-17T08:34:31Z,15651616,NCT04322279,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-23,NA,NA,2021-04-27,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-30,Actual,"April 4, 2020",Actual,2020-04-04,April 2021,2021-04-30,"May 1, 2022",Anticipated,2022-05-01,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,CamoCO-19,,The Impact of Camostat Mesilate on COVID-19 Infection,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial",Recruiting,NA,Phase 1/Phase 2,580,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposals should be addressed to olesoega@rm.dk.,NA,Yes,"Data sharing plan: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan). Data will become available following publication with no planned end date.",2021-10-17T08:34:41Z,2021-10-17T08:34:41Z,15651775,NCT04321096,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-21,NA,NA,2020-03-30,2020-03-21,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 21, 2020",Actual,2020-01-21,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area,Recruiting,NA,Phase 3,2944,Anticipated,Shanghai Jiao Tong University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:34:52Z,2021-10-17T08:34:52Z,15651904,NCT04320238,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-24,NA,NA,2021-04-15,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"August 30, 2021",Anticipated,2021-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,Coalition-I,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients","Active, not recruiting",NA,Phase 3,630,Anticipated,Hospital do Coracao,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:33Z,2021-10-17T08:34:33Z,15651647,NCT04322123,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-24,NA,NA,2020-07-22,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-24,Actual,"April 17, 2020",Actual,2020-04-17,July 2020,2020-07-31,March 2022,Anticipated,2022-03-31,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,NA,Phase 2,800,Anticipated,Nova Scotia Health Authority,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:34:34Z,2021-10-17T08:34:34Z,15651657,NCT04321993,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-20,NA,NA,2020-06-05,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"August 21, 2021",Anticipated,2021-08-21,"April 21, 2021",Anticipated,2021-04-21,NA,Interventional,PROACTIVE-19,,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19),Recruiting,NA,N/A,7576,Anticipated,University of Pecs,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:34:35Z,2021-10-17T08:34:35Z,15651663,NCT04321928,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-20,NA,NA,2020-03-22,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"June 25, 2020",Anticipated,2020-06-25,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,Beijing Chao Yang Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:34:55Z,2021-10-17T08:34:55Z,15651945,NCT04319900,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-13,NA,NA,2021-10-04,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Actual,"March 22, 2020",Actual,2020-03-22,July 2021,2021-07-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,DisCoVeRy,,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,2416,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Study protocol and statistical analysis plan will be available from September 2020 with no time limit.
Other data will be available upon request after first publication of the results for at least 5 years",Study protocol and statistical analysis plan will be published. All requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team that can be contacted via the principal investigator: florence.ader@chu-lyon.fr,NA,Yes,"Study protocol and statistical analysis plan will be available. Systematic individual patient data sharing is not intended, but all requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team.",2021-10-17T08:35:31Z,2021-10-17T08:35:31Z,15652439,NCT04315948,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-20,NA,NA,2020-04-23,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"March 29, 2020",Actual,2020-03-29,April 2020,2020-04-30,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:35:08Z,2021-10-17T08:35:08Z,15652131,NCT04318444,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-19,NA,NA,2020-12-15,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"March 19, 2020",Actual,2020-03-19,December 2020,2020-12-31,"March 19, 2022",Anticipated,2022-03-19,"March 19, 2022",Anticipated,2022-03-19,NA,Observational,COVID-BioB,,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response",Recruiting,NA,NA,1000,Anticipated,UniversitÃ  Vita-Salute San Raffaele,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:35:09Z,2021-10-17T08:35:09Z,15652144,NCT04318366,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-17,NA,NA,2021-05-13,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-13,2021-05-17,Actual,"March 18, 2020",Actual,2020-03-18,May 2020,2020-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Actual,2020-12-31,12 Months,Observational [Patient Registry],COVID19-HCW,,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,Recruiting,NA,NA,731,Anticipated,"University College, London",,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood samples Nasal and oropharygeal swabs Saliva samples
    ",24 months,NA,https://covid-consortium.com,Yes,Publication of results in open access journals; sharing of results in scientific databases.,2021-10-17T08:35:09Z,2021-10-17T08:35:09Z,15652149,NCT04318314,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-18,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,"January 1, 2020",Actual,2020-01-01,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 20, 2020",Anticipated,2020-04-20,3 Months,Observational [Patient Registry],I-COVID,,Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.,Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy,Recruiting,NA,NA,20,Anticipated,Federico II University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,not decided yet,2021-10-17T08:35:32Z,2021-10-17T08:35:32Z,15652456,NCT04315870,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-13,NA,NA,2020-06-04,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Actual,"March 25, 2020",Actual,2020-03-25,June 2020,2020-06-30,"March 3, 2025",Anticipated,2025-03-03,"May 25, 2020",Actual,2020-05-25,NA,Interventional,NO COVID-19,,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,"Active, not recruiting",NA,Phase 4,53,Actual,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:35:26Z,2021-10-17T08:35:26Z,15652393,NCT04316377,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-17,NA,NA,2021-04-13,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-14,Actual,"March 17, 2020",Actual,2020-03-17,April 2021,2021-04-30,"January 1, 2023",Anticipated,2023-01-01,"January 1, 2023",Anticipated,2023-01-01,NA,Observational,CovidTox,,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Recruiting,NA,NA,1000,Anticipated,Groupe Hospitalier Pitie-Salpetriere,,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No individual data is available per se. They need to be retrieved from the World Health Organization.,2021-10-17T08:35:51Z,2021-10-17T08:35:51Z,15652596,NCT04314817,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-15,NA,NA,2021-03-08,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"April 7, 2020",Actual,2020-04-07,March 2021,2021-03-31,"April 7, 2022",Anticipated,2022-04-07,"April 7, 2021",Anticipated,2021-04-07,NA,Interventional,NOpreventCOVID,,NO Prevention of COVID-19 for Healthcare Providers,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers,"Active, not recruiting",NA,Phase 2,24,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:36:14Z,2021-10-17T08:36:14Z,15652946,NCT04312243,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-13,NA,NA,2021-08-16,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"April 13, 2020",Actual,2020-04-13,August 2021,2021-08-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,NA,Phase 2,205,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:36:16Z,2021-10-17T08:36:16Z,15652977,NCT04312009,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-16,NA,NA,2020-03-16,2020-03-16,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-19,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"May 1, 2020",Anticipated,2020-05-01,3 Weeks,Observational [Patient Registry],NA,,The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,Recruiting,NA,NA,80,Anticipated,Xiangya Hospital of Central South University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:35:56Z,2021-10-17T08:35:56Z,15652680,NCT04314271,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-17,NA,NA,2020-06-24,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-26,Actual,"March 18, 2020",Actual,2020-03-18,June 2020,2020-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVID MECH,,Mechanisms for Covid-19 Disease Complications,"Changes in Organ Specific Biomarkers, Virus Expression and Prognosis of Covid-19",Recruiting,NA,NA,200,Anticipated,"University Hospital, Akershus",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:35:56Z,2021-10-17T08:35:56Z,15652687,NCT04314232,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-09,NA,NA,2020-04-08,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"March 8, 2020",Actual,2020-03-08,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study",Recruiting,NA,N/A,150,Anticipated,Peking University First Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:36:30Z,2021-10-17T08:36:30Z,15653219,NCT04310228,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-14,NA,NA,2021-09-05,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-13,Actual,"May 15, 2020",Actual,2020-05-15,September 2021,2021-09-30,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,COVID-AIV,,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure,Completed,NA,Phase 2/Phase 3,196,Actual,"NeuroRx, Inc.",,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Currently available,Public access,NA,Yes,NeuroRx will share study protocol and statistical analysis plan upon request by qualified researchers,2021-10-17T08:36:19Z,2021-10-17T08:36:19Z,15653010,NCT04311697,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-13,NA,NA,2021-09-17,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-24,Actual,"April 9, 2020",Actual,2020-04-09,September 2021,2021-09-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,NA,Phase 2,162,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:36:23Z,2021-10-17T08:36:23Z,15653089,NCT04311177,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-06,NA,NA,2021-05-06,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-11,Actual,"April 29, 2020",Actual,2020-04-29,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COPCOV,,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Recruiting,NA,N/A,40000,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2021-10-17T08:37:33Z,2021-10-17T08:37:33Z,15654090,NCT04303507,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-11,2021-04-26,NA,2021-05-11,2020-03-11,2020-03-16,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 17, 2020",Actual,2020-03-17,May 2021,2021-05-31,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1312,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,Yes,De-identified dataset will be available within 1 month of publication.,2021-10-17T08:36:47Z,2021-10-17T08:36:47Z,15653439,NCT04308668,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-08,NA,NA,2020-07-04,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-04,2020-07-07,Actual,"March 7, 2020",Actual,2020-03-07,July 2020,2020-07-31,"April 21, 2020",Actual,2020-04-21,"April 21, 2020",Actual,2020-04-21,NA,Observational,NA,,Social Media Use During COVID-19,Getting it Right: Towards Responsible Social Media Use During a Pandemic,Completed,NA,NA,1145,Actual,Yale-NUS College,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Due to stipulations by the Institutional Review Board, data cannot be shared.",2021-10-17T08:37:14Z,2021-10-17T08:37:14Z,15653835,NCT04305574,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-09,NA,NA,2020-12-28,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"March 21, 2020",Actual,2020-03-21,December 2020,2020-12-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,"Active, not recruiting",NA,Phase 2,70,Anticipated,Massachusetts General Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:37:15Z,2021-10-17T08:37:15Z,15653851,NCT04305457,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-10,NA,NA,2020-05-12,2020-03-10,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"March 19, 2020",Actual,2020-03-19,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"September 1, 2020",Anticipated,2020-09-01,NA,Observational,NA,,Acute Respiratory Failure and COVID-19 in Real Life,Acute Respiratory Failure and Continuous Positive Airway Pressure Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: a Real Life Evaluation,Recruiting,NA,NA,50,Anticipated,University of Milan,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:36:59Z,2021-10-17T08:36:59Z,15653615,NCT04307459,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-03,NA,NA,2021-02-09,2020-03-03,2020-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-12,Actual,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"April 1, 2021",Anticipated,2021-04-01,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,NA,,Medical Masks vs N95 Respirators for COVID-19,Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial,Recruiting,NA,N/A,576,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:38:31Z,2021-10-17T08:38:31Z,15654915,NCT04296643,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-24,NA,NA,2020-08-18,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"March 5, 2020",Actual,2020-03-05,August 2020,2020-08-31,"July 9, 2020",Actual,2020-07-09,"May 12, 2020",Actual,2020-05-12,NA,Interventional,NA,,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),"A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients",Completed,NA,Phase 2,100,Actual,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"After approval from the steering committee and the Human Genetic Resources Administration of China, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed.",2021-10-17T08:39:52Z,2021-10-17T08:39:52Z,15656005,NCT04288102,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-25,NA,NA,2020-02-28,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-02-28,2020-03-03,Actual,"February 1, 2020",Actual,2020-02-01,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"July 31, 2020",Anticipated,2020-07-31,NA,Observational,NA,,Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19,The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study,Recruiting,NA,NA,15,Anticipated,Shanghai Public Health Clinical Center,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:39:15Z,2021-10-17T08:39:15Z,15655447,NCT04292340,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-23,NA,NA,2020-02-29,2020-02-29,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-02-29,2020-03-03,Actual,"January 1, 2020",Actual,2020-01-01,February 2020,2020-02-29,"July 31, 2020",Anticipated,2020-07-31,"April 30, 2020",Anticipated,2020-04-30,NA,Observational,2019-nCoV,,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV),"Active, not recruiting",NA,NA,400,Anticipated,Fujian Provincial Hospital,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:39:15Z,2021-10-17T08:39:15Z,15655449,NCT04292327,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-10,NA,NA,2020-02-21,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"June 1, 2020",Anticipated,2020-06-01,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:40:42Z,2021-10-17T08:40:42Z,15656722,NCT04282902,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-13,NA,NA,2020-03-15,2020-02-20,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"February 21, 2020",Actual,2020-02-21,March 2020,2020-03-31,"July 30, 2020",Anticipated,2020-07-30,"May 30, 2020",Anticipated,2020-05-30,NA,Observational,NA,,Study for Novel Coronavirus Pneumonia (NCP),Study for Clinical Epidemiology and Methods of Diagnosis and Treatment of Novel Coronavirus Pneumonia (NCP),Recruiting,NA,NA,2000,Anticipated,"Wuhan Union Hospital, China",,NA,NA,NA,FALSE,NA,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:40:37Z,2021-10-17T08:40:37Z,15656651,NCT04283396,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-19,NA,NA,2020-02-19,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"January 20, 2020",Actual,2020-01-20,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,,Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations,Study on Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations in Patients,Recruiting,NA,NA,20,Anticipated,"Third Affiliated Hospital, Sun Yat-Sen University",,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:41:12Z,2021-10-17T08:41:12Z,15657159,NCT04279795,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-15,NA,NA,2020-02-20,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"January 20, 2020",Actual,2020-01-20,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,,Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,Investigation on Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection in Isolation Unit,Recruiting,NA,NA,100,Anticipated,"Third Affiliated Hospital, Sun Yat-Sen University",,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:41:12Z,2021-10-17T08:41:12Z,15657161,NCT04279782,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-13,NA,NA,2021-04-05,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"February 15, 2020",Actual,2020-02-15,December 2020,2020-12-31,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,,NK Cells Treatment for COVID-19,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:41:09Z,2021-10-17T08:41:09Z,15657087,NCT04280224,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-18,NA,NA,2020-10-13,2020-02-18,2020-02-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"March 5, 2020",Actual,2020-03-05,October 2020,2020-10-31,"April 24, 2024",Anticipated,2024-04-24,"April 24, 2024",Anticipated,2024-04-24,NA,Observational,POPS or POP02,,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs",Recruiting,NA,NA,5000,Anticipated,Duke University,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Whole blood, effluent samples, and plasma.
    ",NA,NA,NA,No,NA,2021-10-17T08:41:24Z,2021-10-17T08:41:24Z,15657336,NCT04278404,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-14,NA,NA,2020-09-10,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"May 2, 2020",Actual,2020-05-02,"April 5, 2020",Actual,2020-04-05,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP),Completed,NA,Phase 2,27,Actual,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:41:48Z,2021-10-17T08:41:48Z,15657702,NCT04275414,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-16,NA,NA,2020-09-03,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"February 15, 2020",Actual,2020-02-15,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Completed,NA,Phase 1,24,Actual,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2021-10-17T08:41:35Z,2021-10-17T08:41:35Z,15657511,NCT04276987,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-11,NA,NA,2020-04-13,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 10, 2020",Actual,2020-02-10,April 2020,2020-04-30,"March 31, 2020",Actual,2020-03-31,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:41:38Z,2021-10-17T08:41:38Z,15657538,NCT04276688,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-16,NA,NA,2020-04-07,2020-02-16,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"February 19, 2020",Actual,2020-02-19,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,"April 4, 2020",Actual,2020-04-04,NA,Observational,NA,,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (COV_NUTRIC),"Active, not recruiting",NA,NA,117,Actual,Peking University Third Hospital,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:41:59Z,2021-10-17T08:41:59Z,15657852,NCT04274322,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-06,NA,NA,2021-09-22,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-27,Actual,"February 8, 2020",Actual,2020-02-08,September 2021,2021-09-30,"August 7, 2025",Anticipated,2025-08-07,"March 27, 2020",Actual,2020-03-27,NA,Observational,FrenchCOVID,,French COVID Cohort,Clinical Characterisation Protocol for Severe Emerging Infections,Recruiting,NA,NA,5000,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood, urine, stool /rectal swab, respiratory samples (nose and throat swab, endotracheal
      aspirate, nasopharyngeal aspirate), samples from infected sites/sores, CSF
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:43:52Z,2021-10-17T08:43:52Z,15659276,NCT04262921,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-14,NA,NA,2020-04-29,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"February 16, 2020",Actual,2020-02-16,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"May 10, 2020",Anticipated,2020-05-10,NA,Interventional,NA,,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",NA,N/A,18,Actual,Second Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:42:05Z,2021-10-17T08:42:05Z,15657924,NCT04273763,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 18, 2021",2020-08-10,NA,NA,2021-10-15,2020-08-10,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"August 13, 2020",Actual,2020-08-13,October 2021,2021-10-31,"February 22, 2022",Anticipated,2022-02-22,"February 22, 2022",Anticipated,2022-02-22,NA,Interventional,PREVENT-HD,,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection","A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 Infection",Recruiting,NA,Phase 3,4000,Anticipated,"Janssen Research & Development, LLC",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-10-19T08:28:57Z,2021-10-19T08:28:57Z,16225043,NCT04508023,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-05,NA,NA,2020-05-20,2020-02-05,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"February 4, 2021",Anticipated,2021-02-04,"October 4, 2020",Anticipated,2020-10-04,NA,Observational,Cov-CONTACT,,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection,Recruiting,NA,NA,345,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Nasopharyngeal swabs
    ",NA,NA,NA,Undecided,NA,2021-10-17T08:44:19Z,2021-10-17T08:44:19Z,15659681,NCT04259892,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 15, 2021",2020-01-30,NA,NA,2020-06-29,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"January 28, 2020",Actual,2020-01-28,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"April 30, 2020",Actual,2020-04-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Completed,NA,Phase 4,86,Actual,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:45:27Z,2021-10-17T08:45:27Z,15660521,NCT04252885,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 19, 2021",2021-10-18,NA,NA,2021-10-18,2021-10-18,2021-10-19,Estimate,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"May 14, 2020",Actual,2020-05-14,October 2021,2021-10-31,"September 3, 2021",Actual,2021-09-03,"December 14, 2020",Actual,2020-12-14,NA,Observational,NA,,"Observational Program, Double-blind, Placebo-controlled to Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19","Observational Program, Double-blind, Placebo-controlled to Study the Preventive Efficacy of the BiVac Polio (Oral Polio Vaccine, Divalent, Live Attenuated of Types 1 and 3 ) Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers Aged 18-65",Completed,NA,NA,1500,Actual,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-20T09:37:34Z,2021-10-20T09:37:34Z,16226511,NCT05083039,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 19, 2021",2020-10-06,NA,NA,2021-10-18,2020-10-13,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"June 21, 2021",Actual,2021-06-21,October 2021,2021-10-31,"June 15, 2024",Anticipated,2024-06-15,"June 15, 2024",Anticipated,2024-06-15,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers","Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers",Recruiting,NA,Phase 2,542,Anticipated,Inovio Pharmaceuticals,,10,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,TRUE,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-10-20T09:42:25Z,2021-10-20T09:42:25Z,16227242,NCT04588428,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 21, 2021",2020-06-08,NA,NA,2021-10-20,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"June 22, 2020",Actual,2020-06-22,October 2021,2021-10-31,"January 18, 2022",Anticipated,2022-01-18,"August 22, 2021",Actual,2021-08-22,6 Months,Observational [Patient Registry],CHRONOS19,,Registry of Patients With Hematologic Disease and COVID-19 in Russia,Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19),"Active, not recruiting",NA,NA,666,Actual,"National Research Center for Hematology, Russia",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-22T09:38:36Z,2021-10-22T09:38:36Z,16232051,NCT04422470,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 21, 2021",2020-04-02,NA,NA,2021-10-19,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"June 22, 2020",Actual,2020-06-22,October 2021,2021-10-31,July 2025,Anticipated,2025-07-31,December 2024,Anticipated,2024-12-31,NA,Interventional,HELPCOVID-19,,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-22T09:39:09Z,2021-10-22T09:39:09Z,16232105,NCT04335084,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 19, 2021",2020-06-17,NA,NA,2021-10-15,2020-06-17,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-19,Estimate,"July 9, 2020",Actual,2020-07-09,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,FITE19,,A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19),Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19),Recruiting,NA,Phase 2/Phase 3,380,Anticipated,PTC Therapeutics,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-20T09:43:15Z,2021-10-20T09:43:15Z,16227380,NCT04439071,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 20, 2021",2020-05-12,NA,NA,2021-10-14,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-20,Estimate,"May 28, 2020",Actual,2020-05-28,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Investigating a Vaccine Against COVID-19,"A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19","Active, not recruiting",NA,Phase 2/Phase 3,12390,Anticipated,University of Oxford,,29,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-21T09:55:41Z,2021-10-21T09:55:41Z,16230046,NCT04400838,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 21, 2021",2021-07-26,NA,NA,2021-10-20,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"January 8, 2021",Actual,2021-01-08,July 2021,2021-07-31,"September 15, 2021",Actual,2021-09-15,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Completed,NA,N/A,80,Actual,Catalysis SL,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-22T09:35:25Z,2021-10-22T09:35:25Z,16231488,NCT04980534,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 21, 2021",2021-06-24,NA,NA,2021-10-20,2021-06-24,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"August 11, 2021",Actual,2021-08-11,October 2021,2021-10-31,"April 3, 2022",Anticipated,2022-04-03,"April 3, 2022",Anticipated,2022-04-03,NA,Interventional,MOVe-AHEAD,,Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013),"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19",Recruiting,NA,Phase 3,1332,Anticipated,Merck Sharp & Dohme Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-10-22T09:35:45Z,2021-10-22T09:35:45Z,16231553,NCT04939428,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 22, 2021",2021-10-11,NA,NA,2021-10-21,2021-10-21,2021-10-22,Estimate,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"August 31, 2021",Actual,2021-08-31,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 16, 2021",Actual,2021-09-16,NA,Interventional,NA,,Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity,A Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant New Coronavirus Vaccine (CHO Cells) After Vaccination With Two Inactivated Vaccine in Healthy People Aged 18 and Above,Completed,NA,N/A,360,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T08:55:23Z,2021-10-25T08:55:23Z,16233174,NCT05089045,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 22, 2021",2021-09-30,NA,NA,2021-10-14,2021-09-30,2021-10-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"September 29, 2020",Actual,2020-09-29,October 2021,2021-10-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Observational,NA,,Lung Ultrasound Findings in Patients With COVID-19 in a UK ED,Lung Ultrasound Findings in Patients With COVID-19 in a UK Emergency Department,Completed,NA,NA,43,Actual,Chelsea and Westminster NHS Foundation Trust,,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T08:56:25Z,2021-10-25T08:56:25Z,16233308,NCT05065827,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 22, 2021",2020-08-17,NA,NA,2021-10-20,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"August 19, 2020",Actual,2020-08-19,October 2021,2021-10-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Interventional,NA,,ACTIV-2: A Study for Outpatients With COVID-19,Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID),Recruiting,NA,Phase 2/Phase 3,8797,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,15,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-25T09:01:51Z,2021-10-25T09:01:51Z,16233913,NCT04518410,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 25, 2021",2020-10-16,NA,NA,2021-10-22,2020-10-16,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-25,Estimate,"October 17, 2020",Actual,2020-10-17,October 2021,2021-10-31,"October 9, 2024",Anticipated,2024-10-09,"October 9, 2022",Anticipated,2022-10-09,NA,Observational,NA,,SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida,SARS-CoV-2 Immune Surveillance Among a Population Based Sample of Adults in Florida,Enrolling by invitation,NA,NA,1200,Anticipated,H. Lee Moffitt Cancer Center and Research Institute,,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-26T08:55:31Z,2021-10-26T08:55:31Z,16236145,NCT04596579,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 22, 2021",2020-07-13,NA,NA,2021-10-20,2020-07-21,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 12, 2021",Actual,2021-10-12,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,,SPI-1005 Treatment in Moderate COVID-19 Patients,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients",Enrolling by invitation,NA,Phase 2,60,Anticipated,"Sound Pharmaceuticals, Incorporated",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T09:02:08Z,2021-10-25T09:02:08Z,16233949,NCT04484025,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 22, 2021",2020-07-13,NA,NA,2021-10-20,2020-07-21,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"August 27, 2021",Actual,2021-08-27,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,,SPI-1005 Treatment in Severe COVID-19 Patients,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients",Enrolling by invitation,NA,Phase 2,60,Anticipated,"Sound Pharmaceuticals, Incorporated",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T09:02:09Z,2021-10-25T09:02:09Z,16233953,NCT04483973,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 25, 2021",2021-10-03,NA,NA,2021-10-17,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-17,2021-10-25,Estimate,"October 14, 2021",Actual,2021-10-14,October 2021,2021-10-31,February 2024,Anticipated,2024-02-29,December 2023,Anticipated,2023-12-31,NA,Interventional,NA,,"Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above","A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above",Recruiting,NA,Phase 1/Phase 2,1848,Anticipated,"National Vaccine and Serum Institute, China",,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-26T08:52:02Z,2021-10-26T08:52:02Z,16235575,NCT05069129,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 25, 2021",2021-01-05,NA,NA,2021-10-15,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-25,Estimate,"February 23, 2021",Actual,2021-02-23,April 2021,2021-04-30,"July 8, 2021",Actual,2021-07-08,"July 8, 2021",Actual,2021-07-08,NA,Interventional,COVIMAR,,Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19),Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19,Completed,NA,Phase 2,44,Actual,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-26T08:54:58Z,2021-10-26T08:54:58Z,16236039,NCT04710199,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 25, 2021",2021-10-12,NA,NA,2021-10-12,2021-10-12,2021-10-25,Estimate,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-25,Estimate,"September 9, 2021",Actual,2021-09-09,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells),"Randomized, Double-blind, Parallel-controlled Evaluation of the Immunogenicity Consistency and Safety of the Three Batches of Recombinant Novel Coronavirus Vaccine (CHO Cells) After Process Verification in the 18-59-year-old Population, and the Comparison With the Pilot-scale Batch Immunogenicity Non-inferiority Bridging and Safety Clinical Trials",Recruiting,NA,Phase 3,1680,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-26T08:50:48Z,2021-10-26T08:50:48Z,16235389,NCT05091411,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 25, 2021",2020-05-21,NA,NA,2021-10-22,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-25,Estimate,"June 18, 2020",Actual,2020-06-18,October 2021,2021-10-31,"July 31, 2022",Anticipated,2022-07-31,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,NA,,hCT-MSCs for COVID19 ARDS,Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Duke University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-26T08:56:26Z,2021-10-26T08:56:26Z,16236288,NCT04399889,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 25, 2021",2020-03-23,NA,NA,2021-10-15,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-25,Estimate,"March 24, 2020",Actual,2020-03-24,October 2021,2021-10-31,"December 30, 2022",Anticipated,2022-12-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,B-DT-COV2,,Biomarkers for Identification of COVID-19 Infection,Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection,Recruiting,NA,NA,110,Anticipated,University of Catanzaro,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-26T08:56:41Z,2021-10-26T08:56:41Z,16236330,NCT04322513,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 26, 2021",2020-11-23,NA,NA,2021-10-18,2020-11-23,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"November 30, 2020",Actual,2020-11-30,October 2021,2021-10-31,January 2023,Anticipated,2023-01-31,January 2023,Anticipated,2023-01-31,NA,Interventional,NA,,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure","Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure","Active, not recruiting",NA,Phase 2/Phase 3,7517,Anticipated,Inovio Pharmaceuticals,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-10-27T11:17:49Z,2021-10-27T11:17:49Z,16238560,NCT04642638,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 26, 2021",2021-10-23,NA,NA,2021-10-23,2021-10-23,2021-10-26,Estimate,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"January 1, 2021",Actual,2021-01-01,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,6 Months,Observational [Patient Registry],NA,,Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).,Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).,Completed,NA,NA,350,Actual,Jinnah Postgraduate Medical Centre,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-27T11:11:52Z,2021-10-27T11:11:52Z,16237731,NCT05094687,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 26, 2021",2021-05-11,2021-07-18,NA,2021-10-23,2021-05-21,2021-05-24,Actual,2021-07-29,2021-08-02,Actual,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"December 1, 2020",Actual,2020-12-01,October 2021,2021-10-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,4 Months,Observational [Patient Registry],NA,,Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).,Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19),Completed,NA,NA,300,Actual,Jinnah Postgraduate Medical Centre,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-27T11:16:05Z,2021-10-27T11:16:05Z,16238293,NCT04898166,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 26, 2021",2020-03-20,NA,NA,2021-10-18,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"March 12, 2020",Actual,2020-03-12,October 2021,2021-10-31,"April 1, 2022",Anticipated,2022-04-01,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVIDSOT,,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Recruiting,NA,NA,50,Anticipated,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      -  Biochemical analysis

        -  Hemogram

        -  Microbiological testing will be made: blood culture, pleural liquid culture, gram stain
           and culture of sputum, detection of pneumococcus and Legionella pneumophila antigen in
           urine, in cases of pneumonia.

        -  Nasopharyngeal swabs
    ",One year after the initiation of the study,Spanish Network for Research in Infectious Disease (REIPI) and Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC),NA,Yes,Planning for the study will be shared with potential sites pertaining to Spanish Network for Research in Infectious Disease (REIPI) and Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC) for participation. IPD is not foreseen out of this groups due to the specific characteristics of patients and sites to be candidates for study participation.,2021-10-27T11:19:42Z,2021-10-27T11:19:42Z,16238827,NCT04319172,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 26, 2021",2020-06-22,NA,NA,2021-10-25,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"July 4, 2020",Actual,2020-07-04,October 2021,2021-10-31,"October 14, 2021",Actual,2021-10-14,"May 10, 2021",Actual,2021-05-10,NA,Interventional,RAPID-BRAZIL,,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,UtilizaÃ§Ã£o da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com sÃ­ndrome respiratÃ³ria Aguda Grave Por COVID-19,Completed,NA,Phase 3,465,Actual,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-27T11:19:01Z,2021-10-27T11:19:01Z,16238756,NCT04444700,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 27, 2021",2020-07-21,NA,NA,2021-10-19,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-27,Estimate,"December 9, 2020",Actual,2020-12-09,October 2021,2021-10-31,July 2022,Anticipated,2022-07-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,,Trial of Combination Therapy to Treat COVID-19 Infection,A Phase I Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection,"Active, not recruiting",NA,Phase 2,31,Actual,ProgenaBiome,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-28T09:13:18Z,2021-10-28T09:13:18Z,16241225,NCT04482686,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 27, 2021",2020-11-14,NA,NA,2021-10-26,2020-11-24,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"November 13, 2020",Actual,2020-11-13,October 2021,2021-10-31,"May 18, 2021",Actual,2021-05-18,"May 11, 2021",Actual,2021-05-11,NA,Interventional,NA,,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,"A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19",Completed,NA,Phase 1,30,Actual,Nektar Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-28T09:12:14Z,2021-10-28T09:12:14Z,16241043,NCT04646044,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 27, 2021",2020-07-15,NA,NA,2021-10-21,2020-07-15,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-27,Estimate,"August 22, 2020",Actual,2020-08-22,October 2021,2021-10-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Interventional,NA,,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Phase 2,650,Anticipated,"The University of Texas Health Science Center, Houston",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-28T09:13:29Z,2021-10-28T09:13:29Z,16241238,NCT04478071,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 27, 2021",2020-11-12,NA,NA,2021-10-19,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-27,Estimate,"July 1, 2021",Actual,2021-07-01,August 2021,2021-08-31,"March 31, 2022",Anticipated,2022-03-31,"December 29, 2021",Anticipated,2021-12-29,NA,Interventional,PROPEL,,Intravenous Zotatifin in Adults With Mild or Moderate COVID-19,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial of Intravenous Zotatifin in Adults With Mild or Moderate Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 1,36,Anticipated,Effector Therapeutics,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Following completion of the study, the data may be considered for publication.",2021-10-28T09:12:20Z,2021-10-28T09:12:20Z,16241063,NCT04632381,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 27, 2021",2020-10-28,NA,NA,2021-10-26,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"December 15, 2020",Actual,2020-12-15,October 2021,2021-10-31,"November 14, 2022",Anticipated,2022-11-14,"November 14, 2022",Anticipated,2022-11-14,18 Months,Observational [Patient Registry],INSPIRE,,Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE),Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE),Recruiting,NA,NA,4800,Anticipated,Rush University Medical Center,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-28T09:12:28Z,2021-10-28T09:12:28Z,16241087,NCT04610515,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 28, 2021",2021-08-03,NA,NA,2021-10-20,2021-08-03,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"August 6, 2021",Actual,2021-08-06,October 2021,2021-10-31,"March 2, 2022",Anticipated,2022-03-02,"October 22, 2021",Anticipated,2021-10-22,NA,Interventional,NA,,A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2,"A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Ad26.COV2.S Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2",Recruiting,NA,Phase 2,1540,Anticipated,Janssen Vaccines & Prevention B.V.,,6,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-10-29T09:11:21Z,2021-10-29T09:11:21Z,16242526,NCT04999111,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 28, 2021",2021-08-16,NA,NA,2021-10-27,2021-10-27,2021-10-28,Estimate,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"April 16, 2021",Actual,2021-04-16,October 2021,2021-10-31,"July 16, 2023",Anticipated,2023-07-16,"July 16, 2023",Anticipated,2023-07-16,18 Months,Observational [Patient Registry],NA,,Follow-up of Covid-19 Long Term Sequelae,ORCHESTRA WP2 - Follow-up of Covid-19 Long Term Sequelae,Recruiting,NA,NA,7500,Anticipated,Azienda Ospedaliera Universitaria Integrata Verona,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      COVID-19 biological samples (including blood, naso-pharingeal swabs, urine, and stool) will
      be collected and stored in the biobank of each participating center according to local
      authority regulation.
    ",NA,NA,NA,Undecided,NA,2021-10-29T09:08:51Z,2021-10-29T09:08:51Z,16242240,NCT05097677,Coronavirus Infections,coronavirus infections,NA
"ClinicalTrials.gov processed this data on October 28, 2021",2021-02-25,NA,NA,2021-10-27,2021-02-25,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"November 2, 2021",Anticipated,2021-11-02,"June 2, 2021",2021-06-02,"November 29, 2024",Anticipated,2024-11-29,"November 29, 2024",Anticipated,2024-11-29,NA,Observational,NA,,Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies,Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies,Enrolling by invitation,NA,NA,50,Anticipated,National Institutes of Health Clinical Center (CC),,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-29T09:13:14Z,2021-10-29T09:13:14Z,16242774,NCT04772170,Coronavirus Infections,coronavirus infections,NA
